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General remarks 
 
 
1. 1H NMR spectra were recorded on Bruker avance II 400 MHz NMR spectrometer 
using TMS as an internal reference. 
 
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
 
3. IR spectra were recorded on Schimadzu FT-IR-8400 spectrometer. 
 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
 
6. The chemicals used for the synthesis of compounds were purchased from 
Spectrochem, Merck, Thomas-baker and SD fine chemical. 
 
7. Melting Points were taken in open capillary and are uncorrected. 
 
8. Microwave assisted reaction were carried out in QPro-M microwave synthesizer. 
 
9. All the structures are drawn according to ACS Document 1996 style. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synopsis 
  
The work to be presented in thesis entitled “Studies on Some Compounds of 
Medicinal Interest” is classified into following Chapters.  
 
Chapter 1 General Introduction  
Chapter 2 Biological and medicinal significance of Pyrimidines and related 
heterocycles 
Chapter 3 Synthesis and biological evaluation of thieno[2,3-d]pyrimidines 
Chapter 4 Synthesis and biological evaluation of 1,2,4-triazolo[1,5-a]pyrimidines 
Chapter 5 Microwave assisted synthesis and biological evaluation of pyrazolo 
[3,4-d][1,2,4]triazolo[1,5-a]pyrimidines 
 
 
Chapter 1 General Introduction  
 
Nowadays, the entire pharmaceutical industry is faced with the challenge of 
increasing productivity and innovation. The major hurdles are the increasing costs of 
research and development and a simultaneous stagnating number of new chemical 
entities (NCEs). 
Chapter 1 gives a brief introduction for the pressing need of New Chemical 
Entities (NCEs) for pharmaceutical industry. It also describes importance of bicyclic 
and tricyclic aromatic heterocycles in drug discovery. Concept of “privileged 
structures” is also explained in brief. Chapter 1 also describes aims and objectives of 
the proposed research work. 
 
Chapter 2 Biological and medicinal significance of pyrimidines and related 
heterocycles 
 
Pyrimidines have a long and distinguished history extending from the days of their 
discovery as important constituents of nucleic acids to their current use in the 
chemotherapy of AIDS. 
Chapter 2 outlines the biological significance and medical significance of one 
of the most important heterocycles, the pyrimidine. An attempt has been made to 
cover most of the physiologically as well as medicinally important compounds 
containing pyrimidine and its derivatives. 
 
Chapter 3 Synthesis and biological evaluation of thieno[2,3-d]pyrimidines 
 
The chemistry of pyrimidines and its derivatives has been studied for over a century 
due to their diverse biological activities. Due to formal isoelectronic relationship with 
purines, the thieno[2,3-d]pyrimidine ring system is of special biological interest. It has 
numerous pharmacological and medicinal applications viz, antitumour, 
immunodilator, tuberculosis, antiallergic and radioprotective. 
  
ART- 101 TO 110
S
H3C
O
H
N
CN
NH2R1
S
H3C
O
H
N
R1
N
NH
O
R2
ART- 111 TO 140
Where R1= H, 2-OCH3, 4-OCH3 etc and R2 = H, CH3, CF3  
 
Keeping in mind various biomedical applications and with a view to further 
assess the pharmacological profile of these class of compounds, three novel series of 
thieno[2,3-d]pyrimidines (ART-111 to ART-130) are synthesized in chapter 3. The 
synthesis of thieno[2,3-d]pyrimidines (ART-111 to ART-130) was achieved by acid 
catalysed cyclocondensation of polysubstituted 2-aminothiophenes (ART-101 to 
ART-110) with formic acid, gl. acetic acid and trifluoroacetic acid, respectively. 
Polysubstituted 2-aminothiophenes were prepared via the Gewald reaction. The 
products were characterized by FT-IR, mass spectra, 1H NMR and elemental analysis. 
The newly synthesized compounds are subjected to various biological activities viz., 
antimicrobial, antimycobacterial, anticancer and antiviral. 
 
 
Chapter 4 Synthesis and biological evaluation of 1,2,4-triazolo[1,5-
a]pyrimidines 
 
The biological importance of 1,2,4-triazolo[1,5-a]pyrimidines is well documented. 
Over the years, various substituted derivatives of these heterocycles have shown 
utility against a range of biological targets. For example, they have demonstrated 
activity against malaria and bronchospasm and shown activity as coronary 
vasodilators, antihypertensive agents, leishmanicides, antibiotics, adenosine A2a 
antagonists, immunosuppressants, antitumor agents, fungicides, xanthine oxidase 
inhibitors, and phosphodiesterase inhibitors. 
 In chapter 4, synthesis of four new series of of 1,2,4-triazolo[1,5-
a]pyrimidines (ART-201 to ART-240) containing an acetoacetamide fragment has 
been undertaken. The structures of all the newly synthesized compounds are 
elucidated by FT-IR, mass spectra, 1H NMR and elemental analysis. The newly 
synthesized compounds are subjected to various biological activities viz., 
antimicrobial, antimycobacterial, anticancer and antiviral. 
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Where R1= 4-OCH3, 4-F, 4-CF3, 2-F and R2 = 4-OCH3, 4-CH3, 4-F, 4-Cl etc..
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Chapter 5 Microwave assisted synthesis and biological evaluation of pyrazolo 
[3,4-d][1,2,4]triazolo[1,5-a]pyrimidines 
 
Flat heterocyclic structures are fundamental moieties in anticancer compounds acting 
as DNA intercalating agents. In this context, pyrazolotriazolopyrimidines have been 
the subject of intense research due to the interesting pharmacological activities found 
for several of their derivatives. Among the various pyrazolotriazolopyrimidine ring 
systems, pyrazolo[3,4-d][1,2,4]triazolo[1,5-a]pyrimidines have never been explored, 
and there are no reports on the synthesis and chemical properties of these class of 
compounds. With the aim to extend the synthetic pathways to new planar heterocyclic 
ring systems we focused our studies on the pyrazolo[3,4-d][1,2,4]triazolo[1,5-
a]pyrimidine core structure which was found to be absent in the literature survey 
(Scifinder, CA, STN search). 
Chapter 5 describes synthesis of pyrazolo[3,4-d][1,2,4]triazolo[1,5-a]pyrimi 
dine (ART-301 to ART-330), a new ring system, which was achieved by using a one-
pot, microwave-assisted, catalyst-free biginelli like condensation. All the newly 
synthesized compounds are characterized by FT-IR, mass spectra, 1H NMR and 
elemental analysis. The newly synthesized compounds are subjected to various 
biological activities viz., antimicrobial, antimycobacterial, anticancer and antiviral. 
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 Chapter 1 
 General Introduction   
 
 
 
 
1.1 Heterocycles in drug discovery 
Nowadays, the entire pharmaceutical industry is faced with the challenge of 
increasing productivity and innovation. The major hurdles are the increasing costs of 
research and development and a simultaneous stagnating number of new chemical 
entities (NCEs).  
The cause of this innovation deficit is definitively not the biology. Decoding 
of the human genome has led to a wealth of drug targets. With more than 30,000 
human genes, the assumption is that at least 1,000 are significantly involved in the 
emergence and course of disease. Furthermore, because each of these genes is linked 
to the function of between five and ten proteins, the conclusion is that there might be 
5,000–10,000 targets for new drugs [1]. Despite the successful introduction of protein 
therapeutics and the promise of gene therapy, major pharmaceutical companies are 
still focused on the discovery and development of low-molecular weight compounds. 
Hence, the challenge is to select the most drugable targets and to find the 
corresponding drug-like molecules, substances that not only interact with the target, 
but also have specific pharmacokinetic and toxicological properties, that allow them 
to be developed as a drug.  
 Medicinal chemistry as a scientific discipline has introduced several new 
techniques over the last few years in order to speed up the drug discovery process, 
such as combinatorial chemistry, microwave-assisted organic synthesis (MAOS) and 
high-throughput purification [2]. Despite this steady increase in R & D, the number of 
NCEs reaching the market has actually decreased dramatically. 
 It seems clear that selecting appropriate molecules to synthesize is one of the 
most troublesome questions. It has been estimated that the number of possible 
molecules with a molecular weight of less than 500 Da is 10200, of which only 1060 
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may possess drug-like properties. The proportion of these drug-like molecules 
synthesized to date has been estimated as one part in 1057, or roughly the ratio of the 
mass of one proton to the mass of the sun! The issue is therefore the selection of new 
molecules from this vast universe, which have the potential to be biologically active 
[3]. 
In order to start a new drug discovery project and to find biologically active 
compounds, different options are available. Hits can be obtained via a virtual 
screening approach or can be copied from scientific or patent literature. Very often, 
drug discovery projects start with a high-throughput screening campaign of 
commercially available compound libraries against the target of interest. It became 
clear in recent years that combinatorial libraries are not diverse enough. As the main 
interest of the laboratory of medicinal chemistry lays in the synthesis and biological 
evaluation of aromatic heterocycles, we performed a literature survey of 
commercially available combinatorial libraries. This search revealed that the number 
of available heterocycles is mainly limited to well-known nitrogen containing 
compounds, such as quinazolines (1), indoles (2) and benzimidazole (3). 
 
N
N N
H NH
N
(1) Quinazoline (2) Indole (3) Benzimidazole
N
H
N
O
(4) 1,4-Benzodiazepine-2-one
O O
(5) Coumarine
N
N
(6) Quinoxaline
O
(7) Benzofuran
S
(8) Benzothiophene
Examples of privileged structures  
 
 These structural classes are considered to be privileged structures. The concept 
of “privileged structures” was first proposed by Evans et al. to describe selected 
structural types that bind to multiple, unrelated classes of protein receptors and 
enzymes as high affinity ligands [4]. These privileged structures are typically rigid, 
polycyclic heteroatomic systems capable of orienting the various substituents in a 
well-defined three-dimensional space. Well-known examples of privileged 
substructures include benzodiazepines (4), coumarins (5), quinoxalines (6), 
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benzofurans (7) and benzothiophenes (8) [5]. In order to improve the hit rate in HTS 
campaigns, privileged structures provide an ideal source of lead compounds. A single 
library based upon privileged substructures can lead to active compounds in variety of 
biological assays. Several research groups have utilized these structures in such a 
manner. For example, Nicolau and co-workers constructed a library based on the 
benzopyran (9) privileged scaffold [6], whereas Schultz and co-workers made use of 
the purine (10) scaffold [7]. 
 
O
(9) Benzopyran
N
N NH
N
(10) Purine
Thr benzopyran and purine privileged scaffold
 
 
1.2 Nomenclature of the fused ring system 
As the following chapters deal with the synthesis of bicyclic and tricyclic fused ring 
systems, its nomenclature is herewith shortly reviewed. The nomenclature follows the 
following rules: 
(1) The individual components are named without any application of fused ring 
system. 
(2) The parent component is represented in the fusion name by citing it last in the 
name. The parent component is the one with highest priority according to the 
following criteria: 
(a) A heterocyclic component containing the heteroatom occurring earliest in 
the order: N, F, Cl, Br, I, O, S, Se, Te, P, As, Sb, Bi, Si, Ge, Sn, Pb, B, Hg. 
(b) A component containing the larger ring 
(c) A component containing the greater number of heteroatoms. 
(d) A component containing the greater variety of heteroatoms. 
(3) The attached component is then added as a prefix to the parent component. In 
the name of the prefix, the terminal 'e' is changed to 'o'. 
(4) The bonds of the parent component are indicated by a, b, c…starting with the 
bond normally occupying the 1,2 positions. The atoms of the attached 
component are numbered as usual, following the order of numbers in the 
original heterocycle. 
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(5) The numbering of the final condensed heterocycle is carried out 
independently, starting at an atom adjacent to a bridged-head atom, whereby 
heteroatoms receive the smallest possible number. 
 
1.3 Objectives 
Our interest in the synthesis and biological evaluation of heterocyclic bi and tricycles 
and the fact that some of these compounds are not frequently used (thieno[2,3-d] 
pyrimidines (11), 1,2,4-triazolo[1,5-a]pyrimidines (12) and pyrazolo[3,4-d][1,2,4] 
triazolo[1,5-a]pyrimidines (13)) in commercial compound libraries, prompted us to 
elaborate this type of chemistry and to synthesize three different heterocyclic 
scaffolds. 
 
N
N
S
(11) Thieno[2,3-d]pyrimidine
N
N N
N
N
N N
N
N
N
H
(13) Pyrazolo[3,4-d][1,2,4]triazolo[1,5-a]pyrimidine
(12) 1,2,4-triazolo[1,5-a]pyrimidine
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1                                                                                         General Introduction 
     
   5
1.4 References and notes 
[1] (a) Drews, J. Science 2000, 287, 1960; (b) Wess, G.; Urmann M.; 
Sickenberger, B. Angew. Chem. Int. Ed. 2001, 40, 3341. 
[2] Lombardino, J. G.; Lowe III, J. A. Nat. Rev. Drug Discov. 2004, 3, 853. 
[3] Kolbn H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem. Int. Ed. 2001, 40, 
2004. 
[4] Evans, B. E.; Rittle, K. E.; Bock, M. G.; Dipardo, R. M.; Freidinger, R. M.; 
Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; 
Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, 
J. P.; Hirshfield, J. J. Med. Chem. 1988, 31, 2235. 
[5] Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893. 
[6] Nicolaou, K. C.; Pfefferkorn J. A.; Roecker, A. J.; Cao, G. Q.; Barluenga, S.; 
Mitchell, H. J. J. Am. Chem. Soc. 2000, 122, 9939. 
[7] Ding, S.; Gray, N. S.; Ding, Q.; Schultz, P. G. Tetrahedron Lett. 2001, 42, 
8751. 
 
Chapter 2                                                                              Significance of pyrimidines  
   
   6
 
 Chapter 2 
 Biological and medicinal significance of 
 pyrimidines and related heterocycles 
    
 
2.1 Biological significance 
Pyrimidines have a long and distinguished history extending from the days of their 
discovery as important constituents of nucleic acids to their current use in the 
chemotherapy of AIDS. 
  Alloxan (1) is known for its diabetogenic action in a number of animals [1]. 
Uracil (2), thymine (3) and cytosine (4) are the three important constituents of nucleic 
acids. 
 
HN
H
NO O
O
O
HN
H
NO
O
HN
H
NO
O
N
N
H
CH3 O
NH2
(1) Alloxan (2) Uracil (3) Thymine (4) Cytosine  
 
The pyrimidine ring is found in vitamins like thiamine (5), riboflavin (6) and 
folic acid (7) [2]. Barbitone (8), the first barbiturate hypnotic, sedative and 
anticonvulsant are pyrimidine derivatives [1]. 
 
N N
NH2
CH2
CH3
S
N
H3C
HOH2CH2C
Cl
(5) Thiamine
N
N
N
NH
H3C
H3C O
O
HHO
HHO
HHO
H2C
CH2OH(6) Riboflavin  
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O
OH
H
N
O
H
N
N
O
HN
H2N N N
OHO
(7) Folic acid
N
H
NH
O
O O
C2H5
C2H5
(8) Barbitone
 
 
2.2 Medicinal significance 
During the last two decades, several pyrimidine derivatives have been developed as 
chemotherapeutic agents and have found wide clinical applications. 
 
2.2.1 Antineoplastics and anticancer agents 
There are a large number of pyrimidine-based antimetabolites. Usually, they are 
structurally related to the endogenous substrates that they antagonize. The structural 
modification may be on the pyrimidine ring or on the pendant sugar groups. One of 
the early metabolites prepared was 5-fluorouracil (5-FU, 9a) [3, 4], a pyrimidine 
derivative. 5-Thiouracil (9b) also exhibits some useful antineoplastic activities [5]. 
The antineoplastic compounds [6] possessing the guanine nucleus (10) like 
azathioprine (11) [7], mercaptopurine (12) [8], thioguanine (13) [9], tegafur (14) [10], 
etc. were discovered after formulation of the antimetabolite theory by Woods and 
Fildes in 1940. These drugs prevent the utilization of normal cellular metabolites [6]. 
 
N
H
NH
O
X
R
R1
(9a), X = O, R = F, R1 = H, 5-fluorouracil
(9b), X = O, R = SH, R1 = H, 5-thiouracil
(9a, b)
HN
N N
N
S
R1
R
(10)
NH
N
O
O
O
F
(14) Tegafur
R R1
N
N
NO2
CH3
(12) Mercaptopurine
(11) Azathioprine
(13) Thioguanine
–H
–H–H
–H –NH2  
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 There are many more in recent times, like mopidamol (15) [11], nimustine (16) 
[12], raltitrexed (17) [13], uramustine (18) [14] and trimetrixate (19) [15]. 1-β-D-
Arabinosylcytosine (Ara-C, 20) [16] is also an example of a pyrimidine antimetabolite 
in which the sugar is arabinose having a beta configuration. It is mainly used as an 
anticancer agent and also exhibits significant therapeutic effects in patients with 
herpes virus infections and herpes encephalitis. 
 Gemcitabine (21), a pyrimidine antimetabolite, shows excellent antitumour 
activity against murine solid tumours [17]. 
 
N
N
N
N
N
N
HO
HO
N
OH
OH
N
N CH3
NH2
H
NN
O
NO
Cl
(15) Mopidamol (16) Nimustine
N
H
N
NS
O
N
H
HOOC
HOOC
CH3
O
CH3
(17) Raltitrexed
NH
H
N
N
Cl
Cl
O
O
N
N
N NH2
CH3
H
NO
O
H3C
H3C
O
H3C
(18) Uramustine
(19) Trimetrexate glucuronate
N
NH2
ON
O
OH
HO
HO
(20) Ara-C
N
NH2
ON
O
FOH
F
HO
(21) Gemcitabine
 
 
2.2.2 Drugs for hyperthyroidism 
2-Thiouracil (9c) and its alkyl analogue, thiobarbital (9e) are effective drugs against 
hyperthyroidism. Propylthiouracil (9d) is used as a drug for hyperthyroidism with 
minimum side effects [18]. 
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N
H
NH
O
R
R2 X
R1
(9c), R = R1 = R2 = H, X = S; 2-thiouracil 
(9d), R = R1 = H, R2 = C3H7, X = S; propylthiouracil 
(9e), R = R1  = C2H5, R2 = O, X = S; thiobarbital
(9c–e)
 
 
2.2.3 Antifolates, antibacterials and antiprotozoals 
In 1948, Hitchings made an important observation that a large number of 2,4-
diaminopyrimidines and some 2-amino-4-hydroxypyrimidines are antagonists of folic 
acid [19]. Since then, a large number of 2,4-diaminopyrimidines have been 
synthesized as antifolates. It was eventually proved that these pyrimidines are 
inhibitors of the enzyme dihydrofolate reductase (DHFR) [20, 21]. Notable amongst 
the 2,4-diaminopyrimidine drugs are pyrimethamine (22), a selective inhibitor of the 
DHFR of malarial plasmodia; trimethoprim (23), an antibacterial drug which 
selectively inhibits bacterial DHFR and most importantly, the very potent but non 
selective DHFR inhibitors, methotrexate (24a) and aminopterin (24b), both used in 
cancer chemotherapy [22]. 3’,5’-dichloromethotrexate (24c), which is less toxic and 
more readily metabolized than methotrexate, has recently been introduced for 
anticancer therapy [23]. Brodimoprim (25) is also found to be an effective 
antibacterial compound [24]. 
 
N
N
NH2
NH2
C2H5
Cl
N
N NH2H3CO
OCH3
H3CO
N
N N
N
NH2
H2N
CH2N
R
X
X
CONH CH
COOH
(CH2)2
COOH
(24a) R = CH3, X = H; Methotrexate
(24b) R = X = H; Aminopterin
(24c) R = CH3, X = Cl; 3',5'-dichloromethotrexate
(22) Pyrimethamine (23) Trimethoprim
(24)
N
N NH2Br
OCH3
H3CO
(25) Brodimoprim
NH2
NH2
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2.2.4 Sulfa drugs 
Pyrimidine derivatives of sulfa drugs, namely sulfadiazine, sulfamerazine and 
sulfadimidine are superior to many other sulfonamides and are used in some acute 
UTIs, cerebrospinal meningitis and for patients allergic to penicillins [25]. 
Sulfonamide–trimethoprim combinations are used extensively for opportunistic 
infections in patients with AIDS [26]. Sulfadoxine (26a) [27], a short and intermediate 
acting sulfonamide with a half-life of 7–9 days is used for malarial prophylaxis. 
Sulfisomidine (26b) with a half-life of 7 h is used as a combination sulfa therapy in 
veterinary medicine [28]. Sulfadiazine (27a), sulfamerzine (27b) and sulfadimidine 
(27c) possess good water solubility and therefore carry minimum risk of kidney 
damage, which makes them safe even for patients with impaired renal functions. 
 
NH2S
O
O
HNR
(26)
R
Sulfadoxine (26a)
N
N
CH3
N
N
OCH3
H3CO
Sulfisomidine (26b)
CH3
N
N
R1
R
R2
NH S
O
O
NH2
(27)
                                            R         R1       R2
Sulfadiazine (27a)              H        H         H
Sulfamerazine (27b)           H        CH3     H
Sulfadimidine (27c)            H        CH3     CH3
Sulfametoxydiazine (27f)   OCH3  H         H
Methyldiazine (27e)           CH3     H         H
N
N
OCH3
H3CO
NH S
O
O
NH2
(27d) Sulfadimethoxine
N
N
H3CO
H
N S NH2
OCH3
(28) Sulfamethoxine
O
O
 
 In 1959, sulfadimethoxine (27d) [29] was introduced with a half-life of 
approximately 40 h. The related 4-sulfonamidopyrimidine, sulfamethoxine (28) [29] 
having two methoxy groups at 5 and 6 positions, has by far the longest half-life of 
about 150 h. Methyldiazine (27e) [29] has a half-life of 65 h. Also, sulfamethoxy 
diazine (27f) [29] possesses good half-life. A new broad-spectrum sulfonamide, 
sulfamethomidine (29) [29] is relatively nontoxic and patients do not need extra fluid 
intake or alkalization. Sulfacytine (30) has been reported to be 3–10 times more 
potent than sulfaisoxazole and sulfisodimidine [29]. 
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N
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N
N
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O2S
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C2H5
(29) Sulfamethomidine (30) Sulfacytine
 
 
2.2.5 Antivirals and anti-AIDS 
Recently, pyrimidine derivatives have generated widespread interest due to their 
antiviral properties. 5-Iododeoxyuridine (31) [30] is an antiviral agent of high 
selectivity. 
 
NH
O
ON
O
HOH
HH
HH
HO
I
NH
O
ON
O
OH
HO
X
(31) 5-Iododeoxyuridine (32)
N
NN
N
NH2
O
OH
HO
HO
(33) Ara-A
NH
O
ON
O
N3
HO
H3C
(34) Retrovir
(32a) X = I, 5-iodo-2'-deoxyuridine
(32b) X = CF3, 5-trifluromethyl-2'-deoxyuridine  
 
IDU (5-iodo-2’-deoxyuridine) (32a) has been extensively utilized for viral 
infections. 5-Trifluromethyl-2’-deoxyuridine (F3 TDR, 32b) has been found useful 
against infections resistant to IDU therapy [30]. Ara-A, 9-β-D-arabinofuranosyl 
adenine (33), a relatively new antiviral drug, is effective against herpes infections of 
eye, brain and skin. It is especially effective against IDU-resistant herpes virus [30]. 
Some purine nucleosides are equally noteworthy. Retrovir (AZT-16, 34) is a 
potent inhibitor of the in vivo replication and cytopathic effects of HIV and has been 
recently approved for use against AIDS and severe ARC [31]. At present, Acyclovir 
(35a) is the only remedy for genital herpes. The oral formulation of Acyclovir is 
effective against both first and second degree recurrence genital herpes with minimal 
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side effects [32]. Ganciclovir (35b) [33] has shown good in vivo activity against 
HCV1&2. 
 
HN
N N
N
O
H2N
R
(35)
(35a) Acyclovir
R
O
OH
(35b) Ganciclovir O
OH
OH
(35c) Famicivlovir
O
O
O
CH3
CH3O
(35d) Valaciclovir
O
O
O
NH2
CH3
CH3
(35e) Penciclovir OH
OH
N
N
NH2
R
O
(36)
(36a) Lamivudine
R
O
S OH
(36b) Cidofovir P O
OH
OH
OH
NH
O
ON
O
N3
HO
H3C
(37) Zidovudine
N
NH2
ON
O
HO
(38) Zalcitabine
NH
NN
N
O
O
HO
(39) Didanosine
NH
O
ON
O
HO
H3C
(40) Stavudine
NH
NN
N
NH
HO
NH2
(41) Abacavir
 
 
Several members of a series of acyclic nucleosides, which contain a fused 
pyrimidine ring (mainly purine), are found to be effective antivirals. Famiciclovir 
(35c) and valaciclovir (35d) are drugs used for several DNA viruses, including HSV 
types 1 and 2, Varicella-zoster virus and Epstein-Barr virus [34]. Penciclovir (35e) 
[35] is useful for topical treatment of recurrent herpes, Libialis. Cidofovir (36b) [35], 
an antimetabolite for deoxycytosine triphosphate is used for the treatment of 
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cytomegalovirus (CMV) in AIDS patients. Lamivudine (36a) [35] is an effective anti-
AIDS drug when used in combination with zidovudine (37) [35]. Zidovudine [36] is 
an analogue of thymidine in which the azido group is substituted at the 3-position of 
the dideoxyribose moiety. It is active against RNA tumour viruses (retroviruses) that 
are the causative agents of AIDS and T-cell leukaemia. It is used in AIDS and AIDS-
related complex (ARC) to control opportunistic infections by raising absolute CD4+ 
lymphocyte counts. Also, zalcitabine (38) [36] is another useful alternative drug to 
zidovudine. It is given in combination with zidovudine, when CD4+ cell count falls 
below 300 cells/mm3. Didanosine (39) [37] is a purine dideoxynucleoside, which is an 
analogue of inosine. Didanosine inhibits HIV RT and exerts a virustatic effect on the 
retroviruses. Combined with zidovudine, antiretroviral activity of didanosine is 
increased. Stavudine (40) [37] is a pyrimidine nucleoside analogue that has significant 
activity against HIV-1 after intracellular conversion of the drug to a D4T-triphosphate. 
It is more effective than zidovudine or didenosine for treatment in patients for 
delaying the progression of HIV infection. It is recommended for patients with 
advanced HIV infection. Abacavir sulfate (41) [37] was approved in 1998 as a NRTI 
(Nucleoside Reverse Transcriptase Inhibitor) to be used in combination with other 
drugs for the treatment of HIV and AIDS. The major use of abacavir appears to be in 
combination with other NRTIs. 
 
2.2.6 Antibiotics 
There are few examples of pyrimidine antibiotics. The simplest of all is bacimethrin 
(5-hydroxymethyl-2-methoxypyrimidin-4-amine) (42), which is active against several 
staphylococcal infections [38]. Gourgetin (43), a cytosine derivative is active against 
mycobacteria as well as several Gram-positive and Gram-negative bacteria [39]. 
There are more derivatives of cytosine, namely amicetin (44) and plicacetin (45), 
which exhibit activity against acid fast and Gram-positive bacteria as well as some 
other organisms [38]. Puromycin (46) has a wide spectrum of antitrypanosomal 
activity. Aminoglycoside antibiotics phleomycin (47a), bleomycin (47b) and related 
families are wide-spectrum antibiotics containing the pyrimidine ring. Another 
antibiotic tubercidine (48) is reported to exhibit antitumour properties [39]. In 
addition, they have antineoplastic activity. Bleomycin is already in clinical use against 
certain tumours like Hodgkin’s lymphoma and disseminated testicular cancer [40]. 
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2.2.7 Antifungals 
Pyrimidines also exhibit antifungal properties. Flucytosine (49) [41] is a fluorinated 
pyrimidine used as nucleosidal antifungal agent for the treatment of serious systemic 
infections caused by susceptible strains of candida and Cryptococcus [42]. Hexetidine 
(50) [43] is mainly used for the treatment of aphthous ulceration. 
 
N
H
N
F
O
NH2
(49) Flucytosine
N
N
H2N
CH3
CH3
CH3
CH3
CH3
(50) Hexetidine
 
 
2.2.8 Anthelmentics 
These drugs have the ability of ridding the body of parasitic worms. Pyrantel pamoate 
(51) is a depolarizing neuromuscular blocking agent that causes spastic paralysis in 
helminthes and is employed in the treatment of infestations caused by pinworms and 
roundworms [44]. 
 
N
N
SCH3
(51) Pyrantel pamoate  
 
2.2.9 Antitubercular drugs 
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Capreomycin (52) produced by Streptomyces capreolus is a second-line bacteriostatic 
antituberculin drug containing pyrimidine [45, 46]. 
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N
H
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H2N NH
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(53) Viomycin
 
 
Viomycin (53) is more tuberculostatic than p-aminosalicyclic acid. It is 
effective in the treatment of experimental tuberculosis. 
 
2.2.10 CNS active agents 
2.2.10.1 Sedative/hypnotic/antiepileptic agents 
 
N
N
O
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O
R
O
R2
(54)
R2R R1
(54a) Allobarbital
(54b) Aprobarbital
(54c) Hexobarbital
-H -H
-H -H
-H -CH3
(54d) Cyclobarbital -H -H
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Agents of the anxiolytic, sedative and hypnotic group include a wide variety of 
barbiturates (54a–i) used as sedative and hypnotics and are classified as drugs having 
short, intermediate and long duration of action [47, 48]. Allobarbital (54a), 
aprobarbital (54b), pentobarbital (54e), phenobarbital (54g) and secobarbital (54i) are 
frequently used clinically as hypnotic barbiturates [49]. Hexobarbital (54c), 
cyclobarbital (54d) and propallylonal (54f) are some of the current drugs in the 
market used as sedative hypnotics [50]. Barbiturates as sedative hypnotics have a long 
and fascinating history. In fact Eli Lilly [51] patented secbutabarbital (54h) in 1932, 
while barbitone (8), the first of the barbiturates [1] was introduced in 1903. 
 
2.2.10.2 Anxiolytic agents 
Few of the pyrimidine derivatives are also used as anxiolytics. Most important of 
these is buspirone (55), indicated in the management of anxiety disorders 
accompanied with or without depression. It lacks sedative, anticonvulsant and muscle-
relaxant effects and most importantly abuse potential [52]. Buspirone lacks affinity to 
benzodiazepine receptors, but binds avidly to one subclass of serotonin receptors, the 
5-HT1A subtype [53, 54]. Ritanserin (56), a 5HT2 antagonist with anxiolytic activity is 
a pyrimidine derivative [55]. A simple pyrimidine derivative, mezilamine (57) is 
classified as an antipsychotic agent [56]. Risoperidone (58) is an antipsychotic drug, 
which is a structural hybrid of butyrophenone and can be used as anxiolytic, 
antidepressant and antiparkinsonian drug [57]. 
 
N
N
N N (CH2)4 N
O
O
(55) Buspirone
S
N
N
Cl
H3C
NHCH3N
N
H3C
(56) Ritanserin
N (CH2)2
N
N
S
(57) Mezilamine
N
N
N
CH3
N O
(58) Risoperidone
O
F
F
F  
 
Chapter 2                                                                              Significance of pyrimidines  
   
   18
2.2.10.3 Pyrimidine anaesthetics 
Thimylal (59) is a short acting general anaesthetic drug, which is also a pyrimidine 
analogue [58, 59]. 
 
H
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O
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NHN N
H
N
NH2
HO OH
O
O
H2N
(59) Thimylal (60) Saxitoxin
 
 
Saxitoxin (60) [58] is a naturally occurring pyrimidine containing anaesthetic 
agent, but is too toxic to be of clinical use. Saxitoxin is isolated from some marine 
dinoflagellates. 
 
2.2.10.4 Diuretics and uricosurics 
Several xanthine derivatives (61) containing fused pyrimidine ring systems like 
caffeine (61a) [60], etamiphylline (61b) [61], lomiphylline (61c) [62], etophylline 
(61d) [63], theophylline (61e) [60] and theodrendaline (61f) [64] are known to 
promote a weak diuresis by stimulation of cardiac function and by a direct action on 
the nephron, acting as adenosine receptor antagonists [60]. 
 
N
N N
N
O
O
H3C
CH3
R
(61)
(61a) Caffeine
R
CH3
(61b) Etamiphylline N
O
(61c) Lomiphylline
(61d) Etophylline
(61e) Theophylline
(61f) Theodrendaline
R
OH
-H
OH
OH
HN
HO
 
 
Chapter 2                                                                              Significance of pyrimidines  
   
   19
There are a few examples of diuretics which contain a pyrimidine ring. 
Noteworthy are quinethazine (62a), metolazone (62b) [65] and triamterene (63) [66]. 
 
N
N
N
N
N
NCl
H2NO2S
H
H
R
C6H5
H2N NH2
NH2O
R1
 (63) Triamterene(62)
(62a) R = C2H5, R1 = H; Quinethazine
(62b) R = CH3, R1 = 2-CH3C6H4; Metolazone  
 
2.2.11 Cardiac agents 
2.2.11.1 Antihypertensives 
Several pyrimidine ring-containing drugs have exhibited antihypertensive activity. 
Prazosin (64a), a quinozoline derivative, is a selective α1-adrenergic antagonist [67, 
68]. Its related analogues bunazosin (64b) [69], terazosin (64c) [70] and trimazosin 
(64d) [71] are potent antihypertensive agents. Another quinazoline derivative, 
ketanserin (65) [72] having a similar effect is an antagonist of both a1-adrenergic and 
serotonin-S2 receptors. Its mechanism of action however is still controversial. A 
triaminopyrimidine derivative, minoxidil (66), whose mechanism of action and 
therapeutic action are similar to Prazosin, has been introduced in therapy for its side 
effects, in the treatment of alopecia, male baldness [73]. Besides these, some more 
pyrimidine derivatives given below were found to be antihypertensives [74, 75]. 
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Alfuzocin (67) [74], a prazosin analogue and an α1-adrenoceptor antagonist as 
well as urapidil (68) [75] are used especially in urinary obstruction caused by benign 
prostate hyperplasia. 
 
2.2.11.2 Vasodilators 
A series of xanthine derivatives are used as peripheral and cerebral vasodilators. 
Especially, pentifylline (69a) and pentoxifylline (69b) are used in cardiovascular 
disorders [76]. Other derivatives like xantinol nicotinate (70b) [77], a vasodilator with 
general properties like nicotinic acid used in cerebral and peripheral vascular 
disorders and pimefylline (70a) and pyridofylline (70c) [78] are noteworthy. A new 
dopamine receptor stimulant, pirebidil (71) [79] is reported to have produced 
significant improvement in ADL (Activity of Daily Living) in patients suffering from 
Parkinson’s syndrome. 
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2.2.11.3 Cardiotonics/bronchodialators 
Several xanthine derivatives viz., theophylline (61e), aminophylline (72a) [80] and 
proxyphylline (72b) [80] exhibit good bronchodilator activity. 
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2.2.12 Antihistaminic pyrimidines 
Theophylline (73) is ten times more potent than either astemizole or terfenadine in its 
affinity for H1-histamine binding site and appears to be devoid of CNS activity [81]. 
Another pyrimidine containing antihistaminic drug, temelastine (73a) is comparable 
to mepyramine [82]. Radiolabelled studies have indicated that it does not penetrate 
the CNS appreciably. Icotidine (73b), a structural analogue of temelastine lacks CNS 
activity and is a dual antagonist of both H1 and H2 receptors [83]. 
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Pemirolast (74) [84], a new oral nonbronchodilator antihistaminic agent is also 
a pyrimidine derivative. It has demonstrated sufficient antihistaminic activity to 
warrant its use in severe asthma. Another compound, piprinhydrinate (75) [85] is also 
a pyrimidine derivative. 
 
2.2.13 Analgesics and NSAID drugs 
Acetiamine (76a) [86], bentiamine (76b) [86] and fursultiamine (76c) [87] are new 
lipid-soluble forms of thiamine (vitamin B1) having therapeutic use in beriberi, 
polyneuritis, encephalopathy, pain, malnutrition and alcoholism and especially in the 
treatment of long-standing insulin-dependent diabetes mellitus. Fursultamine has been 
reported to inhibit the arachadonic acid cascade-line activation and reverse the 
increase in CBF (Coronary Blood Flow). 
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Afloqualone (77) [88] has been evaluated as a successful anti-inflammatory 
agent with lower back pain patients. Epirizole (78) [89], another NSAID, is suggested 
to be a COX-2 inhibitor. Ademetionine (79) [90] is primarily used in conjunction to 
glucosamine and chondroitin therapy. Octotiamine (80) [91], a vitamin B1 derivative 
also exhibits anti-inflammatory activity. Proquazone (81) [92], a condensed 
pyrimidin-2-one derivative has been reported to exhibit good NSAID potential. 
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2.2.14 Metabolic electrolytes 
Orotic acid (82) [93], a simple pyrimidine derivative and its mineral forms are used in 
metabolic therapy, especially for cardiovascular patients to prevent heart failure in 
cardiomyopathy. Oroate is needed as a key intermediate in biosynthesis of pyrimidine 
nucleotides, which are building blocks for DNA and RNA required for the final 
protein synthesis. 
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2.3 Conclusion 
Pyrimidines occupy a distinct and unique place in our life. This heterocyclic moiety 
has great biological and medicinal significance. A large array of pyrimidine drugs 
possesses a variety of medicinal properties. These properties include anticancer, 
antibacterial, antiprotozoal, antimicrobial, antiviral, antihypertensive, antihistaminic, 
anti-inflammatory, analgesic, CNS-active to metabolic adjuvant. 
 Keeping in mind various biomedical applications and with a view to further 
assess the pharmacological profile of bi/tricyclic aromatic heterocycles related to 
pyrimidines, three different heterocyclic scaffolds related to pyrimidines (thieno[2,3-
d]pyrimidines, 1,2,4-triazolo[1,5-a]pyrimidines and pyrazolo[3,4-d][1,2,4]triazolo 
[1,5-a]pyrimidines) have been synthesized in the framework of this doctoral thesis. 
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 Chapter 3 
 Synthesis and biological evaluation of     
 thieno[2,3-d]pyrimidines     
 
3.1 Introduction 
Fused pyrimidines continue to attract considerable attention of researchers in different 
countries because of their great practical usefulness, primarily, due to a very wide 
spectrum of their biological activities. Thienopyrimidines occupy a special position 
among these compounds. Along with some other pyrimidine systems containing an 
annelated five membered hetero aromatic ring, thienopyrimidines are structural 
analogues of biogenic purines and can be considered as potential nucleic acid 
antimetabolites. 
There are three isomeric thienopyrimidines corresponding to the three possible 
types of annulation of thiophene to the pyrimidine ring: thieno[2,3-d]pyrimidine (1), 
thieno[3,4-d]pyrimidine (2), and thieno[3,2-d]pyrimidine (3). 
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From the standpoint of biological activity, fused heteroaromatic systems are 
often of much greater interest than the constituent monocyclic compounds. 
Antiallergic [1], antiatherosclerotic [2], antibacterial [3], antidepressive [4], 
antidiabetic [5], antihypertensive [6], antihistaminic [7], analgesic and anti-
inflammatory [8], antiviral [9] and spasmolytic [10] activities have been reported for 
certain thienopyrimidine derivatives. Some examples of published derivatives of 
thienopyrimidine with their biological activities are as following. 
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The similarity between the physicochemical properties of benzene and 
thiophene is striking. For example, the boiling point of benzene is 81.1 °C and the one  
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of thiophene is 84.4 °C (at 760 mm Hg) and therefore, thiophene and benzene is a 
well known example of bioisosterism. The change of a benzene moiety into a 
thiophene often results in superior pharmacodynamic, pharmacokinetic, or 
toxicological properties. For example, the thiophene analogue of piroxicam (a non-
steroidal anti-inflammatory agent used in arthritis patients) has the same biological 
activity, with the same mechanism of action as piroxicam, and even displayed a 
longer plasma half-life than piroxicam [17]. Thiophene isosteres of mianserin (a 
tetracyclic antidepressive agent) also act as serotonin receptor (5-HT) antagonists (16 
and 17) [18]. 
 
S
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OO CH3
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N
H
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OO CH3
S
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N
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N
N
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Thiophene isosteres of piroxicam and mianserin
 
 
The exchange of a phenyl ring by a thiophene ring in bicyclic derivatives can 
generate three regioisomers. For example, Blair and co-workers described the 
replacement of the phenyl ring of N,N-dimethyltryptamine (18) by a thiophene moiety,  
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giving rise to  three isomers: thieno[3,2-b]pyrrole (19), thieno[2,3-b]pyrrole (20) and 
thieno[3,4-b]pyrrole (21) [19]. Biological evaluation demonstrated that both 
thieno[3,2-b]pyrrole and thieno[2,3-b]pyrrole showed similar activity as the parent 
indole analogue, and whereas thieno[3,4-b]pyrrole lost activity. 
As a logical consequence of thiophene – phenyl isosterism, thienopyrimidines 
(23, 24 and 25) can be considered as bioisosteres of quinazolines (22), which are 
extensively described in scientific and patent literature as displaying a plethora of 
biological activities. The synthesis of thienopyrimidine derivatives as potential 
surrogates for the quinazoline core structure has therefore become a routine strategy 
in modern drug design and development. 
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N
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S N
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(22) Quinazoline (23)
Thieno[d]pyrimidines
(24) (25)
Thienopyrimidines as isosteres of quinazolines
 
 
Thienopyrimidines (29) can also be considered as structural analogues of five-
membered heterocycles such as purines (26) and thiazolopyrimidines (27) and (28).  
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7H-purine thiazolo[5,4-d]pyrimidine thiazolo[4,5-d]pyrimidine thieno[2,3-d]pyrimidine
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3.2 Reported synthetic strategies 
Synthetic approaches towards thienopyrimidines can be divided into two main groups 
according to the type of starting material. Either, the synthesis starts from a 
pyrimidine derivative and a thiophene ring is then constructed, or a thiophene 
analogue is used as starting material, followed by the formation of a pyrimidine ring 
(30). 
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Thieno[d]pyrimidines
(30) Retrosynthetic analysis of thienopyrimidines
 
 
3.2.1 Synthesis of thienopyrimidines from a thiophene moiety 
For the synthesis of thienopyrimidines from a thiophene moiety, an appropriately 
substituted aminothiophene serves as the starting material. 2-aminothiophene 
derivatives, which are the starting materials for thieno[2,3-d]pyrimidines, can be 
easily synthesized by Gewald reaction [20]. The first step of this multicomponent 
reaction is the Knoevenagel-Cope condensation of carbonyl compound (ketone or 
aldehyde) with an activated nitrile (α-cyanoester), yielding an α,β–unsaturated nitrile. 
This intermediate is then thiolated at the methylene group by elemental sulfur, 
followed by an intramolecular cyclization yielding a polysubstituted-2-
aminothiophene (Scheme 3.1). 
 
R
O
R' + NC
O
OR'' -H2O OR''
O R'
R
S8
S
R'
RH2N
O
OR''
Scheme 3.1
N
 
 
The Thorpe-Ziegler reaction is one of the most efficient methods for the 
synthesis of 5-membered heterocycles containing an amino group at C-3 position [21]. 
3-aminothiophene derivatives are useful building blocks for the construction of 
thieno[3,2-d]pyrimidines and thieno[3,4-d]pyrimidines.   
 
S
NH2
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X
CNX
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CNX
SR Y
Y = electronwithdrawing grroup
X = COX or CN or H
Scheme 3.2
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The alkylthio olefin intermediates, generated by the reaction of vic-
cyanodimethylaminoethylenes or vic-bromocyanoethylenes or cyanoacetylenes [22] 
with mercapto compounds of general formula HSCH2Y (Y is an electron withdrawing 
group) in the presence of base, undergo a Thorpe-Ziegler cyclization yielding 
polysubstituted 3-aminothiophenes.  
The construction of a pyrimidine ring system from a 2-amino- or 3-amino-
thiophene derivative follows the same reaction sequence. One of the most popular 
approaches to construct the pyrimidine ring is via the synthesis of thienylureas or 
thienylthioureas. In a first step, the amino group of the thiophene moiety is converted 
into a urea by treatment with an isocyanate [23], potassium cyanate hydrochloride 
[24], or chlorosulfonyl isocyanate [25] and into a thiourea by reaction with an 
isothiocyanate [26], or thiophosgene and an amine [27]. The resulting thienylureas 
and thienylthioureas readily undergo an intramolecular cyclization upon treatment 
with bases or acids to afford thienopyrimidines (Scheme 3.3). 
 
X
H2N
A
X
N
H
A
Y
NHR
N
H
A
Y
N
R
Z
A : Thiophene ring
X = CO2Et or CN
Y = O or S
Scheme 3.3
Y = O or S
Z = O or NH
 
 
The synthesis of thienopyrimidin-4(3H)-ones is well studied and can be 
categorized into 4 groups according to the functional groups on the thiophene moiety 
and the structures of the intermediates (Scheme 3.4). 
 
(1) Thienopyrimidinones can be prepared via cyclization of diamides 
intermediates, which are generated from vic-aminocarbamoylthiophenes by 
reaction with acylating agents such as orthoesters [28], acid anhydrides and 
acid chlorides [29], formic acid [30] and diethyl oxalate [31]. 
(2) Alternatively, the synthesis of thienopyrimidinones can be achieved from vic-
aminoalkoxycarbonylthiophenes. Amidine intermediates, formed by the 
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reaction of thiophenes with amides [32], nitrites under acidic conditions [33], 
orthoesters and amines [34], undergo an intramolecular cyclization to afford 
thienopyrimidinones. 
(3) A third procedure is based on the recyclization of thieno-oxazinones, which 
are generated by reaction of vic-aminocarboxylic acids or esters with acid 
chlorides or orthoesters [35]. The recyclization proceeds through the diamide 
intermediate which is generated upon treatment with amines [36]. 
(4) Vic-aminocyanothiophenes also serve as valuable starting materials for the 
synthesis of thienopyrimidinones. Initially, the thieno-oxazinimine interme 
diates are generated by the acylation of the amino group and then recyclization 
in the presence of an acid occurs to afford thienopyrimidinones [37]. 
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3.2.2 Synthesis of thienopyrimidines from a pyrimidine moiety 
Due to the poor availability of appropriately substituted pyrimidines, the synthesis of 
thienopyrimidines from pyrimidines is much less described in literature. In general,  
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thieno[2,3-d]pyrimidines and thieno[3,2-d]pyrimidines can be obtained by the 
intramolecular cyclization of pyrimidine (Scheme 3.5). This pyrimidine derivative can 
be obtained by the substitution of the mercaptoacetic acid residue for the chlorine [38].  
Alkylation of pyrimidinethiones with a chloroacetic acid derivative [39] is also 
a possibility. Depending on the substituents of the pyrimidine ring (X) and of 
mercapto side chain (Y), thienopyrimidines with a different substitution pattern on the 
thiophene moiety can be synthesized. When X = CO2R, 5-hydroxythieno 
pyrimidines (which exist predominantly as the oxo form) are formed. In case of X = 
CN, the Thorpe-Ziegler reaction, affords amino substituted pyrimidines. When X and 
Y are a ketone or an aldehyde, the Claisen-Schmidt condensation affords R 
substituted thienopyrimidines. 
 
Sceme 3.5
X
Cl
B
X
S
B
HSCH2Y
ClCH2Y
X
S
B
Y S
Z
Y
B
B: Pyrimidine ring
Y = Electron withdrawing group
X = CO2R, Z = OH
X = CN, Z = NH2
X = COR, Z = R
 
 
Alternatively, thienopyrimidines can be prepared by the reaction of vic-
chloroalkynylpyrimidines with sodium sulphide [40] (Scheme 3.6). The 
alkynylpyrimidines are obtained via a Sonogashira reaction. 
 
Sceme 3.6
SR
B
Cl
B
R
NaSH
 
  
Sigmatropic rearrangement is a useful method to construct 5-membered 
nitrogen and sulphur containing heterocycles [41]. The thio-Claisen rearrangement of 
propargylic sulfides affords thienopyrimidines via an allene intermediate followed by 
tautomerization, which then ring closes yielding the thiophene analogue [42] (Scheme  
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3.7). Another approach of sigmatropic rearrangement involves the oxidation of sulfide 
to sulfoxide. The sulfoxide undergoes an initial [2,3] sigmatropic rearrangement to 
generate the allene intermediate which then undergoes a Claisen-like [3,3] 
sigmatropic rearrangement through the S-O bond, followed by tautomerization to 
produce intermediate. An intramolecular Michael type addition followed by 
aromatization gives access to the desired thienopyrimidines. 
 
S
B [3, 3]
HS
B
C
H2C
S
B
S
B
R
S
B
R
O
[2, 3]
S
O
B
RC
H2C
[3, 3]
HS
B
H2C
OR
[O]
S
B
R
O
Scheme 3.7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                 Thieno[2,3-d]pyrimidines  
   
   39
3.3 Current work 
The chemistry of pyrimidines and its derivatives has been studied for over a century 
due to their diverse biological activities. Due to formal isoelectronic relationship with 
purines, the thieno[2,3-d]pyrimidine ring system is of special biological interest. It has 
numerous pharmacological and medicinal applications viz, antitumour, immunodilator, 
tuberculostic, antiallergic and radioprotective.  
Keeping in mind various biomedical applications and with a view to further 
assess the pharmacological profile of these class of compounds, three novel series of 
thieno[2,3-d]pyrimidines (ART-111 to ART-130) are synthesized. The synthesis of 
thieno[2,3-d]pyrimidines (ART-111 to ART-130) was achieved by acid catalysed 
cyclocondensation of polysubstituted 2-aminothiophenes (ART-101 to ART-110) 
with formic acid, gl. acetic acid and trifluoroacetic acid, respectively. Polysubstituted 
2-aminothiophenes were prepared via the Gewald reaction [43]. The products were 
characterized by FT-IR, mass spectra, 1H NMR and elemental analysis. The newly 
synthesized compounds were subjected to various biological activities viz., 
antimicrobial, antimycobacterial, anticancer and antiviral. 
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3.4 Reaction scheme 
NH
OCH3
O
+
N
N
R1
ART- 101 TO 110
a
b
Reagents and conditions: (a) K2CO3, EtOH, Stirring, 14-16 h; (b) Conc. H2SO4, 
R2COOH, reflux, 12-17 h.
S
CH3
O
NH
CN
NH2R1
ART- 101 TO 110
S
CH3
O
NH
CN
NH2R1
S
CH3
O
NH
R1
N
NH
O
ART- 111 TO 140
+ S8
R2
 
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
ART-101 H - C13H11N3OS 257 156-158 64 0.46 0.67 
ART-102 4-OCH3 - C14H13N3O2S 287 203-205 69 0.48 0.70 
ART-103 2-OCH3 - C14H13N3O2S 287 221-223 63 0.52 0.73 
ART-104 4-NO2 - C13H10N4O3S 302 179-181 72 0.54 0.75 
ART-105 2,5-CH3 - C15H15N3OS 285 182-184 79 0.46 0.68 
ART-106 4-Cl - C13H10ClN3OS 291 199-201 73 0.51 0.71 
ART-107 3-Cl - C13H10ClN3OS 291 181-183 65 0.56 0.75 
ART-108 4-F - C13H10FN3OS 275 254-256 51 0.50 0.65 
ART-109 2-F - C13H10FN3OS 275 153-155 58 0.58 0.68 
ART-110 3-CF3 - C14H10F3N3OS 325 223-225 62 0.48 0.77 
ART-111 H H C14H11N3O2S 285 128-130 68 0.53 0.61 
ART-112 4-OCH3 H C15H13N3O3S 315 241-243 74 0.58 0.67 
ART-113 2-OCH3 H C15H13N3O3S 315 178-180 70 0.49 0.58 
ART-114 4-NO2 H C14H10N4O4S 330 239-241 80 0.53 0.60 
ART-115 2,5-CH3 H C16H15N3O2S 313 256-258 69 0.59 0.70 
ART-116 4-Cl H C14H10ClN3O2S 319 263-265 56 0.51 0.59 
ART-117 3-Cl H C14H10ClN3O2S 319 229-231 63 0.54 0.61 
ART-118 4-F H C14H10FN3O2S 303 234-236 68 0.56 0.63 
ART-119 2-F H C14H10FN3O2S 303 173-175 52 0.48 0.57 
ART-120 3-CF3 H C15H10F3N3O2S 353 238-240 50 0.58 0.68 
ART-121 H CH3 C15H13N3O2S 299 208-210 68 0.49 0.57 
ART-122 4-OCH3 CH3 C16H15N3O3S 329 243-245 78 0.51 0.63 
ART-123 2-OCH3 CH3 C16H15N3O3S 329 253-255 70 0.54 0.65 
ART-124 4-NO2 CH3 C15H12N4O4S 344 237-239 78 0.48 0.56 
ART-125 2,5-CH3 CH3 C17H17N3O2S 327 261-263 66 0.56 0.60 
ART-126 4-Cl CH3 C15H12ClN3O2S 333 265-267 71 0.52 0.65 
ART-127 3-Cl CH3 C15H12ClN3O2S 333 223-225 59 0.54 0.67 
ART-128 4-F CH3 C15H12FN3O2S 317 270-272 74 0.51 0.64 
ART-129 2-F CH3 C15H12FN3O2S 317 261-263 59 0.49 0.57 
ART-130 3-CF3 CH3 C16H12F3N3O2S 367 256-258 60 0.53 0.61 
ART-131 H CF3 C15H10F3N3O2S 353 192-194 59 0.55 0.63 
ART-132 4-OCH3 CF3 C16H12F3N3O3S 383 198-200 68 0.53 0.65 
ART-133 2-OCH3 CF3 C16H12F3N3O3S 383 188-190 65 0.49 0.69 
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ART-134 4-NO2 CF3 C15H9F3N4O4S 398 118-120 74 0.56 0.66 
ART-135 2,5-CH3 CF3 C17H14F3N3O2S 381 194-196 76 0.58 0.62 
ART-136 4-Cl CF3 C15H9ClF3N3O2S 387 108-110 68 0.54 0.60 
ART-137 3-Cl CF3 C15H9ClF3N3O2S 387 261-263 72 0.50 0.68 
ART-138 4-F CF3 C15H9F4N3O2S 371 242-244 61 0.52 0.67 
ART-139 2-F CF3 C15H9F4N3O2S 371 250-252 63 0.56 0.65 
ART-140 3-CF3 CF3 C16H9F6N3O2S 421 131-133 59 0.58 0.64 
 
TLC Solvent system Rf1: Hexane: Ethyl acetate – 6:4,  
TLC Solvent system Rf2: Chloroform:Methanol – 9:1.  
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3.5 Mechanism 
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It is likely that the first step of reaction is Knoevenagel-cope condensation of a 
carbonyl compound with activated nitrile yielding an α,β-unsaturated nitrile. This 
intermediate is then thiolated at the methylene group by electrophilic elemental 
sulphur, following by ring closure to afford thiophene derivatives (step-1).  
 Polysubstituted 2-aminothiophenes obtained from first step are cyclised to 
thienopyrimidines via formation of two intermediates as per mechanism suggested by 
S. Hesse et al. [44] (step-2). 
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3.6 Experimental 
 
3.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer. Elemental analysis of the all the synthesized compounds was carried out 
on Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
with the structures assigned. 
 
3.6.2 Synthesis of N-(aryl)-3-oxobutanamides 
 
Synthesis of N-(aryl)-3-oxobutanamides was achieved using previously published 
methods [45]. 
 
3.6.3 General procedure for the synthesis of 5-amino-4-cyano-N-(aryl)-3-
methylthiophene-2-carboxamides (ART 101-110) 
 
0.01 mol of an appropriate N-(aryl)-3-oxobutanamide was dissolved in 10 mL of 
EtOH and 0.01 mol each of malononitrile and powdered sulphur were added to the 
same solution. 1 gm of K2CO3 was added to the resulting solution as inorganic basic 
support. The heterogeneous mixture was stirred at room temperature for 14-16 h. 
After the completion of the reaction as monitored by TLC, the reaction mixture was 
filtered off to separate K2CO3 as residue and the filtrate was poured onto 50 mL of 
ice-cold water. The product got precipitated out, which was filtered and recrystallized 
from methanol. 
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3.6.3.1 5-amino-4-cyano-N-(phenyl)-3-methylthiophene-2-carboxamide (ART-101) 
Yield: 64%; mp 156-158 ºC; MS: m/z 257; Anal. 
Calcd. for C13H11N3OS: C, 60.68; H, 4.31; N, 
16.33. Found: C, 60.55; H, 4.20; N, 16.21 
 
3.6.3.2 5-amino-4-cyano-N-(4-methoxyphenyl)-3-methylthiophene-2-carboxamide  
(ART-102) Yield: 69%; mp 203-205 ºC; IR 
(cm-1): 3397 and 3335 (N-H stretching of 
primary amine), 3221 (N-H stretching of 
amide), 3032 (C-H stretching of aromatic ring), 
2985 (C-H asymmetrical stretching of CH3 
group), 2837 (C-H symmetrical stretching of CH3 group), 2210 (C≡N stretching of 
nitrile group), 1701 (C=O stretching of amide), 1616 (N-H deformation of NH2 
group), 1548, 1494 and 1440 (C=C stretching of aromatic ring), 1408 (C-H 
asymmetrical deformation of CH3 group), 1336 (C-H symmetrical deformation of CH3 
group), 1238 (C-O-C stretching), 700 (C-S-C stretching); 1H NMR (DMSO-d6) δ 
ppm: 2.42 (s, 3H, Ha), 3.76 (s, 3H, Hb), 6.80-6.83 (d, 2H, Hcc’, J = 8.96 Hz), 7.28 (s, 
2H, Hd) 7.48-7.51 (d, 2H, Hee’, J = 8.92 Hz), 9.10 (s, 1H, Hf); MS: m/z 287; Anal. Calcd. 
for C14H13N3O2S: C, 58.52; H, 4.56; N, 14.62. Found: C, 58.49; H, 4.30; N, 14.48%. 
 
3.6.3.3 5-amino-4-cyano-N-(2-methoxyphenyl)-3-methylthiophene-2-carboxamide  
(ART-103) Yield: 63%; mp 221-223 ºC; IR (cm-1): 
3427 and 3323 (N-H stretching of primary amine), 
3213 (N-H stretching of amide), 3020 (C-H 
stretching of aromatic ring), 2964 (C-H 
asymmetrical stretching of CH3 group), 2839 (C-H 
symmetrical stretching of CH3 group), 2206 (C≡N stretching of nitrile group), 1701 (C=O 
stretching of amide), 1620 (N-H deformation of NH2 group), 1539, 1500 and 1494 (C=C 
stretching of aromatic ring), 1410 (C-H asymmetrical deformation of CH3 group), 1344 (C-H 
symmetrical deformation of CH3 group), 1251 (C-O-C stretching), 740 (C-S-C stretching): 1H 
NMR (DMSO-d6) δ ppm: 2.49 (s, 3H, Ha), 3.91 (s, 3H, Hb), 6.89-6.97 (m, 2H, Hcd), 7.02-7.06 (t, 
1H, He), 7.48 (s, 2H, Hf), 8.18 (s, 1H, Hg), 8.20 (d, 1H, Hh); MS: m/z 287; Anal. Calcd. for 
C14H13N3O2S: C, 58.52; H, 4.56; N, 14.62. Found: C, 58.49; H, 4.30; N, 14.48%. 
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3.6.3.4 5-amino-4-cyano-N-(4-nitrophenyl)-3-methylthiophene-2-carboxamide 
(ART-104) Yield: 72%; mp 179-181 ºC; MS: 
m/z 302; Anal. Calcd. for C13H10N4O3S: C, 
51.65; H, 3.33; N, 18.53. Found: C, 51.55; H, 
3.39; N, 18.25%. 
 
3.6.3.5 5-amino-4-cyano-N-(2,5-methylphenyl)-3-methylthiophene-2-carboxamide  
(ART-105) Yield: 79%; mp 182-184 ºC; IR  
(cm-1):  3331 and 3300 (N-H stretching of 
primary amine), 3184 (N-H stretching of amide), 
3025 (C-H stretching of aromatic ring), 2978 
(C-H asymmetrical stretching of CH3 group), 
2914 (C-H symmetrical stretching of CH3 group), 2208 (C≡N stretching of nitrile 
group), 1701 (C=O stretching of amide), 1627 (N-H deformation of NH2 group), 1527, 
1491 and 1446 (C=C stretching of aromatic ring), 1410 (C-H asymmetrical 
deformation of CH3 group), 1319 (C-H symmetrical deformation of CH3 group), 717 
(C-S-C stretching); 1H NMR (DMSO-d6) δ ppm: 2.18 (s, 3H, Ha), 2.25 (s, 3H, Hb), 
2.47 (s, 3H, Hc), 6.89-6.91 (d, 1H, Hd), 7.06-7.08 (d, 1H, He), 7.34 (s, 1H, Hf), 8.32 (s, 
1H, Hg); MS: m/z 285; Anal. Calcd. for C15H15N3OS: C, 63.13; H, 5.30; N, 14.73. 
Found: C, 63.03; H, 5.19; N, 14.62%. 
 
3.6.3.6 5-amino-4-cyano-N-(4-chlorophenyl)-3-methylthiophene-2-carboxamide  
(ART-106) Yield: 73%; mp 199-201 ºC; MS: 
m/z 291; Anal. Calcd. for C13H10ClN3OS: C, 
53.52; H, 3.45; N, 14.40. Found: C, 53.46; H, 
3.29; N, 14.30%. 
 
3.6.3.7 5-amino-4-cyano-N-(3-chlororphenyl)-3-methylthiophene-2-carboxamide  
 (ART-107) Yield: 65%; mp 181-183 ºC; MS: 
m/z 291; Anal. Calcd. for C13H10ClN3OS: C, 
53.52; H, 3.45; N, 14.40. Found: C, 53.44; H, 
3.30; N, 14.32%. 
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3.6.3.8 5-amino-4-cyano-N-(4-fluorophenyl)-3-methylthiophene-2-carboxamide  
(ART-108) Yield: 51%; mp 254-256 ºC; MS: 
m/z 275; Anal. Calcd. for C13H10FN3OS: C, 
56.72; H, 3.66; N, 15.26. Found: C, 56.62; H, 
3.59; N, 15.21%. 
 
3.6.3.9 5-amino-4-cyano-N-(2-fluorophenyl)-3-methylthiophene-2-carboxamide  
(ART-109) Yield: 58%; mp 153-155 ºC; MS: m/z 
275; Anal. Calcd. for C13H10FN3OS: C, 56.72; H, 
3.66; N, 15.26. Found: C, 56.65; H, 3.60; N, 
15.16%. 
 
3.6.3.10 5-amino-4-cyano-N-(3-trifluorophenyl)-3-methylthiophene-2-carboxamide           
 (ART-110) Yield: 62%; mp 223-225 ºC; MS: 
m/z 325; Anal. Calcd. for C14H10F3N3OS: C, 
51.69; H, 3.10; N, 12.92. Found: C, 51.52; H, 
3.03; N, 12.82%. 
 
3.6.4 General procedure for the synthesis of 3,4-dihydro-N-(aryl)-5-methyl-4-
oxothieno[2,3-d]pyrimidine-6-carboxamides (ART 111-120) 
 
A mixture of an appropriate 5-amino-4-cyano-N-(aryl)-3-methylthiophe ne-2-
carboxamide (0.01 mol) and formic acid (20 mL) was stirred under reflux for 12- 14 h. 
in the presence of catalytic amount of concentrated H2SO4 (under TLC analysis). The 
reaction mixture was allowed to cool to room temperature and was poured onto 
crushed ice. The solid thus formed was collected by filtration, washed with ethanol 
(20 mL), dried and crystallized from dimethylformamide to afford the desired 
products ART 111-120. 
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3.6.4.1 3,4-dihydro-N-(phenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6-carboxami 
de (ART-111) Yield: 68%; mp 128-130 ºC; 
MS: m/z 285; Anal. Calcd. for C14H11N3O2S: 
C, 58.93; H, 3.89; N, 14.73. Found: C, 58.56; 
H, 3.79; N, 14.66%.  
 
3.6.4.2 3,4-dihydro-N-(4-methoxyphenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6- 
carboxamide (ART-112) Yield: 74%; mp 
241-243 ºC; IR (cm-1): 3294 (N-H stretching 
of secondary amine), 3070 (C-H stretching of 
aromatic ring), 2962 (C-H asymmetrical 
stretching of CH3 group), 2897 (C-H 
asymmetrical stretching of OCH3 group), 2829 (C-H symmetrical stretching of CH3 
group), 1697 (C=O stretching of amide), 1660 (C=O stretching of pyrimidine ring), 
1624 (C=N stretching of pyrimidine ring), 1600 and 1537 (C=C stretching of aromatic 
ring), 1435 (C-H asymmetrical deformation of OCH3 group), 1415 (C-H asymmetrical 
deformation of CH3 group), 1296 (C-H symmetrical deformation of CH3 group), 1114 
(C-O-C stretching), 696 (C-S-C stretching); 1H NMR (DMSO-d6) δ ppm: 2.78 (s, 3H, 
Ha), 3.78 (s, 3H, Hb), 6.85-6.87 (d, 2H, Hcc’, J = 9.04 Hz), 7.59-7.61 (d, 2H, Hdd’, J = 
8.96 Hz), 8.02 (s, 1H, He), 9.87 (s, 1H, Hf), 12.45 (s, 1H, Hg); MS: m/z 315; Anal. 
Calcd. for C15H13N3O3S: C, 57.13; H, 4.16; N, 13.33. Found: C, 57.03; H, 4.09; N, 13.29%. 
 
3.6.4.3 3,4-dihydro-N-(2-methoxyphenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6-
carboxamide (ART-113) Yield: 70%; mp 
178-180 ºC; MS: m/z 315; Anal. Calcd. for 
C15H13N3O3S: C, 57.13; H, 4.16; N, 13.33. 
Found: C, 57.06; H, 4.10; N, 13.26%. 
 
3.6.4.4 3,4-dihydro-N-(4-nitrophenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6-car 
boxamide (ART-114) Yield: 80%; mp 239-
241 ºC; MS: m/z 330; Anal. Calcd. for 
C14H10N4O4S: C, 50.91; H, 3.05; N, 16.96. 
Found: C, 50.82; H, 2.99; N, 16.88%. 
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3.6.4.5 3,4-dihydro-N-(2,5-methylphenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6- 
carboxamide (ART-115) Yield: 69%; mp 256 
258 ºC; IR (cm-1): 3275 and 3244 (N-H 
stretching of secondary amine), 3022 (C-H 
stretching of aromatic ring), 2960 (C-H 
asymmetrical stretching of CH3 group), 2860 
(C-H asymmetrical stretching of CH3 group), 1691 (C=O stretching of amide), 1670 
(C=O stretching of pyrimidine ring), 1626 (C=N stretching of pyrimidine ring), 1577, 
1539 and 1485 (C=C stretching of aromatic ring), 1421 (C-H asymmetrical 
deformation of -CH3 group), 1313 (C-H symmetrical deformation of CH3 group), 694 
(C-S-C stretching); 1H NMR (DMSO-d6) δ ppm: 2.23 (s, 3H, Ha), 2.30 (s, 3H, Hb), 
2.82 (s, 3H, Hc), 6.95-6.97 (d, 1H, Hd), 7.10-7.12 (d, 1H, He), 7.23 (s, 1H, Hf), 8.05 (s, 
1H, Hg), 9.48 (s, 1H, Hh), 12.52 (s, 1H, Hi); MS: m/z 313; Anal. Calcd. for 
C16H15N3O2S: C, 61.32; H, 4.82; N, 13.41. Found: C, 61.25; H, 4.76; N, 13.31%. 
 
3.6.4.6 3,4-dihydro-N-(4-chlorophenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-
6-carboxamide (ART-116) Yield: 56%; mp 
263-265 ºC; IR (cm-1): MS: m/z 319; Anal. 
Calcd. for C14H10ClN3O2S: C, 52.59; H, 3.15; 
N, 13.14. Found: C, 52.50; H, 3.05; N, 13.07%. 
 
 
3.6.4.7 3,4-dihydro-N-(3-chlorophenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6-ca 
rboxamide (ART-117) Yield: 63%; mp 229-
231 ºC; 3259 (N-H stretching of secondary 
amine), 3066 (C-H stretching of aromatic ring), 
2937 (C-H asymmetrical stretching of CH3 
group), 2879 (C-H symmetrical stretching of 
CH3 group), 1680 (C=O stretching of amide), 
1658 (C=O stretching of pyrimidine ring), 1591 (C=N stretching of pyrimidine ring), 
1560, 1550 and 1502 (C=C stretching of aromatic ring), 1406 (C-H asymmetrical 
deformation of -CH3 group), 1313 (C-H symmetrical deformation of CH3 group), 692 
(C-S-C stretching); 1H NMR (DMSO-d6) δ ppm: 2.78 (s, 3H, Ha). 7.01-7.06 (t, 2H, 
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Hbb’), 7.69-7.72 (m, 2H, Hcc’), 8.00 (s, 1H, Hd), 10.00 (s, 1H, He), 12.43 (s, 1H, Hf); 
MS: m/z 319; Anal. Calcd. for C14H10ClN3O2S: C, 52.59; H, 3.15; N, 13.14. Found: C, 
52.49; H, 3.07; N, 13.03% 
 
3.6.4.8 3,4-dihydro-N-(4-fluorophenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6-ca 
rboxamide (ART-118) Yield: 68%; mp 234-236 
ºC; MS: m/z 303; Anal. Calcd. for C14H10FN3O2S: 
C, 55.44; H, 3.32; N, 13.85. Found: C, 55.36; H, 
3.24; N, 13.78%. 
 
3.6.4.9 3,4-dihydro-N-(2-fluorophenyl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6-ca 
rboxamide (ART-119) Yield: 52%; mp 173-175 
ºC; MS: m/z 303; Anal. Calcd. for C14H10FN3O2S: 
C, 55.44; H, 3.32; N, 13.85. Found: C, 55.32; H, 
3.26; N, 13.71%. 
 
3.6.4.10 3,4-dihydro-N-(3-trifluoromethylphenyl)-5-methyl-4-oxothieno[2,3-d]pyrim 
idine-6-carboxamide (ART-120) Yield: 50%; 
mp 238-240 ºC; MS: m/z 353; Anal. Calcd. For 
C15H10F3N3O2S: C, 50.99; H, 2.85; N, 11.89. 
Found: C, 50.90; H, 2.78; N, 11.79%. 
 
 
3.6.5 General procedure for the synthesis of 3,4-dihydro-N-(aryl)-2,5-dimethyl-4-
oxothieno[2,3-d]pyrimidine-6-carboxamides (ART 121-130) 
 
A mixture of an appropriate 5-amino-4-cyano-N-(aryl)-3-methylthiophe ne-2-
carboxamide (0.01 mol) and glacial acetic acid (20 mL) was stirred under reflux for 
14-16 h. in the presence of catalytic amount of concentrated H2SO4 (under TLC 
analysis). The reaction mixture was allowed to cool to room temperature and was 
poured onto crushed ice. The solid thus formed was collected by filtration, washed 
with ethanol (20 mL), dried and crystallized from dimethylformamide to  
afford the desired products ART 121-130. 
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3.6.5.1 3,4-dihydro-N-(phenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidine-6-carbox 
amide (ART-121) Yield: 68%; mp 208-210 ºC; 
MS: m/z 299; Anal. Calcd. for C15H13N3O2S: C,  
60.18; H, 4.38; N, 14.04. Found: C, 60.10; H, 
4.29; N, 13.99%. 
 
3.6.5.2 3,4-dihydro-N-(4-methoxyphenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidi- 
ne-6-carboxamide (ART-122) Yield: 78%; mp 
243-245 ºC; MS: m/z 329; Anal. Calcd. for 
C16H15N3O3S: C, 58.34; H, 4.59; N, 12.76. 
Found: C, 58.27; H, 4.51; N, 12.70%. 
 
 3.6.5.3 3,4-dihydro-N-(2-methoxyphenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidi- 
ne-6-carboxamide (ART-123) Yield: 70%; mp 
253-255 ºC; MS: m/z 329; Anal. Calcd. For 
C16H15N3O3S: C, 58.34; H, 4.59; N, 12.76. 
Found: C, 58.28; H, 4.49; N, 12.68%. 
 
 3.6.5.4 3,4-dihydro-N-(4-nitrophenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidine-6-
carboxamide (ART-124) Yield: 78%; mp 237-
239 ºC; MS: m/z 344; Anal. Calcd. For 
C15H12N4O4S: C, 52.32; H, 3.51; N, 16.27. 
Found: C, 52.23; H, 3.45; N, 16.19%. 
 
 
 3.6.5.5 3,4-dihydro-N-(2,5-methylphenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidine 
-6-carboxamide (ART-125) Yield: 66%; mp 
261-263 ºC; MS: m/z 327; Anal. Calcd. For 
C17H17N3O2S: C, 62.36; H, 5.23; N, 12.83. 
Found: C, 62.26; H, 5.12; N, 12.75%. 
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3.6.5.6 3,4-dihydro-N-(4-chlorophenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidine-
6-carboxamide (ART-126) Yield: 71%; mp 
265-267 ºC; MS: m/z 333; Anal. Calcd. For 
C15H12ClN3O2S: C, 53.97; H, 3.62; N, 12.59. 
Found: C, 53.88; H, 3.56; N, 12.51%. 
 
 
3.6.5.7 3,4-dihydro-N-(3-chlorophenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidine-
6-carboxamide (ART-127) Yield: 59%; mp 
223-225 ºC; MS: m/z 333; Anal. Calcd. For 
C15H12ClN3O2S: C, 53.97; H, 3.62; N, 12.59. 
Found: C, 53.89; H, 3.58; N, 12.49%. 
 
 
3.6.5.8 3,4-dihydro-N-(4-fluorophenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidine-
6-carboxamide (ART-128) Yield: 74%; mp  
270-272 ºC; IR (cm-1): 3298 (N-H stretching of 
secondary amine), 3066 (C-H stretching of 
aromatic ring), 2960 (C-H asymmetrical 
stretching of CH3 group), 2833 (C-H 
symmetrical stretching of CH3 group), 1685 (C=O stretching of amide), 1643 (C=O 
stretching of pyrimidine ring), 1608 (C=N stretching of pyrimidine ring), 1548, 1518 
and 1502 (C=C stretching of aromatic ring), 1404 (C-H asymmetrical deformation of 
-CH3 group), 1311 (C-H symmetrical deformation of CH3 group), 700 (C-S-C 
stretching); 1H NMR (DMSO-d6) δ ppm: 2.41 (s, 3H, Ha), 2.76 (s, 3H, Hb), 7.02-7.08 
(t, 2H, Hcc’), 7.68-7.72 (q, 2H, Hdd’), 10.02 (s, 1H, He), 12.40 (s, 1H, Hf) ; MS: m/z 
317; Anal. Calcd. for C15H12FN3O2S: C, 56.77; H, 3.81; N, 13.24. Found: C, 56.69; H, 
3.73; N, 13.18%. 
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3.6.5.9 3,4-dihydro-N-(2-fluorophenyl)-2,5-dimethyl-4-oxothieno[2,3-d]pyrimidine 
-6-carboxamide (ART-129) Yield: 59%; mp 
261-263 ºC; IR (cm-1): 3282 (N-H stretching of 
secondary amine), 3070 (C-H stretching of 
aromatic ring), 2885 (C-H asymmetrical 
stretching of CH3 group), 2729 (C-H 
symmetrical stretching of CH3 group), 1697 (C=O stretching of amide), 1639 (C=O 
stretching of pyrimidine ring), 1597 (C=N stretching of pyrimidine ring), 1539, 1487 
and 1454 (C=C stretching of aromatic ring), 1420 (C-H asymmetrical deformation of 
-CH3 group), 1332 (C-H symmetrical deformation of CH3 group), 657 (C-S-C 
stretching); 1H NMR (DMSO-d6) δ ppm: 2.44 (s, 3H, Ha), 2.87 (s, 3H, Hb), 7.15-7.18 
(m, 3H, Hc-e), 7.90-7.92 (m, 1H, Hf), 9.15 (s, 1H, Hg), 12.41 (s, 1H, Hh) ; MS: m/z 317; 
Anal. Calcd. for C15H12FN3O2S: C, 56.77; H, 3.81; N, 13.24. Found: C, 56.68; H, 3.71; 
N, 13.16%. 
 
3.6.5.10 3,4-dihydro-N-(3-trifluoromethylphenyl)-2,5-dimethyl-4-oxothieno[2,3-d] 
pyrimidine-6-carboxamide (ART-130) Yield:     
60%; mp 256-258 ºC; IR (cm-1): 3408 and 3308 
(N-H stretching of secondary amine), 3066 (C-
H stretching of aromatic ring), 2956 (C-H 
asymmetrical stretching of CH3 group), 2891 
(C-H symmetrical stretching of CH3 group), 1718 (C=O stretching of amide), 1641 
(C=O stretching of pyrimidine ring), 1593 (C=N stretching of pyrimidine ring), 1537 
and 1518 (C=C stretching of aromatic ring), 1410 (C-H asymmetrical deformation of 
-CH3 group), 1320 (C-H symmetrical deformation of CH3 group), 686 (C-S-C 
stretching); 1H NMR (DMSO-d6) δ ppm: 2.43 (s, 3H, Ha), 2.80 (s, 3H, Hb), 7.35-7.37 
(d, 1H, Hc), 7.47-7.51 (t, 1H, Hd), 7.93-7.95 (d, 1H, He), 8.14 (s, 1H, Hf), 10.24 (s, 
1H, Hg), 12.41 (s, 1H, Hh); MS: m/z 367; Anal. Calcd. for C16H12F3N3O2S: C, 52.31; 
H, 3.29; N, 11.44. Found: C, 52.22; H, 3.20; N, 11.36%. 
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3.6.6 General procedure for the synthesis of 2-(trifluoromethyl)-3,4-dihydro-N-
(aryl)-5-methyl-4-oxothieno[2,3-d]pyrimidine-6-carboxamides (ART 131-140) 
 
A mixture of an appropriate 5-amino-4-cyano-N-(aryl)-3-methylthiophe-2-carbo 
xamide (0.01 mol) and trifluoroacetic acid (20 mL) was stirred under reflux for 15-17 
h. in the presence of catalytic amount of Concentrated H2SO4 (under TLC analysis). 
The reaction mixture was allowed to cool to room temperature and was poured onto 
water (100 mL). The solid thus formed was collected by filtration, washed with 
ethanol (20 mL), dried and crystallized from dimethylformamide to afford the desired 
products ART 131-140. 
 
3.6.6.1 2-(trifluoromethyl)-3,4-dihydro-N-(phenyl)-5-methyl-4-oxothieno[2,3-d]pyri 
midine-6-carboxamide (ART-131) Yield: 
59%; mp 192-194 ºC; MS: m/z 353; Anal. 
Calcd. For C15H10F3N3O2S: C, 50.99; H, 2.85; 
N, 11.89. Found: C, 50.90; H, 2.76; N,  
                                                                11.81%. 
 
3.6.6.2 2-(trifluoromethyl)-3,4-dihydro-N-(4-methoxyphenyl)-5-methyl-4-oxothieno 
[2,3-d]pyrimidine-6-carboxamide (ART-132)   
Yield: 68%; mp 198-200 ºC; IR (cm-1): 3292 
(N-H  stretching of secondary amine), 3103 
(C-H stretching of aromatic ring), 2999 (C-H 
asymmetrical stretching of CH3 group), 2869 
(C-H asymmetrical stretching of OCH3 group), 2837 (C-H symmetrical stretching of 
CH3 group), 1720 (C=O stretching of amide), 1647 (C=O stretching of pyrimidine 
ring), 1629 (C=N stretching of pyrimidine ring), 1580 and 1532 (C=C stretching of 
aromatic ring), 1458 (C-H asymmetrical deformation of OCH3 group), 1404 (C-H 
asymmetrical deformation of CH3 group), 1290 (C-H symmetrical deformation of CH3 
group), 1166 (C-O-C stretching), 705 (C-S-C stretching); 1H NMR (DMSO-d6) δ 
ppm: 2.68 (s, 3H, Ha), 3.77 (s, 3H, Hb), 6.84-6.86 (d, 2H, Hcc’, J = 9.00 Hz), 7.57-7.59 
(d, 2H, Hdd’, J = 8.96 Hz), 9.84 (s, 1H, He), 13.61 (s, 1H, Hf) ; MS: m/z 383; Anal. 
Calcd. for C16H12F3N3O3S: C, 50.13; H, 3.16; N, 10.96. Found: C, 50.06; H, 3.09; N, 10.90%. 
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3.6.6.3 2-(trifluoromethyl)-3,4-dihydro-N-(2-methoxyphenyl)-5-methyl-4-oxothieno 
[2,3-d]pyrimidine-6-carboxamide (ART-133) 
Yield: 65%; mp 188-190 ºC; MS: m/z 383; 
Anal. Calcd. for C16H12F3N3O3S: C, 50.13; H, 
3.16; N, 10.96. Found: C, 50.05; H, 3.05; N, 
10.92%. 
 
3.6.6.4 2-(trifluoromethyl)-3,4-dihydro-N-(4-nitrophenyl)-5-methyl-4-oxothieno[2,3 
-d]pyrimidine-6-carboxamide (ART-134) 
Yield: 74%; mp 118-120 ºC; MS: m/z 398; 
Anal. Calcd. for C15H9F3N4O4S: C, 45.23; H, 
2.28; N, 14.07. Found: C, 45.18; H, 2.19; N, 
13.99%. 
 
3.6.6.5 2-(trifluoromethyl)-3,4-dihydro-N-(2,5-methylphenyl)-5-methyl-4-oxothieno 
[2,3-d]pyrimidine-6-carboxamide (ART-135) 
Yield: 76%; mp 194-196 ºC; IR (cm-1): 3300 
and 3223 (N-H stretching of secondary amine), 
3020 (C-H stretching of aromatic ring), 2874 
(C-H asymmetrical stretching of CH3 group), 
2820 (C-H asymmetrical stretching of CH3 group), 1707 (C=O stretching of amide), 
1647 (C=O stretching of pyrimidine ring), 1626 (C=N stretching of pyrimidine ring), 
1556, 1529 and 1504 (C=C stretching of aromatic ring), 1400 (C-H asymmetrical 
deformation of -CH3 group), 1301 (C-H symmetrical deformation of CH3 group), 659 
(C-S-C stretching); 1H NMR (DMSO-d6) δ ppm: 2.21 (s, 3H, Ha), 2.29 (s, 3H, Hb), 
2.70 (s, 3H, Hc), 6.94-7.24 (m, 3H, Hd-f), 9.42 (s, 1H, Hg), 13.42 (s, 1H, Hh); MS: m/z 
381; Anal. Calcd. for C17H14F3N3O2S: C, 53.54; H, 3.70; N, 11.02. Found: C, 53.47; 
H, 3.69; N, 10.94%. 
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3.6.6.6 2-(trifluoromethyl)-3,4-dihydro-N-(4-chlorophenyl)-5-methyl-4-oxothieno[2, 
3-d]pyrimidine-6-carboxamide (ART-136) 
Yield: 68%; mp 108-110 ºC; MS: m/z 387; Anal. 
Calcd. for C15H9ClF3N3O2S: C, 46.46; H, 2.34; N, 
10.84. Found: C, 46.39; H, 2.27; N, 10.75%. 
 
 
3.6.6.7 2-(trifluoromethyl)-3,4-dihydro-N-(3-chlorophenyl)-5-methyl-4-oxothieno[2, 
3-d]pyrimidine-6-carboxamide (ART-137) 
Yield: 72%; mp 261-263 ºC; MS: m/z 387; Anal 
Calcd. for C15H9ClF3N3O2S: C, 46.46; H, 2.34; N, 
10.84. Found: C, 46.70; H, 2.26; N, 10.77%. 
 
 
3.6.6.8 2-(trifluoromethyl)-3,4-dihydro-N-(4-fluorophenyl)-5-methyl-4-oxothieno[2, 
3-d]pyrimidine-6-carboxamide (ART-138) 
Yield: 61%; mp 242-244 ºC; MS: m/z 371; 
Anal. Calcd. for C15H9F4N3O2S: C, 53.97; H, 
3.62; N, 12.59. Found: C, 53.89; H, 3.58; N, 
12.49%. 
 
3.6.6.9 2-(trifluoromethyl)-3,4-dihydro-N-(2-fluorophenyl)-5-methyl-4-oxothieno[2, 
3-d]pyrimidine-6-carboxamide (ART-139) 
Yield: 63%; mp 250-252 ºC; MS: m/z 371; 
Anal. Calcd. for C15H9F4N3O2S: C, 53.97; H, 3.6; 
N, 2.59. Found: C, 53.90; H, 3.56; N, 12.50%. 
 
3.6.6.10 2-(trifluoromethyl)-3,4-dihydro-N-(3-trifluoromethylphenyl)-5-methyl-4-ox 
othieno[2,3-d]pyrimidine-6-carboxamid (ART 
-140) Yield: 59%; mp 131-133 ºC; IR (cm-1): 
3387 and 3300 (N-H stretching of secondary 
amine), 3026 (C-H stretching of aromatic ring), 
2991 (C-H asymmetrical stretching of CH3 
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group), 2897 (C-H symmetrical stretching of CH3 group), 1720 (C=O stretching of 
amide), 1647 (C=O stretching of pyrimidine ring), 1564 (C=N stretching of 
pyrimidine ring), 1492 and 1450 (C=C stretching of aromatic ring), 1400 (C-H 
asymmetrical deformation of CH3 group), 1334 (C-H symmetrical deformation of CH3 
group), 696 (C-S-C stretching). 1H NMR (DMSO-d6) δ ppm: 2.73 (s, 3H, Ha), 7.34-
7.36 (d, 1H, Hb), 7.44-7.48 (t, 1H, Hc), 7.93-7.95 (d, 1H, Hd), 8.09 (s, 1H, He), 10.10 
(s, 1H, Hf), 13.60 (s, 1H, Hg); MS: m/z 421; Anal. Calcd. for C16H9F6N3O2S: C, 45.61; 
H, 2.15; N, 9.97. Found: C, 45.55; H, 2.06; N, 9.89%. 
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3.7 Spectral discussion 
3.7.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
3.7.1.1 Mass fragmentation pattern for ART-102 
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3.7.1.2 Mass fragmentation pattern for ART-112 
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3.7.1.3 Mass fragmentation pattern for ART-128 
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3.7.1.4 Mass fragmentation pattern for ART-132 
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3.7.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For thiophenes ART-101 to 110, a characteristic band of 
nitrile group was observed in the range of 2206-2210 cm-1. Confirmatory bands for 
primary amine, amide and amidic carbonyl groups were observed at 3300-3427 cm-1, 
3184-3281 cm-1 and 1701 cm-1 respectively. For pyrimidines ART-111 to 140, the 
characteristic nitrile absorption band at 2206-2210 cm-1 was found to be absent 
confirming the cyclisation from corresponding thiophenes. Another characteristic 
carbonyl stretching band of pyrimidine was observed at 1658-1670 cm-1 suggesting 
formation of desired products ART-111 to 140.     
  
3.7.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
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For thiophenes ART-101 to 110, characteristic singlets were observed for 
methyl and amide group at 2.18-2.49 δ ppm and 8.18-9.10 δ ppm respectively. The 
aromatic ring protons were observed at 6.80-8.32 δ ppm and J value were found to be 
in accordance with substitution pattern on phenyl ring. The primary amine proton 
peak was observed as a broad singlet around 7.28-7.48 δ ppm.  
While, for pyrimidines ART-111 to 140, characteristic singlets were observed 
for methyl, amide and secondary amine protons at 2.68-3.32, 9.15-10.24 and 12.40-
12.61 δ ppm. The appearance of secondary amine proton peak confirmed the 
conversion of thiophenes to pyrimidines. In addition to that, characteristic methine 
proton peak was observed at 8.00-8.05 δ ppm for pyrimidines ART-111 to 120, which 
further confirmed the cyclisation. While, the appearance of a characteristic methyl 
singlet at 2.41-2.43 δ ppm suggested the formation of pyrimidines ART-121 to 130. 
The aromatic ring protons were observed at 6.84-8.14 δ ppm and J value were found 
to be in accordance with substitution pattern on phenyl ring. 
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IR spectrum of ART-102 
 
 
Mass spectrum of ART-102 
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1H NMR spectrum of ART-102 
 
 
Expanded 1H NMR spectrum of ART-102 
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IR spectrum of ART-103 
 
 
Mass spectrum of ART-103 
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1H NMR spectrum of ART-103 
 
 
Expanded 1H NMR spectrum of ART-103 
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IR spectrum of ART-105 
 
 
Mass spectrum of ART-105 
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1H NMR spectrum of ART-105 
 
 
Expanded 1H NMR spectrum of ART-105 
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IR spectrum of ART-112 
 
 
Mass spectrum of ART-112 
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1H NMR spectrum of ART-112 
 
 
Expanded 1H NMR spectrum of ART-112 
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IR spectrum of ART-115 
 
 
Mass spectrum of ART-115 
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1H NMR spectrum of ART-115 
 
 
Expanded 1H NMR spectrum of ART-115 
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IR spectrum of ART-117 
 
 
Mass spectrum of ART-117 
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1H NMR spectrum of ART-117 
 
 
Expanded 1H NMR spectrum of ART-117 
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IR spectrum of ART-128 
 
 
Mass spectrum of ART-128 
 
 
Chapter 3                                                                                 Thieno[2,3-d]pyrimidines  
   
   74
1H NMR spectrum of ART-128 
 
 
Expanded 1H NMR spectrum of ART-128 
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IR spectrum of ART-129 
 
 
Mass spectrum of ART-129 
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1H NMR spectrum of ART-129 
 
 
Expanded 1H NMR spectrum of ART-129 
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IR spectrum of ART-130 
 
 
Mass spectrum of ART-130 
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1H NMR spectrum of ART-130 
 
 
Expanded 1H NMR spectrum of ART-130 
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IR spectrum of ART-132 
 
 
Mass spectrum of ART-132 
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1H NMR spectrum of ART-132 
 
 
Expanded 1H NMR spectrum of ART-132 
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IR spectrum of ART-135 
 
 
Mass spectrum of ART-135 
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1H NMR spectrum of ART-135 
 
 
Expanded 1H NMR spectrum of ART-135 
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IR spectrum of ART-140 
 
 
Mass spectrum of ART-140 
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1H NMR spectrum of ART-140 
 
 
Expanded 1H NMR spectrum of ART-140 
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3.8 Biological evaluation 
3.8.1 Antimicrobial evaluation 
All of the synthesized compounds (ART-101 to 140) were tested for their antibacterial 
and antifungal activity (MIC) in vitro by broth dilution method [46-48] with two 
Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus pyogenes 
MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, Pseudomonas 
aeruginosa MTCC 441 and three fungal strains Candida albicans MTCC 227, 
Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking ampicillin, 
chloramphenicol, ciprofloxacin, norfloxacin, nystatin, and griseofulvin as standard 
drugs. The standard strains were procured from the Microbial Type Culture Collection 
(MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [46].  Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations of 
1.56, 3.12, 6.25, 10, 12.5, 25, 50, 62.5, 100, 125, 250, 500 and 1000 µg mL-1. The 
tubes were inoculated with 108 cfu mL-1 (colony forming unit/mL) and incubated at 
37 ºC for 24 h. The MIC was the lowest concentration of the tested compound that 
yields no visible growth (turbidity) on the plate. To ensure that the solvent had no 
effect on the bacterial growth, a control was performed with the test medium 
supplemented with DMSO at the same dilutions as used in the experiments and it was 
observed that DMSO had no effect on the microorganisms in the concentrations 
studied. The results obtained from antimicrobial susceptibility testing are depicted in 
Table 1. 
  
 
 
 
 
  
 
Chapter 3                                                                                 Thieno[2,3-d]pyrimidines  
   
   86
Table 1. Antibacterial and antifungal activity of synthesized compounds ART-101 to 140 
 
Minimum inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
Code 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
ART-101 500 500 500 500 500 500 >1000 
ART-102 1000 1000 1000 1000 1000 500 500 
ART-103 >1000 500 250 500 1000 250 250 
ART-104 100 62.5 125 100 500 500 500 
ART-105 1000 1000 1000 1000 1000 >1000 500 
ART-106 25 100 200 100 1000 500 500 
ART-107 125 200 500 250 500 500 250 
ART-108 100 125 100 100 1000 500 500 
ART-109 50 100 25 100 >1000 500 1000 
ART-110 25 50 100 50 500 500 1000 
ART-111 1000 500 100 1000 >1000 500  >1000 
ART-112 500 >1000 500 100 500 250 1000 
ART-113 500 500 500 1000 >1000 500 125 
ART-114 125 100 50 250 250 1000 500 
ART-115 500 >1000 500 500 500 500 1000 
ART-116 50 125 100 200 >1000 500 >1000 
ART-117 125 100 250 125 500 500 >1000 
ART-118 125 250 125 50 500 1000 500 
ART-119 100 125 100 250 500 1000 >1000 
ART-120 50 125 250 100 100 1000 500 
ART-121 >1000 1000 500 500 500 1000 500 
ART-122 500 500 500 500 500 500 500 
ART-123 1000 250 500 1000 500 >1000 500 
ART-124 250 125 100 125 1000 500 >1000 
ART-125 >1000 500 >1000 >1000 500 500 500 
ART-126 125 62.5 125 50 500 1000 >1000 
ART-127 250 200 100 125 100 1000 250 
ART-128 25 250 125 100 500 1000 >1000 
ART-129 250 125 250 125 500 1000 250 
ART-130 50 62.5 125 62.5 1000 1000 >1000 
ART-131 500 500 500 500 1000 500 >1000 
ART-132 >1000 500 500 250 500 500 1000 
ART-133 500 500 125 1000 500 100 1000 
ART-134 125 125 100 125 250 >1000 500 
ART-135 500 1000 1000 >1000 500 100 500 
ART-136 100 125 225 50 100 250 1000 
ART-137 250 50 125 250 100 1000 1000 
ART-138 62.5 250 125 500 500 1000 >1000 
ART-139 250 125 125 100 100 1000 100 
ART-140 12.5 125 62.5 25 250 500 500 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
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3.8.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds ART-101 to ART-140 is currently under investigation and results are 
awaited.  
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 Chapter 4 
 Synthesis and biological evaluation of 
 1,2,4-triazolo[1,5-a]pyrimidines  
 
 
4.1 Introduction 
The condensation of a ring of 1,2,4-triazole and another one of pyrimidine gives rise 
to the formation of bicyclic heterocycles known as 1,2,4-triazolopyrimidines. Four 
different possibilities exist for the relative orientation of both rings, so four different 
isomeric families of compounds are defined: 1,2,4-triazolo[1,5-a]pyrimidine (1), 
1,2,4-triazolo[1,5-c]pyrimidine (2), 1,2,4-triazolo[4,3-a]pyrimidine (3) and 1,2,4-
triazolo[4,3-c]pyrimidine (4). 
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(1) 1,2,4-triazolo[1,5-a]pyrimidine (2) 1,2,4-triazolo[1,5-c]pyrimidine
(3) 1,2,4-triazolo[4,3-a]pyrimidine (4) 1,2,4-triazolo[4,3-c]pyrimidine  
 
Among these isomeric families of compounds, 1,2,4-triazolo[1,5-a]pyrimidine 
derivatives are  thermodynamically more stable and, thus, the most studied ones [1], a 
few of them being commercially available. Revisions surveying the synthesis, 
reactivity, spectroscopic characterization and crystallographic studies of 1,2,4-
triazolo[1,5-c]pyrimidines [2], 1,2,4-triazolo[4,3-a]pyrimidines [3] and 1,2,4-triazolo 
[4,3-c]pyrimidines [4] have also been published. 
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 From the standpoint of biological activity, fused heteroaromatic systems are 
often of much greater interest than the constituent monocyclic compounds. Recently, 
1,2,4-triazolo[1,5-a]pyrimidines have aroused increasing attention from the chemical 
and biological view points, due to their diverse pharmacological activities, such as 
antitumor potency [5, 6], inhibition of KDR kinase [7], antifungal effect [8] and 
macrophage activation [9]. They have proved to be promising anticancer agents with 
dual mechanisms of tubulin polymerization promotion [5, 6] as well as cyclin 
dependent kinases 2 inhibition [10]. Some examples of published derivatives of 1,2,4-
triazolo[1,5-a]pyrimidine with their biological activities are as following. 
N
N
N
N
NH2
O
(5) Acticity: A2A adenosine receptor antagonists [11]
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Chapter 4                                                                       1,2,4-triazolo[1,5-a]pyrimidines 
     
   94
4.2 Reported synthetic strategies 
4.2.1 Amino-1,2,4-triazole and 1,3-bifunctional synthons 
4.2.1.1 Principle and Conditions 
By far the most triazolo[1,5-a]pyrimidine synthesis are condensations of 
dinucleophilic 5-amino-1,2,4-triazoles with 1,3-bifunctional synthons as shown in the 
formation of triazolo[1,5-a]pyrimidine (15) (Scheme 4.1) [21-24]. New synthetic 
conditions recently described involve melting under microwave irradiation, a reaction 
that is environmental friendly and gives higher yields than conventional heating in 
solvent [25]. Furthermore, certain lithium 1,3-diketonates have proven to be better 
synthons than the corresponding diketones [26].  
 
COOEt
OH3C
+
NHN
NH2N NH
N
N
N
O
H3C
(15)
Scheme 4.1
 
 
 Previous mechanistic conclusions have been confirmed by isolating stable 
intermediate 5-amino-1,2,4-triazole derivatives such as enamine (16) (Scheme 4.2) on 
reacting 5-amino-1,2,4-triazoles with 3-ketovinyl ethers [27], 3-ketoenamines [28], 3-
ketoaldehydes [29], enamine-2-carboxylic esters [30] or ethoxymethylene malonates 
[31].  
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Ar
O
EtOOC
EtOH
EtOOC
CH3CN /KF
N
N
N
N
Ar
EtOOC
 
That means, the overall reaction starts with the interaction of the amino-1,2,4-
triazole amino group and the enolic (or analogous) functionality of the three-carbon 
synthon. In the two-step examples, just mentioned, the first step proceeds under 
milder conditions (sometimes just in ethanol at room temperature), but the final 
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cyclization (or the one-step reaction, if the intermediate is not trapped) requires 
stronger means (e.g., PPA or boiling acetic acid). Under extreme conditions, 
triazolylamide (17) was subject to flash vacuum pyrolysis between 300 and 450 ºC to 
give about 50% triazolo[1,5-a]pyrimidine (18) (Scheme 4.3) [32]. Libraries of fused 
3-aminopyrimidin-4-ones (19) and other compounds were just recently prepared by 
the solid-phase and by the solution-phase parallel synthesis [33]. The latter method 
turned out to be advantageous with respect to yield and purity. 
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COOEt
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O N
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N
N
H
N
O
H2N
HCl
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Scheme 4.3
 
 
4.2.1.2 Use of Modified 5-Amino-1,2,4-triazoles 
Scheme 4.4 shows two parallel paths of pyrimidine ring annulation: the conventional 
method, route A and a route B using a reactive amino-1,2,4-triazole derivative [34]. 
Amidine (22), formed from 5-amino-1,2,4-triazole and DMF dimethylacetal, can be 
regarded as the result of incorporating one carbon of the three-carbon synthon (20) 
into the 5-amino-1,2,4-triazole molecule; condensation with a reactive two-carbon 
component leads to target triazolo[1,5-a]pyrimidine (21).  
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Path B also serves in confirming the structure of product (21). Similar 
syntheses of 7-aryl and 7-heterocyclyl triazolo[1,5-a]pyrimidines have been described 
[35-37], for example, that of an antipyrine derivative [38]. 
 
4.2.1.3 The diversity of 1,3-bifunctional synthons  
Examples of triazolo[1,5-a]pyrimidine synthesis published in the relevant period are 
listed in Table 1, arranged according to the bifunctional synthons used and to the 
substituents entering the positions 5 and 7. Triazolo[1,5-a]pyrimidines are included in 
reviews dealing with heterocyclic synthesis by the use of enamines [39], enamine-2-
carboxylic esters [40] and ketene mercaptals [41]. 
 
N
N N
N
1
2
34
5
6
7 8
 
 
Table 1. Syntheses of triazolo[1,5-a]pyrimidines from 1,3-bifunctional synthons and 5-amino-1,2,4-
triazoles 
Bifunctional  
Synthons 
R-5b R-7b Bifunctional  
Synthons 
R-5b R-7b 
1,3-Dialdehyde [42] H H Enamine-2-carboxylate [59] H OH 
2-Formylacetal [43] H H Acetylenedicarboxylate [60] CO2Me OH 
1,3-Diacetal [44] H H 3-Ketocarboxylate [61] R OH 
2-Formylvinyl ether [45] H H 3-Alkoxyacrylate [62] OH R 
2-Formylvinylchloride [46] H R Alkoxyalkylene malonate [63] R OH 
3-Iminiovinylchloride [47] H R 2-Chloroacrylate [64]  OH R 
2-Formylenamine [48] H R Malonic ester [65] OH OH 
3-Iminioenamine [49] H R Malonyl chloride [66] OH OH 
3-Ketoaldehyde [50] R H 2-Acylketene mercaptal [67] SR R’ 
3-Ketoacetal [51] R H 2-Cyanoketene mercaptal [68] SR NH2 
3-Ketovinyl ether [52] H R Alkoxyalkylene cyanoacetate [69] R NH2 
3-Ketovinyl sulfone [53]c  R H Alkoxyalkylene malonitrile [70] R NH2 
3-Ketoenamine [54] H R 2-Formylnitrile [71] H NH2 
1,3-Diketone [55] R R’ 2-Cyanoenamine [72] H NH2 
3-Ketoalkyne [56] Rd H Malonitrile [73] NH2 NH2 
2-Formylcarboxylate [57] R OH 2-Thiocarbamylcarboxylate [74] NHR OH 
2-Alkoxycarbonylacetal [58] OH H    
aor tautomeric form. 
bSubstituents on C-5 and C-7, respectively; R and R’ mean (possibly substituted) alkyl, aryl, 
heterocyclyl and H; OH means hydroxy or tautomeric oxo form. 
cAnd regioisomeric 7-R compound. 
dDeoxyaltrose derivative relating C-glycosides [75]. 
 
 In recent years, 3-ketoenamines have growing interest as building blocks for 
7-aryl triazolo[1,5-a]pyrimidines (Scheme 4.4, Path A) [76, 77]. They also serve to 
synthesize 7-heterocyclyl triazolo[1,5-a]pyrimidines [78, 79]. In addition to usual N, 
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N-dimethyl compounds also analogues having a free amino group can be used as in 
the synthesis of 7-trifluoromethyl derivatives [80]. Enaminones can be formed in situ, 
for instance, from dimedone and DMF dimethylacetal [81]. 
 In the course of the cyclization of the stable tetrafluorobenzoyl derivative (23) 
(Scheme 4.5) fluorine at the o-position is involved in the reaction and is replaced to 
give trifluorobenzo triazolo[1,5-a]pyrimidine (24) [82]. Acetonyl is introduced as 
substituent into the 7-position by the use of triketone heptan-2,4,6-trione [83]. 
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F
F
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F
F
F
N
H
N
N
N
O
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NC CN
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NHN
NH2N
N
N
N
N
CN
NC
H2N
(25)
COOEtAc
PhHN S
+
NHN
NH2N
N
H
N
N
N
O
(27)
PhHN
Scheme 4.5
(26)
 
 
The electron acceptor tetracyanoethylene on interaction with amino-1,2,4-
triazole first forms a charge transfer complex that after loss of hydrocyanic acid is 
transformed into dicyano triazolo[1,5-a]pyrimidine (25) [84]. Fusion of 1,4-
naphthoquinone or indenone onto triazolo[1,5-a]pyrimidine can in a similar way be 
performed by the use of 2,3-dicyano-1,4-naphthoquinone or dicyanomethylene 
indane-1,3-dione, respectively. Another indeno triazolo[1,5-a]pyrimidine is accessible 
from triketone 2-acetylindane-1,3-dione [85]. On the other hand, acetoacetic ester 
(26) with 5-amino-1,2,4-triazole suffers ester group cleavage to form anilino 
triazolo[1,5-a]pyrimidine (27) [86]. 
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4.2.2 Other pyrimidine ring synthesis 
The annulation of pyrimidine onto the triazole ring can be accomplished by the use of 
heterocyclic precursors that can be regarded as masked 1,3-bifunctional reagents. This 
way, triacetic acid lactone (27) (Scheme 4.6) reacts as a masked 1,3-diketone and 
transforms 5-amino-1,2,4-triazole to triazolo[1,5-a]pyrimidine (28) together with ring 
isomer (29) and decarboxylation product (30) [87]. Oxazolones play a similar part 
[88-90]. Thus, enol ether (31) behaves as a masked 3-ethoxyacrylate and yields, 
through intermediate (32), benzamido TP (33) that, under harsher conditions, directly 
forms from compound [30]. 
 
Scheme 4.6
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4.2.3 2-Hydrazinopyrimidines and one-carbon synthons 
A second common triazolo[1,5-a]pyrimidine synthesis consists in the condensation of 
a C1-synthon with a 2-hydrazinopyrimidine derivative (e.g., 34, Scheme 4.7). A 
triazolo[4,3-a]-pyrimidine (35) initially forms that often can be isolated [91]. Harsher 
conditions allow it to isomerize to the target triazolo[1,5-a]pyrimidine (36) by 
Dimroth rearrangement.  
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4.2.4 Other triazole ring synthesis 
Most cyclization of 2,3-diaminopyrimidones (37) [92] or corresponding quinazolones 
proceed with the participation of carboxylic acids or their derivatives (esters, 
anhydrides, chlorides, or orthoesters) as shown in Scheme 4.8. Noncyclized or 
saturated intermediates (38, 39) can frequently be found during synthesis of 
triazolo[1,5-a]pyrimidines .  
 
N
N
NH2
NH2
F3C
O
EtCOCl
MeC(OEt)3
N
N
NH2
NH
F3C
O COEt
N
N
N
H
H
N
O
F3C
CH3
OEt
AcOH
AcOH
N
N
N
H
H
N
O
F3C
CH3
N
N
N
H
H
N
O
F3C
Et
(37)
(38)
(39)
Scheme 4.8
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4.3 Current work 
The biological importance of 1,2,4-triazolo[1,5-a]pyrimidines is well documented. 
Over the years, various substituted derivatives of these heterocycles have shown 
utility against a range of biological targets. For example, they have demonstrated 
activity against malaria and bronchospasm and shown activity as coronary 
vasodilators, antihypertensive agents, leishmanicides, antibiotics, adenosine A2a 
antagonists, immunosuppressants, antitumor agents, fungicides, xanthine oxidase 
inhibitors, and phosphodiesterase inhibitors.  
One of the synthetic pathways to 1,2,4-triazolo[1,5-a]pyrimidines is based on 
the Biginelli like cyclocondensation of aromatic aldehydes and acetoacetic acid 
derivatives with aminoazoles containing a guanidine fragment. There are literary data 
about the synthesis of triazolopyrimidines by treatment of 5-amino-1,2,4-triazole or 5-
aminotetrazole with aldehydes and ethyl acetoacetate or cyclic β-diketones [93]. The 
cyclocondensations were realized by heating of the starting materials in ethanol with 
catalytic amounts of hydrochloric acid under reflux conditions [93a-c] or using DMF 
as solvent [93d-e]. The use of acetoacetamides in these or similar reactions has not 
been described. 
Recognizing these facts, we have synthesised four new series of 1,2,4-
triazolo[1,5-a]pyrimidines (ART-201 to ART-240) containing an acetoacetamide 
fragment. The structures of all the newly synthesized compounds were elucidated by 
FT-IR, mass spectra, 1H NMR and elemental analysis. The newly synthesized 
compounds were subjected to various biological activities viz., antimicrobial, 
antimycobacterial, anticancer and antiviral. 
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4.4 Reaction Scheme 
NH
OCH3
O
+
R1
a
Reagents and conditions: (a) DMF, Reflux, 12-15 Minutes
HO
R2
HN N
NH2N
N
H
N
N
N
H3C
N
H
OR1
R2
ART-201 T0 240
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
ART-201 4-OCH3 4-OCH3 C21H21N5O3 391 219-221 78 0.56 0.71 
ART-202 4-OCH3 4-CH3 C21H21N5O2 375 179-181 72 0.51 0.69 
ART-203 4-OCH3 4-F C20H18FN5O2 379 257-259 82 0.48 0.64 
ART-204 4-OCH3 4-Cl C20H18ClN5O2 395 179-181 69 0.50 0.68 
ART-205 4-OCH3 4-NO2 C20H18N6O4 406 261-263 80 0.53 0.70 
ART-206 4-OCH3 3-NO2 C20H18N6O4 406 183-185 75 0.44 0.74 
ART-207 4-OCH3 3-Cl C20H18ClN5O2 395 244-246 69 0.51 0.70 
ART-208 4-OCH3 3,4,5-OCH3 C23H25N5O5 451 274-276 76 0.50 0.63 
ART-209 4-OCH3 3,4-OCH3 C22H23N5O4 421 169-171 82 0.41 0.62 
ART-210 4-OCH3 2-Cl C20H18ClN5O2 395 183-185 70 0.49 0.74 
ART-211 4-F 4-OCH3 C20H18FN5O2 379 256-258 73 0.52 0.69 
ART-212 4-F 4-CH3 C20H18FN5O 363 227-229 85 0.56 0.68 
ART-213 4-F 4-F C19H15F2N5O 367 257-259 78 0.50 0.66 
ART-214 4-F 4-Cl C19H15ClFN5O 383 247-249 72 0.52 0.69 
ART-215 4-F 4-NO2 C19H15FN6O3 394 273-275 76 0.61 0.77 
ART-216 4-F 3-NO2 C19H15FN6O3 394 242-244 66 0.54 0.61 
ART-217 4-F 3-Cl C19H15ClFN5O 383 233-235 78 0.53 0.71 
ART-218 4-F 2-NO2 C19H15FN6O3 394 196-198 71 0.64 0.78 
ART-219 4-F 2-Cl C19H15ClFN5O 383 207-209 65 0.48 0.62 
ART-220 4-F 3,4-OCH3 C21H20FN5O3 409 217-219 79 0.61 0.72 
ART-221 3-CF3 4-OCH3 C21H18F3N5O2 429 208-210 68 0.45 0.56 
ART-222 3-CF3 4-CH3 C21H18F3N5O 413 233-235 74 0.55 0.62 
ART-223 3-CF3 4-F C20H15F4N5O 417 215-217 82 0.52 0.70 
ART-224 3-CF3 4-Cl C20H15ClF3N5O 433 248-250 71 0.50 0.58 
ART-225 3-CF3 4-NO2 C20H15F3N6O3 444 253-255 79 0.58 0.73 
ART-226 3-CF3 3-NO2 C20H15F3N6O3 444 236-238 68 0.43 0.55 
ART-227 3-CF3 3-Cl C20H15ClF3N5O 433 239-241 66 0.53 0.69 
ART-228 3-CF3 2-NO2 C20H15F3N6O3 444 238-240 72 0.52 0.67 
ART-229 3-CF3 2-Cl C20H15ClF3N5O 433 258-260 67 0.53 0.61 
ART-230 3-CF3 3,4-OCH3 C22H20F3N5O3 459 220-222 68 0.48 0.68 
ART-231 2-F 4-OCH3 C20H18FN5O2 379 228-230 75 0.51 0.59 
ART-232 2-F 4-CH3 C20H18FN5O 363 229-231 76 0.45 0.63 
ART-233 2-F 4-F C19H15F2N5O 367 281-283 71 0.47 0.60 
ART-234 2-F 4-Cl C19H15ClFN5O 383 276-278 81 0.57 0.64 
ART-235 2-F 4-NO2 C19H15FN6O3 394 277-279 82 0.49 0.67 
ART-236 2-F 3-NO2 C19H15FN6O3 394 259-261 74 0.52 0.65 
ART-237 2-F 3-Cl C19H15ClFN5O 383 256-258 72 0.48 0.55 
ART-238 2-F 2-NO2 C19H15FN6O3 394 275-277 78 0.43 0.59 
ART-239 2-F 2-Cl C19H15ClFN5O 383 221-223 68 0.50 0.68 
ART-240 2-F 3,4-OCH3 C21H20FN5O3 409 256-258 72 0.54 0.64 
TLC Solvent system Rf1: Hexane: Ethyl acetate – 6:4; TLC Solvent system Rf2: Chloroform: Methanol - 9:1. 
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4.5 Reaction Mechanism 
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The reaction mechanism of this three-component condensation is probably similar to 
the described [94] mechanism for the “classical” Biginelli reaction (Pathway 1). The 
first step is a nucleophilic addition of N2 of the aminoazole to a carbonyl carbon of 
aldehyde, followed by subsequent cyclization with acetoacetamide to form the 
dihydropyrimidine ring. An alternate sequence is also possible and cannot be 
excluded [95] (Pathway 2), which is the initial formation of an enamine by reaction of 
aminoazole with the acetoacetamide followed by cyclocondensation. The third 
alternative involving the formation of 2-benzylidene-N-aryl-3-oxobutanamide 
derivatives as intermediates requires the presence of a strong base [96] and is most 
likely not possible for the case described herein. 
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4.6 Experimental 
 
4.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer. Elemental analysis of the all the synthesized compounds was carried out 
on Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
with the structures assigned. 
 
4.6.2 Synthesis of N-(aryl)-3-oxobutanamides 
 
Synthesis of N-(aryl)-3-oxobutanamides was achieved using previously published 
methods [97]. 
 
4.6.3 General procedure for the synthesis of 7-(aryl)-4,7-dihydro-N-(4-methoxy 
phenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamides (ART 201-210) 
 
A mixture of the aminoazole (0.01 mol), N-(4-methoxyphenyl)-3-oxobutanamide 
(0.01 mol) and an appropriate aromatic aldehyde (0.01 mol) was refluxed in 0.4 mL 
of DMF for 12-15 min. After cooling, methanol (~10 mL) was added. The reaction 
mixture was allowed to stand overnight and then filtered to give the solid 
triazolopyrimidine products ART 201-210, which were crystallized from ethanol and 
subsequently dried in air. 
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4.6.3.1 7-(4-methoxyphenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-201) Yield: 78%; mp 219-221 ºC; IR 
(cm-1): 3259 (N-H stretching of secondary 
amine), 3032 (C-H stretching of aromatic ring), 
2920 (C-H asymmetrical stretching of CH3 
group), 2875 (C-H asymmetrical stretching of 
CH3 group), 1668 (C=O stretching of amide), 1606 (C=N stretching of triazole ring), 
1550 (N-H deformation of pyrimidine ring), 1514 and 1480 (C=C stretching of 
aromatic ring), 1440 (C-H asymmetrical deformation of CH3 group), 1410 (C-H 
symmetrical deformation of CH3 group), 1330 (C-N stretching), 1247 (C-O-C 
stretching), 1028 (C-H in plane deformation of aromatic ring), 821 (C-H out of plane 
bending of 1,4-disubstituion); 1H NMR (DMSO-d6) δ ppm: 2.27 (s, 3H, Ha), 3.74 (s, 
2×3H, Hb), 6.52 (s, 1H, Hc), 6.75-6.77 (d, 2H, Hdd’, J = 9.14 Hz), 6.80-6.82 (d, 2H, 
Hee’, J = 8.68 Hz), 7.24-7.27 (d, 2H, Hff’, J = 8.64 Hz), 7.36-7.38 (d, 2H, Hgg’, J = 8.96 
Hz), 7.56 (s, 1H, Hh), 9.15 (s, 1H, Hi), 10.02 (s, 1H, Hj); MS: m/z 391; Anal. Calcd. 
for C21H21N5O3: C, 64.44; H, 5.41; N, 17.89. Found: C, 64.38; H, 5.29; N, 17.75%. 
 
4.6.3.2   7-(4-methylphenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4]                        
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-202) Yield: 72%; mp 179-181 ºC; MS: 
m/z 375; Anal. Calcd. for C21H21N5O2: C, 67.18; 
H, 5.64; N, 18.65. Found: C, 67.10; H, 5.54; N, 
18.49%. 
 
 
4.6.3.3 7-(4-flourophenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4]triazo 
lo[1,5-a]pyrimidine-6-carboxamide (ART-203) 
Yield: 82%; mp 257-259 ºC; IR (cm-1): 3269 
(N-H stretching of secondary amine), 3024 (C-
H stretching of aromatic ring), 2922 (C-H 
asymmetrical stretching of CH3 group), 2868 
(C-H asymmetrical stretching of CH3 group), 
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1666 (C=O stretching of amide), 1618 (C=N stretching of triazole ring), 1550 (N-H 
deformation of pyrimidine ring), 1510, 1479 and 1442 (C=C stretching of aromatic 
ring), 1413 (C-H asymmetrical deformation of CH3 group), 1329 (C-H symmetrical 
deformation of CH3 group), 1280 (C-N stretching), 1247 (C-O-C stretching), 1033 (C-
H in plane deformation of aromatic ring), 825 (C-H out of plane bending of 1,4-
disubstituion); 1H NMR (DMSO-d6) δ ppm: 2.28 (s, 3H, Ha), 3.74 (s, 3H, Hb), 6.59 (s, 
1H, Hc), 6.76-6.78 (d, 2H, Hdd’, J = 8.84 Hz), 6.96-7.00 (t, 2H, Hee’), 7.32-7.38 (m, 
4H, Hf-i), 7.57 (s, 1H, Hj), 9.26 (s, 1H, Hk), 10.06 (s, 1H, Hl); MS: m/z 379; Anal. 
Calcd. for C20H18FN5O2: C, 63.32; H, 4.78; N, 18.46. Found: C, 63.32; H, 4.78; N, 
18.46%. 
 
4.6.3.4 7-(4-chlorophenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4]triazo  
lo[1,5-a]pyrimidine-6-carboxamide (ART-204) 
Yield: 69%; mp 179-181 ºC; MS: m/z 395; 
Anal. Calcd. for C20H18ClN5O2: C, 60.68; H, 
4.58; N, 17.69. Found: C, 60.61; H, 4.50; N, 
17.54%. 
 
 
4.6.3.5 7-(4-nitrophenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-205) 
Yield: 80%; mp 261-263 ºC; IR (cm-1): 3217 
(N-H stretching of secondary amine), 3045 (C-
H stretching of aromatic ring), 2964 (C-H 
asymmetrical stretching of CH3 group), 2872 
(C-H asymmetrical stretching of CH3 group), 
1666 (C=O stretching of amide), 1595 (C=N stretching of triazole ring), 1516 (N-H 
deformation of pyrimidine ring), 1440, 1400 (C=C stretching of aromatic ring), 1411 
(C-H asymmetrical deformation of CH3 group), 1344 (C-H symmetrical deformation 
of CH3 group), 1280 (C-N stretching), 1247 (C-O-C stretching), 1033 (C-H in plane 
deformation of aromatic ring), 819 (C-H out of plane bending of 1,4-disubstituion); 
1H NMR (DMSO-d6) δ ppm: 2.41 (s, 3H, Ha), 3.74 (s, 3H, Hb), 6.72 (s, 1H, Hc), 6.76-
6.78 (d, 2H, Hdd’, J = 8.96 Hz Hz), 7.36-7.39 (d, 2H, Hee’, J = 8.96 Hz), 7.50-7.52 (d, 
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2H, Hff’, J = 8.68 Hz), 7.57 (s, 1H, Hg), 8.12-8.14 (d, 2H, Hhh’, J = 8.68 Hz), 9.36 (s, 
1H, Hi), 10.14 (s, 1H, Hj); MS: m/z 406; Anal. Calcd. for C20H18N6O4: C, 59.11; H, 
4.46; N, 20.68. Found: C, 59.05; H, 4.38; N, 20.51%. 
 
4.6.3.6 7-(3-nitrophenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-206) 
Yield: 75%; mp 183-185 ºC; MS: m/z 406; 
Anal. Calcd. for C20H18N6O4: C, 59.11; H, 4.46; 
N, 20.68. Found: C, 59.08; H, 4.39; N, 20.61%. 
 
4.6.3.7 7-(3-chlorophenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-207)Yield: 69%; mp 244-246 ºC; MS: 
m/z 395; Anal. Calcd. for C20H18ClN5O2: C, 
60.68; H, 4.58; N, 17.69. Found: C, 60.56; H, 
4.45; N, 17.58%. 
 
4.6.3.8 7-(3,4,5-methoxyphenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-208) Yield: 76%; mp 274-276 ºC; MS: 
m/z 451; Anal. Calcd. for C23H25N5O5: C, 61.19; 
H, 5.58; N, 15.51. Found: C, 61.09; H, 5.48; N, 
15.44%. 
 
 
4.6.3.9 7-(3,4-methoxyphenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide (ART-209) 
Yield: 82%; mp 169-171 ºC; MS: m/z 421; 
Anal. Calcd. for C22H23N5O4: C, 62.70; H, 5.50; 
N, 16.62. Found: C, 62.61; H, 5.39; N, 16.57%. 
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4.6.3.10 7-(2-chlorophenyl)-4,7-dihydro-N-(4-methoxyphenyl)-5-methyl[1,2,4]triazo 
lo[1,5-a]pyrimidine-6-carboxamide (ART-210) 
Yield: 70%; mp 183-185 ºC; MS: m/z 395; 
Anal. Calcd. for C20H18ClN5O2: C, 60.68; H, 
4.58; N, 17.69. Found: C, 60.59; H, 4.47; N, 
17.60%. 
 
4.6.4 General procedure for the synthesis of 7-(aryl)-4,7-dihydro-N-(4-flourophenyl) 
-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamides (ART 211-220) 
 
A mixture of the 5-amino-1,2,4-triazole (0.01 mol), N-(4-flourophenyl)-3-oxobutana 
mide (0.01 mol) and an appropriate aromatic aldehyde (0.01 mol) was refluxed in 0.4 
mL of DMF for 12-15 min. After cooling, methanol (~10 mL) was added. The 
reaction mixture was allowed to stand overnight and then filtered to give the solid 
triazolopyrimidine products ART 211-220, which were crystallized from ethanol and 
subsequently dried in air. 
 
4.6.4.1 7-(4-methoxyphenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo[1,5-a] 
pyrimidine-6-carboxamide (ART-211) Yield: 
73%; mp 256-258 ºC; MS: m/z 379; Anal. 
Calcd. for C20H18FN5O2: C, 63.32; H, 4.78; N, 
18.46. Found: C, 63.25; H, 4.68; N, 18.39%. 
 
 
4.6.4.2 7-(4-methylphenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-212) 
Yield: 85%; mp 227-229 ºC; IR (cm-1): 3267 
(N-H stretching of secondary amine), 3032 (C-
H stretching of aromatic ring), 2980 (C-H 
asymmetrical stretching of CH3 group), 2862 
(C-H asymmetrical stretching of CH3 group), 
1666 (C=O stretching of amide), 1602 (C=N 
stretching of triazole ring), 1516 (N-H deformation of pyrimidine ring), 1510 and 
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1450 (C=C stretching of aromatic ring), 1404 (C-H asymmetrical deformation of CH3 
group), 1329 (C-H symmetrical deformation of CH3 group), 1280 (C-N stretching), 
1014 (C-H in plane deformation of aromatic ring), 831 (C-H out of plane bending of 
1,4-disubstituion); 1H NMR (DMSO-d6) δ ppm: 2.25-2.27 (2×s, 2×3H, Ha), 6.58 (s, 
1H, Hb), 6.90-6.96 (t, 2H, Hcc’), 7.07-7.09 (d, 2H, Hdd’, J = 7.96), 7.16-7.18 (d, 2H, 
Hee’, J = 8.08), 7.47-7.51 (m, 3H, Hff’-g), 9.52 (s, 1H, Hh), 10.00 (s, 1H, Hi); MS: m/z 
363; Anal. Calcd. for C20H18FN5O: C, 66.10; H, 4.99; N, 19.27. Found: C, 65.99; H, 
4.92; N, 19.21%. 
 
4.6.4.3 7-(4-flourophenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-213) 
Yield: 78%; mp 257-259 ºC; IR (cm-1): 3279 
(N-H stretching of secondary amine), 3047 (C-
H stretching of aromatic ring), 2989 (C-H 
asymmetrical stretching of CH3 group), 2864 
(C-H asymmetrical stretching of CH3 group), 
1658 (C=O stretching of amide), 1602 (C=N stretching of triazole ring), 1558 (N-H 
deformation of pyrimidine ring), 1514, 1494 and 1446 (C=C stretching of aromatic 
ring), 1420 (C-H asymmetrical deformation of CH3 group), 1323 (C-H symmetrical 
deformation of CH3 group), 1280 (C-N stretching), 1060 (C-H in plane deformation 
of aromatic ring), 827 (C-H out of plane bending of 1,4-disubstituion); 1H NMR 
(DMSO-d6) δ ppm: 2.27 (s, 3H, Ha), 6.61 (s, 1H, Hb), 6.91-7.00 (m, 4H, Hcc’-dd’), 7.30-
7.33 (m, 2H, Hee’), 7.46-7.49 (m, 2H, Hff’), 7.71-7.72 (s, 1H, Hg), 9.49 (s, 1H, Hh), 
10.05 (s, 1H, Hi); MS: m/z 367; Anal. Calcd. for C19H15F2N5O: C, 62.12; H, 4.12; N, 
19.06. Found: C, 62.03; H, 4.06; N, 19.00%. 
 
4.6.4.4 7-(4-chlorophenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-214) 
Yield: 72%; mp 247-249 ºC; MS: m/z 383; 
Anal. Calcd. for C19H15ClFN5O: C, 59.46; H, 
3.94; N, 18.25. Found: C, 59.36; H, 3.83; N, 
18.17%. 
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4.6.4.5 7-(4-nitrophenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-215) 
Yield: 76%; mp 273-275 ºC; IR (cm-1): 3230 
(N-H stretching of secondary amine), 3034 (C-
H stretching of aromatic ring), 2910 (C-H 
asymmetrical stretching of CH3 group), 2856 
(C-H asymmetrical stretching of CH3 group), 
1666 (C=O stretching of amide), 1602 (C=N stretching of triazole ring), 1550 (N-H 
deformation of pyrimidine ring), 1529, 1510 and 1450 (C=C stretching of aromatic 
ring), 1406 (C-H asymmetrical deformation of CH3 group), 1344 (C-H symmetrical 
deformation of CH3 group), 1280 (C-N stretching), 1014 (C-H in plane deformation 
of aromatic ring), 823 (C-H out of plane bending of 1,4-disubstituion); 1H NMR 
(DMSO-d6) δ ppm: 2.25 (s, 3H, Ha), 6.72 (s, 1H, Hb), 6.93-6.98 (t, 2H, Hcc’), 7.48-
7.51 (m, 4H, Hdd’-ee’), 7.56 (s, 1H, Hf), 8.14-8.16 (d, 2H, Hgg’, J = 8.40), 9.74 (s, 1H, 
Hh), 10.32 (s, 1H, Hi): MS: m/z 394; Anal. Calcd. for C19H15FN6O3: C, 57.87; H, 3.83; 
N, 21.31. Found: C, 57.79; H, 3.75; N, 21.19%. 
 
4.6.4.6 7-(3-nitrophenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-216) 
Yield: 66%; mp 242-244 ºC; MS: m/z 394; 
Anal. Calcd. for C19H15FN6O3: C, 57.87; H, 
3.83; N, 21.31. Found: C, 57.77; H, 3.78; N, 
21.21%. 
 
4.6.4.7 7-(3-chlorophenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-217) 
Yield: 78%; mp 233-235 ºC; MS: m/z 383; 
Anal. Calcd. for C19H15ClFN5O: C, 59.46; H, 
3.94; N, 18.25. Found: C, 59.38; H, 3.85; N, 
18.15%. 
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4.6.4.8 7-(2-nitrophenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-218) 
Yield: 71%; mp 196-198 ºC; MS: m/z 394; 
Anal. Calcd. for C19H15FN6O3: C, 57.87; H, 
3.83; N, 21.31. Found: C, 57.74; H, 3.75; N, 
21.23%. 
 
4.6.4.9 7-(2-chlorophenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-219) 
Yield: 65%; mp 207-209 ºC; MS: m/z 383; 
Anal. Calcd. for C19H15ClFN5O: C, 59.46; H, 
3.94; N, 18.25. Found: C, 59.36; H, 3.82; N, 
18.17%. 
 
4.6.4.10 7-(3,4-methoxyphenyl)-4,7-dihydro-N-(4-flourophenyl)-5-methyl[1,2,4] 
triazlo[1,5-a]pyrimidine-6-carboxamide (ART-
220) Yield: 79%; mp 217-219 ºC; MS: m/z 409; 
Anal. Calcd. for C21H20FN5O3: C, 61.61; H, 
4.92; N, 17.11. Found: C, 61.55; H, 4.82; N, 
17.03%. 
 
 
4.6.5 General procedure for the synthesis of 7-(aryl)-4,7-dihydro-N-(3-
triflouromethylphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamides 
(ART 221-230) 
 
A mixture of the 5-amino-1,2,4-triazole (0.01 mol), N-(3-triflouromethylphenyl)-3-
oxobutanamide (0.01 mol) and an appropriate aromatic aldehyde (0.01 mol) was 
refluxed in 0.4 mL of DMF for 12-15 min. After cooling, methanol (~10 mL) was 
added. The reaction mixture was allowed to stand overnight and then filtered to give 
the solid triazolopyrimidine products ART 221-230, which were crystallized from 
ethanol and subsequently dried in air. 
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4.6.5.1 7-(4-methoxyphenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2, 
4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-221) Yield: 68%; mp 208-210 ºC; IR 
(cm-1): 3246 (N-H stretching of secondary 
amine), 3045 (C-H stretching of aromatic ring), 
2926 (C-H asymmetrical stretching of CH3 
group), 2837 (C-H asymmetrical stretching of 
CH3 group), 1668 (C=O stretching of amide), 1602 (C=N stretching of triazole ring), 
1552 (N-H deformation of pyrimidine ring), 1516 and 1489 (C=C stretching of 
aromatic ring), 1442 (C-H asymmetrical deformation of CH3 group), 1332 (C-H 
symmetrical deformation of CH3 group), 1282 (C-N stretching), 1251 (C-O-C 
stretching), 1031 (C-H in plane deformation of aromatic ring), 831 (C-H out of plane 
bending of 1,4-disubstituion); 1H NMR (DMSO-d6) δ ppm: 2.29 (s, 3H, Ha), 3.73 (s, 
3H, Hb), 6.59 (s, 1H, Hc), 6.78-7.74 (m, 8H, Hdd’-i), 7.93 (s, 1H, Hj), 9.71 (s, 1H, Hk), 
10.07 (s, 1H, Hl); MS: m/z 429; Anal. Calcd. for C21H18F3N5O2: C, 58.74; H, 4.23; N, 
16.31. Found: C, 58.68; H, 4.15; N, 16.26%. 
 
4.6.5.2 7-(4-methylphenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-222) Yield: 74%; mp 233-235 ºC; IR 
(cm-1): 3246 (N-H stretching of secondary 
amine), 3041 (C-H stretching of aromatic ring), 
2924 (C-H asymmetrical stretching of CH3 
group), 2833 (C-H asymmetrical stretching of 
CH3 group), 1664 (C=O stretching of amide), 1626 (C=N stretching of triazole ring), 
1600 (N-H deformation of pyrimidine ring), 1525 and 1489 (C=C stretching of 
aromatic ring), 1444 (C-H asymmetrical deformation of CH3 group), 1330 (C-H 
symmetrical deformation of CH3 group), 1276 (C-N stretching), 1070 (C-H in plane 
deformation of aromatic ring), 792 (C-H out of plane bending of 1,4-disubstituion); 
1H NMR (DMSO-d6) δ ppm: 2.27 (s, 3H, Ha), 2.31 (s, 3H, Hb), 6.60 (s, 1H, Hc), 7.08-
7.10 (d, 2H, Hdd’, J = 7.92 Hz), 7.19-7.21 (d, 2H, Hee’, J = 8.08 Hz), 7.24-7.26 (d, 2H, 
Hf), 7.35-7.38 (t, 2H, Hg), 7.54 (s, 1H, Hh), 7.72-7.74 (d, 1H, Hi), 7.93 (s, 1H, Hj),  
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9.68 (s, 1H, Hk), 10.09 (s, 1H, Hl); MS: m/z 413; Anal. Calcd. for C21H18F3N5O: C, 
61.01; H, s4.39; N, 16.94; Found: C, 61.01; H, 4.39; N, 16.94%. 
 
4.6.5.3 7-(4-flourophenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-223) Yield: 82%; mp 215-217 ºC; MS: 
m/z 417; Anal. Calcd. for C20H15F4N5O: C, 
57.56; H, 3.62; N, 16.78. Found: C, 57.48; H, 
3.56; N, 16.71%. 
 
 
4.6.5.4 7-(4-chlorophenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6carboxamide 
(ART-224) Yield: 71%; mp 248-250 ºC; MS: 
m/z 433; Anal. Calcd. for C20H15ClF3N5O: C, 
55.37; H, 3.49; N, 16.14. Found: C, 55.37; H, 
3.49; N, 16.14%. 
 
 
4.6.5.5 7-(4-nitrophenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-225) Yield: 79%; mp 253-255 ºC; MS: 
m/z 444; Anal. Calcd. for C20H15F3N6O3: C, 
54.06; H, 3.40; N, 18.91. Found: C, 53.96; H, 
3.30; N, 18.85%. 
 
 
4.6.5.6 7-(3-nitrophenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-226) Yield: 68%; mp 236-238 ºC; MS: 
m/z 444; Anal. Calcd. for C20H15F3N6O3: C, 
54.06; H, 3.40; N, 18.91. Found: C, 53.99; H, 
3.32; N, 18.81%. 
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4.6.5.7 7-(3-chlorophenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide  
(ART-227) Yield: 66%; mp 239-241 ºC; IR 
(cm-1): 3248 (N-H stretching of secondary 
amine), 3051 (C-H stretching of aromatic ring), 
2972 (C-H asymmetrical stretching of CH3 
group), 2835 (C-H asymmetrical stretching of CH3 group), 1666 (C=O stretching of 
amide), 1626 (C=N stretching of triazole ring), 1599 (N-H deformation of pyrimidine 
ring), 1552, 1527 and 1514 (C=C stretching of aromatic ring), 1442 (C-H 
asymmetrical deformation of CH3 group), 1330 (C-H symmetrical deformation of 
CH3 group), 1274 (C-N stretching), 1070 (C-H in plane deformation of aromatic ring), 
777 (C-H out of plane bending of 1,3-disubstituion); 1H NMR (DMSO-d6) δ ppm: 
2.28 (s, 3H, Ha), 6.62 (s, 1H, Hb), 7.22-7.30 (m, 5H, Hc-g), 7.38-7.42 (t, 1H, Hh), 7.56 
(s, 1H, Hi), 7.33-7.50 (d, 1H, Hj), 7.94 (s, 1H, Hk), 9.90 (s, 1H, Hl), 10.25 (s, 1H, Hm); 
MS: m/z 433; Anal. Calcd. for C20H15ClF3N5O: C, 55.37; H, 3.49; N, 16.14. Found: C, 
55.31; H, 3.42; N, 16.06%. 
 
4.6.5.8 7-(2-nitrophenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-228) Yield: 72%; mp 238-240 ºC; MS: 
m/z 444; Anal. Calcd. for C20H15F3N6O3: C, 
54.06; H, 3.40; N, 18.91. Found: C, 54.00; H, 
3.30; N, 18.79%. 
 
4.6.5.9 7-(2-chlorophenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(ART-229) Yield: 67%; mp 258-260 ºC; MS: 
m/z 433; Anal. Calcd. for C20H15ClF3N5O: C, 
55.37; H, 3.49; N, 16.14; Found. C, 55.26; H, 
3.40; N, 16.06%. 
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4.6.5.10 7-(3,4-methoxyphenyl)-4,7-dihydro-N-(3-triflouromethylphenyl)-5-methyl 
[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxami 
de (ART-230) Yield: 68%; mp 220-222 ºC; 
MS: m/z 459; Anal. Calcd. for C22H20F3N5O3: 
C, 57.51; H, 4.39; N, 15.24. Found: C, 57.45; 
H, 4.32; N, 15.16%. 
 
4.6.6 General procedure for the synthesis of 7-(aryl)-4,7-dihydro-N-(2-flourophenyl) 
-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamides (ART 231-240) 
 
A mixture of the 5-amino-1,2,4-triazole (0.01 mol), N-(2-flourophenyl)-3-oxobuta 
namide (0.01 mol) and an appropriate aromatic aldehyde (0.01 mol) was refluxed in 
0.4 mL of DMF for 12-15 min. After cooling, methanol (~10 mL) was added. The 
reaction mixture was allowed to stand overnight and then filtered to give the solid 
triazolopyrimidine products ART 231-240, which were crystallized from ethanol and 
subsequently dried in air. 
 
4.6.6.1 7-(4-methoxyphenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-231) 
Yield: 75%; mp 228-230 ºC; IR (cm-1): 3282 
(N-H stretching of secondary amine), 3014 (C-
H stretching of aromatic ring), 2966 (C-H 
asymmetrical stretching of CH3 group), 2837 
(C-H asymmetrical stretching of CH3 group), 
1658 (C=O stretching of amide), 1599 (C=N stretching of triazole ring), 1562 (N-H 
deformation of pyrimidine ring), 1516 and 1446 (C=C stretching of aromatic ring), 
1410 (C-H asymmetrical deformation of CH3 group), 1336 (C-H symmetrical 
deformation of CH3 group), 1284 (C-N stretching), 1257 (C-O-C stretching), 1028 (C-
H in plane deformation of aromatic ring), 839 (C-H out of plane bending of 1,4-
disubstituion); 1H NMR (DMSO-d6) δ ppm: 2.33 (s, 3H, Ha), 3.75 (s, 3H, Hb), 6.50 (s, 
1H, Hc), 6.82-7.69 (m, 8H, Hdd’-i), 7.80 (s, 1H, Hj), 8.86 (s, 1H, Hk), 10.13 (s, 1H, Hl); 
MS: m/z 379; Anal. Calcd. for C20H18FN5O2: C, 63.32; H, 4.78; N, 18.46. Found: C, 
63.29; H, 4.61; N, 18.35%. 
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4.6.6.2 7-(4-methylphenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-232) 
Yield: 76%; mp 229-231 ºC; IR (cm-1): 3267 
(N-H stretching of secondary amine), 3014 (C-
H stretching of aromatic ring), 2968 (C-H 
asymmetrical stretching of CH3 group), 2870 
(C-H asymmetrical stretching of CH3 group), 
1662 (C=O stretching of amide), 1599 (C=N stretching of triazole ring), 1558 (N-H 
deformation of pyrimidine ring), 1529, 1506 and 1479 (C=C stretching of aromatic 
ring), 1450 (C-H asymmetrical deformation of CH3 group), 1325 (C-H symmetrical 
deformation of CH3 group), 1284 (C-N stretching), 1028 (C-H in plane deformation 
of aromatic ring), 839 (C-H out of plane bending of 1,4-disubstituion); 1H NMR 
(DMSO-d6) δ ppm: 2.29 (s, 3H, Ha), 2.30 (s, 3H, Hb), 6.52 (s, 1H, Hc), 7.03-7.63 (m, 
9H, Hdd’-j), 9.06 (s, 1H, Hk), 10.12 (s, 1H, Hl); MS: m/z 363; Anal. Calcd. for 
C20H18FN5O: C, 66.10; H, 4.99; N, 19.27. Found: C, 66.01; H, 4.88; N, 19.15%. 
 
4.6.6.3 7-(4-flourophenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-233) 
Yield: 71%; mp 281-283 ºC; IR (cm-1): 3214 
(N-H stretching of secondary amine), 3045 (C-
H stretching of aromatic ring), 2968 (C-H 
asymmetrical stretching of CH3 group), 2831 
(C-H asymmetrical stretching of CH3 group), 
1662 (C=O stretching of amide), 1600 (C=N stretching of triazole ring), 1556 (N-H 
deformation of pyrimidine ring), 1525 and 1506 (C=C stretching of aromatic ring), 
1448 (C-H asymmetrical deformation of CH3 group), 1325 (C-H symmetrical 
deformation of CH3 group), 1280 (C-N stretching), 1012 (C-H in plane deformation 
of aromatic ring), 823 (C-H out of plane bending of 1,4-disubstituion); 1H NMR 
(DMSO-d6) δ ppm: 2.31 (s, 3H, Ha), 6.58 (s, 1H, Hb), 6.99-7.58 (m, 9H, Hcc’-i), 9.13 
(s, 1H, Hj), 10.18 (s, 1H, Hk); MS: m/z 367; Anal. Calcd. for C19H15F2N5O: C, 62.12; 
H, 4.12; N, 19.06. Found: C, 62.01; H, 4.02; N, 19.03%. 
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4.6.6.4 7-(4-chlorophenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-234) 
Yield: 81%; mp 276-278 ºC; MS: m/z 383; 
Anal. Calcd. for C19H15ClFN5O: C, 59.46; H, 
3.94; N, 18.25. Found: C, 59.38; H, 3.84; N, 
18.14%. 
 
 
4.6.6.5 7-(4-nitrophenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-235) 
Yield: 82%; mp 277-279 ºC; MS: m/z 394; 
Anal. Calcd. for C19H15FN6O3: C, 57.87; H, 
3.83; N, 21.31. Found: C, 57.78; H, 3.73; N, 
21.17%. 
 
 
4.6.6.6 7-(3-nitrophenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-236) 
Yield: 74%; mp 259-261 ºC; MS: m/z 394; 
Anal. Calcd. for C19H15FN6O3: C, 57.87; H, 
3.83; N, 21.31. Found: C, 57.74; H, 3.80; N, 
21.25%. 
 
4.6.6.7 7-(3-chlorophenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-237) 
Yield: 72%; mp 256-258 ºC; MS: m/z 383; 
Anal. Calcd. for C19H15ClFN5O: C, 59.46; H, 
3.94; N, 18.25. Found: C, 59.40; H, 3.81; N, 
18.12%. 
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4.6.6.8 7-(2-nitrophenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-238) 
Yield: 78%; mp 275-277 ºC; MS: m/z 394; 
Anal. Calcd. for C19H15FN6O3: C, 57.87; H, 
3.83; N, 21.31. Found: C, 57.75; H, 3.76; N, 
21.21%. 
 
4.6.6.9 7-(2-chlorophenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (ART-239) 
Yield: 68%; mp 221-223 ºC; MS: m/z 383; 
Anal. Calcd. for C19H15ClFN5O: C, 59.46; H, 
3.94; N, 18.25. Found: C, 59.39; H, 3.85; N, 
18.12%. 
 
4.6.6.10 7-(3,4-methoxyphenyl)-4,7-dihydro-N-(2-flourophenyl)-5-methyl[1,2,4]triaz 
olo[1,5-a]pyrimidine-6-carboxamide (ART-240) 
Yield: 72%; mp 256-258 ºC; MS: m/z 409; 
Anal. Calcd. for C21H20FN5O3: C, 61.61; H, 
4.92; N, 17.11. Found: C, 61.57; H, 4.79; N, 
17.01%. 
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4.7 Spectral discussion 
4.7.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
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4.7.1.2 Mass fragmentation pattern for ART-213  
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4.7.1.3 Mass fragmentation pattern for ART-221 
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4.7.1.4 Mass fragmentation pattern for ART-233 
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4.7.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For triazolopyrimidines ART-201 to 240, confirmatory 
bands for secondary amine and amidic carbonyl groups were observed at 3214-3282 
cm-1 and 1658-1668 cm-1 respectively. Another characteristic C=N stretching band of 
triazole ring was observed at 1595-1626 cm-1, which suggested formation of desired 
products ART-201 to 240.   
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4.7.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
1H NMR spectra confirmed the structures of triazolopyrimidines ART-201 to 
240 on the basis of following signals: a singlet for the methine proton of pyrimidine 
ring at 6.50-6.72 δ ppm, a singlet for the methine proton of triazole ring at 7.50-7.94 δ 
ppm and singlets for amino and amide group protons at 8.86-9.90 and 10.02-10.32 δ 
ppm, respectively. The aromatic ring protons and J value were found to be in 
accordance with substitution pattern on phenyl ring.  
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IR spectrum of ART-201 
 
 
Mass spectrum of ART-201 
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1H NMR spectrum of ART-201  
 
 
Expanded 1H NMR spectrum of ART-201 
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IR spectrum of ART-203 
 
 
Mass spectrum of ART-203 
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1H NMR spectrum of ART-203 
 
 
Expanded 1H NMR spectrum of ART-203 
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IR spectrum of ART-205 
 
 
Mass spectrum of ART-205 
 
 
Chapter 4                                                                       1,2,4-triazolo[1,5-a]pyrimidines 
     
   128
1H NMR spectrum of ART-205 
 
 
Expanded 1H NMR spectrum of ART-205 
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IR spectrum of ART-212 
 
 
Mass spectrum of ART-212 
 
 
Chapter 4                                                                       1,2,4-triazolo[1,5-a]pyrimidines 
     
   130
1H NMR spectrum of ART-212 
 
 
Expanded 1H NMR spectrum of ART-212 
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IR spectrum of ART-213 
 
 
Mass spectrum of ART-213 
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1H NMR spectrum of ART-213 
 
 
Expanded 1H NMR spectrum of ART-213 
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IR spectrum of ART-215 
 
 
Mass spectrum of ART-215 
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1H NMR spectrum of ART-215 
 
 
Expanded 1H NMR spectrum of ART-215 
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IR spectrum of ART-221 
 
 
Mass spectrum of ART-221 
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1H NMR spectrum of ART-221 
 
 
Expanded 1H NMR spectrum of ART-221 
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IR spectrum of ART-222 
 
 
Mass spectrum of ART-222 
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1H NMR spectrum of ART-222 
 
 
Expanded 1H NMR spectrum of ART-222 
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IR spectrum of ART-227 
 
 
Mass spectrum of ART-227 
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1H NMR spectrum of ART-227 
 
 
Expanded 1H NMR spectrum of ART-227 
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IR spectrum of ART-231 
 
 
Mass spectrum of ART-231 
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1H NMR spectrum of ART-231 
 
 
Expanded 1H NMR spectrum of ART-231 
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IR spectrum of ART-232 
 
 
Mass spectrum of ART-232 
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1H NMR spectrum of ART-232 
 
 
Expanded 1H NMR spectrum of ART-232 
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IR spectrum of ART-233 
 
 
Mass spectrum of ART-233 
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1H NMR spectrum of ART-233 
 
 
Expanded 1H NMR spectrum of ART-233 
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4.8 Biological evaluation 
4.8.1 Antimicrobial evaluation 
All of the synthesized compounds (ART-201 to 240) were tested for their antibacterial 
and antifungal activity (MIC) in vitro by broth dilution method [98-100] with two 
Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus pyogenes 
MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, Pseudomonas 
aeruginosa MTCC 441 and three fungal strains Candida albicans MTCC 227, 
Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking ampicillin, 
chloramphenicol, ciprofloxacin, norfloxacin, nystatin, and griseofulvin as standard 
drugs. The standard strains were procured from the Microbial Type Culture Collection 
(MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [98].  Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations of 
1.56, 3.12, 6.25, 10, 12.5, 25, 50, 62.5, 100, 125, 250, 500 and 1000 µg mL-1. The 
tubes were inoculated with 108 cfu mL-1 (colony forming unit/mL) and incubated at 
37 ºC for 24 h. The MIC was the lowest concentration of the tested compound that 
yields no visible growth (turbidity) on the plate. To ensure that the solvent had no 
effect on the bacterial growth, a control was performed with the test medium 
supplemented with DMSO at the same dilutions as used in the experiments and it was 
observed that DMSO had no effect on the microorganisms in the concentrations 
studied. The results obtained from antimicrobial susceptibility testing are depicted in 
Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds ART-201 to 240 
 
 
 
 
 
 
Minimum inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
Code 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
ART-201 500 1000 500 100 1000 500 500 
ART-202 1000 500 1000 1000 500 500 1000 
ART-203 500 500 250 500 >1000 1000 500 
ART-204 250 62.5 125 250 1000 500 250 
ART-205 125 100 1000 500 100 1000 500 
ART-206 500 1000 250 1000 500 500 >1000 
ART-207 1000 250 500 500 500 100 250 
ART-208 100 125 100 62.5 >1000 1000 1000 
ART-209 100 >1000 500 1000 >1000 500 1000 
ART-210 25 500 250 100 500 1000 >1000 
ART-211 1000 100 100 500 250 100 250 
ART-212 125 100 100 500 500 250 1000 
ART-213 500 500 1000 >1000 1000 500 125 
ART-214 125 100 50 250 500 1000 500 
ART-215 100 1000 250 1000 1000 500 1000 
ART-216 50 500 250 250 >1000 1000 >1000 
ART-217 500 1000 500 1000 500 500 100 
ART-218 125 25 100 100 500 >1000 500 
ART-219 125 500 500 250 100 1000 250 
ART-220 >1000 250 >1000 500 1000 1000 500 
ART-221 1000 500 1000 500 >1000 1000 1000 
ART-222 500 >1000 500 1000 500 500 1000 
ART-223 500 1000 1000 >1000 100 >1000 >1000 
ART-224 250 125 250 500 500 500 1000 
ART-225 1000 500 >1000 1000 250 500 500 
ART-226 50 25 125 500 1000 1000 500 
ART-227 250 250 100 500 100 500 500 
ART-228 100 500 125 1000 500 1000 1000 
ART-229 250 1000 250 500 500 250 250 
ART-230 50 125 250 62.5 1000 1000 500 
ART-231 500 500 500 >1000 100 500 250 
ART-232 1000 500 1000 1000 500 500 100 
ART-233 500 1000 1000 500 500 100 500 
ART-234 62.5 100 250 125 1000 >1000 1000 
ART-235 1000 500 500 1000 500 100 500 
ART-236 100 125 500 500 250 500 100 
ART-237 250 1000 1000 250 500 1000 1000 
ART-238 100 250 100 500 500 1000 1000 
ART-239 250 125 250 250 100 1000 250 
ART-240 62.5 100 100 250 250 500 250 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
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4.8.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds ART-201 to ART-240 is currently under investigation and results are 
awaited.  
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 Chapter 5 
 Microwave assisted synthesis and    
 biological evaluation of pyrazolo[3,4-d] 
 [1,2,4]triazolo[1,5-a]pyrimidines 
 
5.1 Microwave-Assisted Organic Synthesis (MAOS) – A Brief History 
While fire is now rarely used in synthetic chemistry, it was not until Robert Bunsen 
invented the burner in 1855 that the energy from this heat source could be applied to a 
reaction vessel in a focused manner. The Bunsen burner was later superseded by the 
isomantle, the oil bath or the hot plate as a means of applying heat to a chemical 
reaction. In the past few years, heating and driving chemical reactions by microwave 
energy has been an increasingly popular theme in the scientific community [1, 2]. 
 Microwave energy, originally applied for heating foodstuffs by Percy Spencer 
in the 1940s, has found a variety of technical applications in the chemical and related 
industries since the 1950s, in particular in the food-processing, drying and polymer 
industries. Other applications range from analytical chemistry (microwave digestion, 
ashing and extraction) [3] to biochemistry (protein hydrolysis, sterilization) [3], 
pathology (histoprocessing, tissue fixation) [4] and medical treatments (diathermy) [5]. 
Somewhat surprisingly, microwave heating has only been implemented in organic 
synthesis since the mid-1980s. The first reports on the use of microwave heating to 
accelerate organic chemical transformations (MAOS) were published by the groups of 
Richard Gedye (Scheme 5.1) [6] and Raymond J. Giguere/George Majetich [7] in 
1986.  
 
NH2
O
OH
O
20% H2SO4
MW or thermal
Thermal: 1h, 90% yield  (reflux)
MW: 10 min, 99% yield  (sealed vessel)
Scheme 5.1 Hydrolysis of benzamide: The first published example (1986) of 
microwave-assisted organic synthesis.
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In those early days, experiments were typically carried out in sealed teflon or 
glass vessels in a domestic household microwave oven without any temperature or 
pressure measurements. The results were often violent explosions due to the rapid 
uncontrolled heating of organic solvents under closed-vessel conditions. In the 1990s, 
several groups started to experiment with solvent-free microwave chemistry (so-
called dry-media reactions), which eliminated the danger of explosions [8]. Here, the 
reagents were pre-adsorbed onto either an essentially microwave-transparent (i.e., 
silica, alumina or clay) or strongly absorbing (i.e., graphite) inorganic support, that 
additionally may have been doped with a catalyst or reagent. Particularly in the early 
days of MAOS, the solvent-free approach was very popular since it allowed the safe 
use of domestic microwave ovens and standard open-vessel technology. While a large 
number of interesting transformations using “dry-media” reactions have been 
published in the literature [8], technical difficulties relating to non-uniform heating, 
mixing and the precise determination of the reaction temperature remained unresolved, 
in particular when scale-up issues needed to be addressed. 
 Alternatively, microwave-assisted synthesis has been carried out using 
standard organic solvents under open-vessel conditions. If solvents are heated by 
microwave irradiation at atmospheric pressure in an open vessel, the boiling point of 
the solvent typically limits the reaction temperature that can be achieved. In order to 
nonetheless achieve high reaction rates, high-boiling microwave-absorbing solvents 
have been frequently used in open-vessel microwave synthesis [9]. However, the use 
of these solvents presented serious challenges in relation to product isolation and 
recycling of the solvent. Because of the recent availability of modern microwave 
reactors with on-line monitoring of both temperature and pressure, MAOS in 
dedicated sealed vessels using standard solvents-a technique pioneered by Christopher 
R. Strauss in the mid-1990s [10]-has been celebrating a comeback in recent years. 
This is clearly evident surveying the recently published (since 2001) literature in the 
area of controlled microwave-assisted organic synthesis (MAOS). It appears that the 
combination of rapid heating by microwaves with sealed-vessel (autoclave) 
technology will most likely be the method of choice for performing MAOS on a 
laboratory scale in the future. Importantly, recent innovations in microwave reactor 
technology now allow controlled parallel and automated sequential  
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processing under sealed-vessel conditions, and the use of continuous- or stop-flow 
reactors for scale-up purposes. 
 Since the early days of microwave synthesis, the observed rate accelerations 
and sometimes altered product distributions compared to oil-bath experiments have 
led to speculation on the existence of so-called “specific” or “non-thermal” 
microwave effects [11]. Historically, such effects were claimed when the outcome of 
a synthesis performed under microwave conditions was different from that of the 
conventionally heated counterpart at the same apparent temperature. Reviewing the 
present literature [12], it appears that today most scientists agree that in the majority 
of cases the reason for the observed rate enhancements is a purely thermal/kinetic 
effect, i.e., a consequence of the high reaction temperatures that can rapidly be 
attained when irradiating polar materials in a microwave field, although effects that 
are caused by the unique nature of the microwave dielectric heating mechanism 
(“specific microwave effects”) clearly also need to be considered. While for the 
medicinal chemist in industry this discussion may seem largely irrelevant, the debate 
on “microwave effects” is undoubtedly going to continue for many years in the 
academic world. Regardless of the nature of the observed rate enhancements, 
microwave synthesis has now truly matured and has moved from a laboratory 
curiosity in the late 1980s to an established technique in organic synthesis, heavily 
used in both academia and industry. 
The initially slow uptake of the technology in the late 1980s and 1990s has 
been attributed to its lack of controllability and reproducibility, coupled with a general 
lack of understanding of the basics of microwave dielectric heating. The risks 
associated with the flammability of organic solvents in a microwave field and the lack 
of available dedicated microwave reactors allowing for adequate temperature and 
pressure control were major concerns. Important instrument innovations now allow 
for careful control of time, temperature and pressure profiles, paving the way for 
reproducible protocol development, scale-up and transfer from laboratory to 
laboratory and from scientist to scientist. Today, microwave chemistry is as reliable as 
the vast arsenal of synthetic methods that preceded it. Since 2001, therefore, the 
number of publications related to MAOS has increased dramatically, to such a level 
that it might be assumed that, in a few years, most chemists will probably use 
microwave energy to heat chemical reactions on a laboratory scale [1, 2]. Not only is 
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direct microwave heating able to reduce chemical reaction times significantly, but it is 
also known to reduce side reactions, increase yields and improve reproducibility. 
Therefore, many academic and industrial research groups are already using MAOS as 
a technology for rapid reaction optimization, for the efficient synthesis of new 
chemical entities or for discovering and probing new chemical reactivity. 
 
5.2 Applications of microwaves in heterocyclic ring formation 
5.2.1 Five-membered heterocyclic rings 
5.2.1.1 Pyrroles 
The classical Paal-Knorr cyclization of 1,4-diketones to give pyrroles is dramatically 
speeded- up under microwave irradiation and high yields are obtained as shown in 
Scheme 5.2 [13]. 
 
O
O
RNH2
N
R
R = CH2C6H5,
4-MeOC6H4, 
2-ClC6H4
MW, 100-200 W, 0.5-2.0 min., solvent-free
Microwave: 2 min., Convential: Lewis acid activation, 12h.
Scheme 5.2
 
 
5.2.1.2 Pyrazoles 
Another recent application of microwaves in cyclization is the preparation of 
pyrazoles from hydrazones using the Vilsmeier cyclization method by treatment with  
 
MW, 210 W, 30-50 sec., DMF
Microwave: 35-50 sec., 45-78%
 Convential: 4-5 h, 41-76%
Scheme 5.3
R2 R1
R5
N
NH
R3
R4
POCl3
R2 R1
N N
R5
R4R3
R1 = H, OH; R2 = H, CH3; R3 = H, NO2; 
R4 = NO2; R5 = CH3, C2H5,
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POCl3 and DMF [14].
 
As shown in Scheme 5.2, once again the reaction is speeded-up 
by factors of several 100-fold. 
 
5.2.1.3 Imidazoles 
An important classical preparation of imidazoles is from an α-diketone, an aldehyde 
and ammonia. Here again, excellent yields can be obtained in reaction times of a few 
minutes as shown in Scheme 5.4 [15]. 
 
Scheme 5.4
R1 H
O
+
R2
O
R3
O
Al2O3
NH4OAc
N NH
R3 R2
R1
MW, 130 W, 10 min., solvent-free
Microwave: 10 sec., 45-78%
 Convential: 4h, AcOH, reflux
R1 = C6H5; 4-ClC6H4, 2-thiophenyl etc.
R2 = R3 =  C6H5; 4-MeC6H4
 
 
5.2.1.4 Oxazolines 
The example of Scheme 5.5, the preparation of oxazolines shows that partially 
saturated five-membered rings can also be prepared advantageously using 
microwaves [16]. 
 
+
R OH
O
NH2
OH
HO
OH
-H2O NH
OH
HO
HO
O
R
-H2O
N
OR
OH
OH
80-95%
MW, 850 W, 200 ºC, 5 min., solvent-free
 Convential: 15-16 h
R = 2-Furyl, Phenyl, Heptadecenyl
Scheme 5.5
 
 
5.2.1.5 Triazoles and Tetrazoles 
Schemes 5.6 and 5.7 continue the overview of five-membered rings with illustrations 
of the advantageous preparation of 1,2,4–triazoles (Scheme 4.6) [17] and tetrazoles 
(Scheme 5.7) [18]
 
using microwaves. Notice that in Scheme 5.6 the starting aryl 
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cyanides are also made by a Pd-catalyzed but microwave-enhanced replacement of 
aryl bromides using zinc cyanide. 
 
Ar C N
NH2NH2-2HCl
NH2NH2-H2O
NN
N
NH2
Ar Ar
MW: 60 W, 130 ºC, 36-96%
Convential: 60 min., 130 ºC, 45-60%
Ar = C6H5; 4-OCH3C6H4,  4-NH2C6H4,  
4-OHC6H4, 4-CH3C6H4 etc.
Scheme 4.6
Br
R
Zn(CN)2
Pd(PPh3)4
CN
R
NaN3
NH4Cl R
N
N
NHN
R = OCH3, NO2, CH3 etc.
MW: 60 W, 175 ºC, 2 min., DMF, 78-93%
Convential: 2-16 h, 71-97%
MW: 20 W, 220 ºC, 10-25 min., DMF, 36-96%
Convential: 3-96 h, 35-97%
Scheme 5.7
 
 
5.2.1.6 Oxadiazoles 
The dehydration of unsymmetrical diacylhydrazines (themselves prepared by a 
conventional Mitsunobu reaction) using Burgess’s reagent is shown in Scheme 5.8 to 
give 1,3,4-oxadiazoles rapidly under microwave irradiation [19]. 
 
MW: 150 ºC, 5 min., DMF
 Convential :90 min., 150 ºC
R = alkyl, aryl; R2 = Cl, OMe
Scheme 5.8
+
R1 OH
O
N
H
O
H2N
R2
DDC
N
H
OH
N
R2
R1
O
MeO N
S
NEt3
O O
O
NN
OR1
100%
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5.2.1.7 Isoxazolines and pyrazolines 
The acceleration of 1,3-dipolar cycloaddition reactions to give isoxazolines and 
pyrazolines by the addition of activated olefins to nitrile oxides or nitrile imides, 
respectively, is illustrated in Scheme 5.9; the resulting compounds are obtained in far  
high yield than under conventional conditions [20]. 
 
N
XH
ClAr
Al2O3
Ar C N X
Ar C N X
RC CY
RHC C(Y)(Z)
O N Me
N
X
YR
Ar
+
N
X
RY
Ar
25-73% 0-22%
N
X
YR
Ar
Z
MW: 110-140 ºC, 30 min., xylene, 50-85%
 Convential :22-40%
R = H, Ph, CO2Me;
Y = CO2Me, CO2Et;
Z = H, CN
Scheme 5.9
 
5.2.2 Benzo-derivatives of five-membered rings 
5.2.2.1 Benz-imidazoles, -oxazoles, and –thiazoles 
Ring closure reactions of appropriate o-substituted anilines to give benzimidazoles, 
benzoxazoles, and benzthiazoles takes place much faster and in significantly high 
yield under microwave conditions  than conventionally [21] as shown in Scheme 5.10.  
 
NH2
Z
+
EtO CF3
OEt O
Y
N
F3C
O
Z = NH2, OH, SH MW: 980 W, 9-11 min., toluene, 86-96% Convential : 3-5 h, 40-80%
Scheme 5.10
Y = NH, O, S
 
 
5.2.2.2 Indoles 
The classical Fischer-indole synthesis from an aryl hydrazine and a ketone is speeded-
up by several 100-fold as documented in Scheme 5.11 [22].  
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H
N
NH2 +
O
N
H
MW:30 Sec., AcOH
 Convential : AcOH rerflux, 2h
Scheme 5.11
 
 
5.2.2.3 γ-Carbolines 
The Graebe-Ullmann synthesis which converts 1-arylbenzotriazoles into carbazoles or 
their heterocyclic analogs is also accelerated under microwave conditions as shown in 
Scheme 5.12 where the 1-(4-pyridyl)benzotriazole is converted into a γ-carboline [23].  
 
N
H
N
NR2
R3
+
N
Cl
R1
N
N
NR2
R3
N
R1
H2P2O7
N
H
R2
R3
N
R1
MW, 160W, 10 min., solvent-free
MW, 160W, 5 min., solvent-free
MW: 15 min., 30-76%
Convential: 150 min., 28-80%
R1 = H, Me
R2 = R3 = H, Me
Scheme 5.12
 
 
5.2.3 Six-membered rings 
5.2.3.1 Dihydropyridines   
Me OEt
O O
+
Ar H
O
25% aq NH4OH
N
H
CO2EtEtO2C
Me Me
Ar
(5 equiv)
MW: 140 ºC, 10-15 min., Solvent-free, 51-92%
Convential:12 h, 15-61%
Ar = C6H5, 2-NO2C6H4,
2-CH3OC6H4, 2-ClC6H4
Scheme 5.13
 
 
Chapter 5                                                                         Pyrazolo- triazolo-pyrimidines 
     
   164
The Hantzsch dihydropyridine synthesis remains one of the most important routes to 
pyridine ring systems. Under conventional conditions long periods of heating are 
required and yields are poor to moderate. Microwaves dramatically reduce the heating 
times and also significantly increase the yields as shown in Scheme 5.13 [24].  
 
5.2.3.2 Dihydropyridopyrimidinones  
Dihydropyridopyrimidinones have been produced by ring annulations of 
aminopyrimidinones. Once again the reaction time is dramatically reduced and yields 
are much better with the solvent-free microwave conditions (Scheme 5.14) [25]. 
 
N
N
O
NH2X
Me
R
+ Ph
O
CN + Ar H
O
N
H
N
N
Ar
CN
Ph
R
X
Me
O
X = O, S; R = H, CH3;
Ar = C6H5, 2-CH3OC6H4, 2-ClC6H4
MW: 600 W, 20 min., Solvent-free, 70-75%
Convential: EtOH reflux, 40-48 h, 21-25 %
Scheme 5.14
 
 
5.2.3.3 Dihydropyrimidines 
The Biginelli reaction is important for the preparation of dihydropyrimidine 
derivatives and excellent results are found for reactions carried out with microwave 
enhancement (Scheme 5.15) [19].  
 
MW: 5 min., 60-90%
Convential:12-24 h, 15-60%
R1 OEt
O O
+
H2N
O
NH2 R2 H
O
+ HN
N
H
O
O
OEt
R1
R2
R1 = H, CH3 R2 =  C6H5, 2-CH3OC6H4,   2-ClC6H4
Scheme 5.15
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5.2.3.4 Tetrazines 
The Diels-Alder reaction between aza-olefins and aza-dicarboxylic ester to give 
tetrazines is speeded-up by a factor of 1000 by microwave enhancement as shown in 
Scheme 5.16 [26]. 
 
Ph
N
N
R
+ N N CO2EtEtO2C
N
N
N
N
Ph
CO2Et
CO2Et
R = Carbohydrate MW: 300 W, 15 min., 80-96%
Convential: 30 days
Scheme 5.16
R
 
 
5.2.4 Polycyclic six-membered rings 
5.2.4.1 Quinolines 
The Skraup synthesis has a bad reputation as it involves very messy conditions and 
gives only low yields of quinolines when carried out conventionally. Recently, it has 
been reported that microwave enhancement reduces the reaction time to a few minutes 
and allows high yields to be isolated (Scheme 5.17) [27]. 
 
NH2
R + R1
R2
R3
O
InCl3/SiO2
N
R3
R2
R1
R
R = H,  o-CH3, m-CH3, p-CH3, o-OMe, p-OMe, m-OH, m-Cl etc.
R1 = H, CH3, n-C3H7; R2 = H, C2H5;
R3 = CH3, p-MeOC6H4
MW: 600 W, 5-12 min., Solvent-free, 80-87%
Convential: H2SO4/150 ºC, low yileds
Scheme 5.17
 
 
5.2.4.2 Pyrimido[1,2-a]pyrimidines 
Pyrimido[1,2-a]pyrimidines are prepared from dihydroaminopyrimidines and 
chromone-3-aldehydes as is shown in Scheme 5.18 [28].
 
Although the conventional 
reaction must proceed in refluxing ethanol, reactions are much faster and better yields 
have been obtained with microwaves. 
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N
H
N
NH2
EtO2C
Ph
HAr
+
O
O
O
H N
N
EtO2C
Ph
HAr
N
H
H
OH
O
N
N
EtO2C
Ph
Ar
N
H
H
OH
O
H
4H
2H
Ar = C6H5, 4-CH3C6H4, 4-CH3OC6H4, 
4-ClC6H4, 2-thienyl
MW: 400 W, 20 min., Solvent-free, >95%
Convential: EtOH reflux, 4 h, 60-70 %
Scheme 5.18
 
 
5.2.5 Nucleophilic Substitutions 
5.2.5.1 Heterocyclic C-alkylations 
Nucleophilic substitution reactions can be speeded-up very considerably as is 
illustrated in Scheme 5.19 for a chloro-naphthyridine derivative [29]. 
 
N N
O
F
F
F
Cl
NH
N N
O
F
F
F
N
COOEt
COOEt
NH2
N N
O
F
F
F
HN
COOEtF3C
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Microwave: 175 ºC, 10 min, 100%
Convential: 100 ºC, 12-24 h, 35-60%
Scheme 5.19
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5.2.5.2 Heterocyclic N-alkylations 
Another class of nucleophilic substitution is involved in heterocyclic N-alkylation 
which we have illustrated in Scheme 5.20. This shows that nucleophilic substitution 
on the nitrogen atom of saccharin is significantly speeded-up by microwave 
irradiation [19].  
 
Microwave: 750 W, 2-10 min, solvent-free, 71-92%
Convential: DMF reflux, 30 min.
Scheme 5.20
S
NH
O
O O
NaOH, RX
silica gel S
NR
O
O O
R = CH2C6H5, n-C16H33, CH2COOC2H5 etc.
 
 
5.2.5.3 Selective-alkylation 
In Scheme 5.21, the results presented indicate that selectivity is achieved in the N 
alkylation of 1,2,4-triazole under microwave conditions where only the N1-alkyl 
derivative was formed in contradistinction to the conventional conditions which give 
a considerable amount of the di-1,4-substituted compound [30]. 
 
N
N
H
N + PhCH2Br
N
N
N
CH2Ph
+
N
N
N
CH2Ph
PhH2C Br
molar ratio 1:1 N1 N1,4
Microwave: 90-165 ºC, 1.5-5 min, 70%
Convential: 14%; only N1,4 isolated
Scheme 5.21
 
 
5.2.5.4 Transition metal cross-coupling 
An important type of nucleophilic substitution reactions which are recently much 
exploited are comprised of transition metal cross-coupling. A Suzuki coupling is 
shown at the top of Scheme 5.22 to give significantly better yield in the presence of 
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microwave irradiation [31].
 
At the bottom of Scheme 4.22 another Suzuki coupling is 
speeded-up by a factor of 100 [32]. 
 
N Br
Pd(OAC)2, (C6H5)4BNa
Na2CO3 N Ph
Microwave:160 W, 105 ºC, 12 min, H2O, 73%
Convential: 42%
N
N
H
HN
O
+
B
HO OH
Me
Cu(OAc)2, pyr-NMP
TFA
N
N
H2N
O
MeMicrowave: 30 sec., 60%
Convential: 48h
Scheme 5.22
 
 
5.2.6 Hetero-Diels−Alder reactions 
5.2.6.1 Intramolecular reactions 
We have already seen one example of a hetero-Diels−Alder reaction involving acyclic 
components. Hetero-Diels−Alder reactions involving cyclic components which lead 
to polycyclic ring systems are of great importance. An intramolecular example shown 
in Scheme 5.23 indicates that the reaction was accelerated by a factor of around 1000 
by microwave irradiation [33]. 
 
N
N
R
Cl
O
O
(CH2)n N
N
O
R Cl
O
(CH2)n
+H2O
N
NH
O
R O
O
(CH2)n
Microwave: 300 W, 190 ºC, 8-15 min., DCE, bmimPF6 Microwave: 300 W, 130 ºC, 5 min., 57-77%Convential: PhCl reflux, 2-3 days
R = Bn, Ph; n = 2,3
Scheme 5.23
 
5.2.6.2 Intermolecular reactions 
Scheme 5.24 shows two impressive examples of rate enhancement for intermolecular 
hetero-Diels−Alder reactions [33]. In the first example on the top of Scheme 4.24 the  
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initial reaction is followed by elimination thus involving the conversion of a pyrazine 
derivative into a pyridine. Perhaps more impressive is the lower example in Scheme 
5.24 where an autoclave is required under conventional conditions but which can be 
dispensed with when microwave acceleration is utilized. 
 
CO2MeMeO2C
N
N
O
Ph Cl
MeO2C
MeO2C
CN -ClCN
N
CO2Me
O
NC CO2Me
Ph
N
CO2Me
CO2Me
Cl CN
-PhNCO
N
N
Ph
Cl
O
CN
Microwave: 300 W, 190 ºC, 5 min., DCE, bmimPF6
Convential: 30 min.
N
N
Ph
Cl
O
R
ethene
N
N
O
Ph Cl
R
Microwave: 300 W, 190 ºC, 40-190 min., DCB, 86-89%
Convential: Autoclave, 25 atm., 110 ºC, 12h
Scheme 5.24
 
 
5.2.7 1,3-Dipolar cycloaddition reactions 
5.2.7.1 Synthesis of C-carbamoyl-1,2,3-triazoles 
 
N3 4 or 5
NN
N
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R2
R
N34 or 5
1 2
7-12
O N3
4 or 5
O
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O
N
5 3
Microwave: 120-170 W, 55-85 ºC, 30 min., solvent-free, 62-80%
Convential: 24h to 1 week, 120 ºC
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Ph(CH2)2
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9
Ph(CH2)210
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C(CH3)(CH2OCH2)
C(CH3)(CH2OCH2)
R R1
H
H
H
H
H
H
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CONHCH2Ph
COpiperidinyl
COpiperidinyl
CONHCH2Ph
CONHCH2Ph
COpiperidinyl
Scheme 5.25
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We now turn to some of our own recent work which has involved microwave induced 
1,3-dipolar cycloaddition of organic azides to acetylenic amides. As shown in Scheme 
4.25 we were able to achieve these reactions under microwave conditions in a 
reasonable time at temperatures of around 70±15 ºC [34]. Under conventional 
conditions the times were roughly 100 times as long and the temperature had to be 
taken up to 120 ºC [35]. 
 
5.2.8 Oxidation 
The osmium-catalyzed dihydroxylation reaction, the addition of osmium tetroxide to 
olefins to produce a vicinal diol, is one of the most selective and reliable organic 
transformations. Recent work by Sharpless, Fokin, and coworkers [36] has uncovered 
that electron-deficient olefins can be converted into the corresponding diols much 
more efficiently when the reaction medium is kept acidic (Scheme 5.26). 
 
F
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F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
K2OsO2(OH)4, NMO
citric acid/BuOH/H2O
Microwave: 120 ºC, 150 min., 81%
Scheme 5.26
OH
OH
 
 
5.3 Biological significance of pyarazlo-triazolo-pyrimidines 
In recent years pyrazolotriazolopyrimidines have been the subject of intense research 
due to the interesting pharmacological activities found for several of their derivatives 
[37-39].  
 
N N
N
N
N
N
NH2
O
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N N
N
N
NH2
O
Cl
(1) (2)
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Pyrazolo-triazolo-pyrimidine nucleus (1) represents an attractive key 
intermediate for obtaining adenosine receptor antagonists due to its strong structural 
correlation with the nonselective adenosine receptor antagonist CGS15943 (2) [40].  
The great advantage of this nucleus with respect to the reference compound (2) is 
related to a large number of substitutions that could be done on this nucleus, such as 
in positions N7, N8, N5, C9, or C2 opening kaleidoscopic possibilities for different 
substituted heterocycles as adenosine receptor antagonists. Structures and binding 
affinities of various pyrazolo-triazolo-pyrimidines as adenosine receptors are as 
following.  
 
N N
N
N
HN
N
NH2
O
(4)
F
8FB-PTP
Ki rA1 = 3.3 nM
Ki rA2A = 1.2 nM
N N
N
N
N
N
NH2
O
(5)
Ki rA1 = 236 nM
Ki rA2A = 8.9 nM
N N
N
N
N
N
NH2
O
(6)
Ki rA1 = 30.4 nM
Ki rA2A = 2.4 nM
Structures and binding affinities of the first synthesized pyrazolo-triazolo-pyrimidines [41, 42]
N N
N
N
N
N
NH2
O
(7) SCH 58261
Ki rA1 = 121 nM
Ki rA2A = 2.3 nM
Ki hA2B = >10000 nM
Ki hA3 = >10000 nM
N N
N
N
N
N
NH2
O
(8) SCH 63390
Ki rA1 = 504 nM
Ki rA2A = 2.4 nM
Ki hA3 = >10000 nM
First generation of pyrazolo-triazolo-pyrimidines as potent and selective 
A2A adenosine receptor antagonists [42-44]
N N
N
N
N
N
NH2
O N N
N
N
N
N
NH2
OHO
HO
(8)
Ki rA1 = 444 nM
Ki rA2A = 1.7 nM
Ki hA3 = >10000 nM
(9)
Ki rA1 = 741 nM
Ki rA2A = 0.94 nM
Ki hA3 = >10000 nM
Hydrophilic pyrazolotriazolopyrimidines as A2A adenosine receptor antagonists [43]
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N N
N
N
N
N
HN
O
(10)
Ki hA1 = 594 nM
Ki hA2A = 381 nM
Ki hA2B = 222 nM
Ki hA3 = 0.16 nM
N N
N
N
N
N
HN
O
(11)
Ki hA1 = >10000 nM
Ki hA2A = 594 nM
Ki hA3 = 0.16 nM
Structures and binding affinities of the most interesting
compounds modified at the phenyl ring [44]
N N
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N
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O
N N
N
N
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O
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N
H
O
N
H
O
Ki hA2B =  >10000 nM
(12)
Ki hA1 = 2 nM
Ki hA2A = 0.8 nM
Ki hA2B = 9 nM
Ki hA3 = 700 nM
NH3
O
(13)
Ki hA1 = 1.6 nM
Ki hA2A = 54 nM
Ki hA2B = 27 nM
Ki hA3 = 65 nM
N N
N
N
N
N
HN
O
H3C
(14)
Ki hA1 = 702 nM
Ki hA2A = 423 nM
Ki hA2B = 165 nM
Ki hA3 = 0.81 nM
O
Structures and binding affinities of pyrazolo-triazolopyrimidines
as A2B adenosine receptor antagonists [45]
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5.4 Current work 
Flat heterocyclic structures are fundamental moieties in anticancer compounds acting 
as DNA intercalating agents [46]. In fact, they play a determinant role in the π–π 
stacking interactions with the DNA base pairs. Consequently, the modulation of their 
electronic and steric features by the presence of opportune substituents or heteroatoms, 
could improve this capability. 
 In this context, pyrazolotriazolopyrimidines have been the subject of intense 
research due to the interesting pharmacological activities found for several of their 
derivatives. Among the various pyrazolotriazolopyrimidine ring systems, pyrazolo 
[3,4-d][1,2,4]triazolo[1,5-a]pyrimidines have never been explored, and there are no 
reports on the synthesis and chemical properties of these class of compounds.  
With the aim to extend the synthetic pathways to new planar heterocyclic ring 
systems, we focused our studies on the pyrazolo[3,4-d][1,2,4]triazolo[1,5-
a]pyrimidine  core structure which was found to be absent in the literature survey 
(Scifinder, CA, STN search).  
Synthesis of pyrazolo[3,4-d][1,2,4]triazolo[1,5-a]pyrimidine (ART-301 to 
ART-330), a new ring system, was achieved by using a one-pot, microwave-assisted, 
catalyst-free biginelli like condensation. All the newly synthesized characterized by 
FT-IR, mass spectra, 1H NMR and elemental analysis. The newly synthesized 
compounds were subjected to various biological activities viz., antimicrobial, 
antimycobacterial, anticancer and antiviral.  
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5.5 Reaction Scheme 
+
a
Reagents and conditions: (a) EtOH, MW, 120 ºC, 10-12 min
HO
R2
HN N
NH2N
N
H
N
N
N
R2
ART-301 T0 330
N
N
H O
R1
N
N
H
R1
 
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
ART-301 CH3 4-OCH3 C14H14N6O 282 204-206 69 0.52 0.68 
ART-302 CH3 4-F C13H11FN6 270 158-160 68 0.49 0.59 
ART-303 CH3 4- NO2 C13H11N7O2 297 185-187 75 0.55 0.66 
ART-304 CH3 4-Cl C13H11ClN6 286 221-223 74 0.41 0.69 
ART-305 CH3 4- CH3 C14H14N6 266 205-207 56 0.43 0.59 
ART-306 CH3 4-OH C13H12N6O 268 216-218 72 0.42 0.69 
ART-307 CH3 3-NO2 C13H11N7O2 297 226-228 58 0.49 0.66 
ART-308 CH3 3-Cl C13H11ClN6 286 188-190 68 0.54 0.62 
ART-309 CH3 3-OH C13H12N6O 268 198-200 75 0.43 0.68 
ART-310 CH3 3-Br C13H11BrN6 331 212-214 72 0.50 0.70 
ART-311 CH3 3,4-OCH3 C15H16N6O2 312 148-150 68 0.42 0.59 
ART-312 CH3 2-NO2 C13H11N7O2 297 235-237 72 0.51 0.66 
ART-313 CH3 2-Cl C13H11ClN6 286 208-210 69 0.55 0.65 
ART-314 CH3 2-OH C13H12N6O 268 201-203 70 0.39 0.66 
ART-315 CH3 H C13H12N6 252 193-195 59 0.44 0.64 
ART-316 NH2 4-OCH3 C13H13N7O 283 238-240 66 0.40 0.62 
ART-317 NH2 4-F C12H10FN7 271 213-215 71 0.41 0.63 
ART-318 NH2 4- NO2 C12H10N8O2 298 218-220 63 0.38 0.70 
ART-319 NH2 4-Cl C12H10ClN7 287 221-223 79 0.39 0.68 
ART-320 NH2 4- CH3 C13H13N7 267 179-181 78 0.42 0.70 
ART-321 NH2 4-OH C12H11N7O 269 167-169 82 0.45 0.66 
ART-322 NH2 3-NO2 C12H10N8O2 298 148-150 78 0.51 0.66 
ART-323 NH2 3-Cl C12H10ClN7 287 207-209 75 0.48 0.65 
ART-324 NH2 3-OH C12H11N7O 269 208-210 71 0.37 0.64 
ART-325 NH2 3-Br C12H10BrN7 332 229-231 61 0.46 0.71 
ART-326 NH2 3,4-OCH3 C14H15N7O2 313 177-179 72 0.44 0.67 
ART-327 NH2 2-NO2 C12H10N8O2 298 183-185 68 0.41 0.65 
ART-328 NH2 2-Cl C12H10ClN7 287 213-215 68 0.40 0.71 
ART-329 NH2 2-OH C12H11N7O 269 238-240 75 0.39 0.68 
ART-330 NH2 H C12H11N7 253 186-188 70 0.36 0.63 
 
TLC Solvent system Rf1: Hexane: Ethyl acetate – 6:4; TLC Solvent system Rf2: Chloroform: Methanol - 9:1. 
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5.6 Reaction Mechanism 
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N
H O
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N
N
H O
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H
N
N
N
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N
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The reaction mechanism of this three-component condensation is probably similar to 
the described [47] mechanism for the “classical” Biginelli reaction (Pathway 1). The 
first step is a nucleophilic addition of N(2) of the aminoazole to a carbonyl carbon of 
aldehyde, followed by subsequent cyclization with 3-sub-1H-pyrazol-5(4H)-one to 
form the dihydropyrimidine ring. An alternate sequence is also possible and cannot be 
excluded [48] (Pathway 2), which is the initial formation of an enamine by reaction of 
aminoazole with the 3-sub-1H-pyrazol-5(4H)-one followed by cyclocondensation. 
The third alternative involving the formation of 3-sub-4-benzylidene-1H-pyrazol-
5(4H)-one derivatives as intermediates requires the presence of a strong base [49] and 
is most likely not possible for the cases described herein. 
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5.7 Experimental 
 
5.7.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. Microwave assisted reaction were 
carried out in QPro-M microwave synthesizer. IR spectra were recorded Shimadzu 
FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded on 
Shimadzu GC-MS-QP-2010 model using Direct Injection Probe technique. 1H NMR 
was determined in DMSO-d6 solution on a Bruker Ac 400 MHz spectrometer. 
Elemental analysis of the all the synthesized compounds was carried out on Elemental 
Vario EL III Carlo Erba 1108 model and the results are in agreements with the 
structures assigned. 
 
5.7.2 Synthesis of 3-sub-1H-pyrazol-5(4H)-ones 
 
Syntheses of 3-substituted-1H-pyrazol-5(4H)-ones were achieved using previously 
published methods [50]. 
 
5.7.3 General procedure for the synthesis of 4-(aryl)-3-methyl-4,9-dihydro-1H-
pyrazolo[3,4-d][1,2,4]triazolo[1,5-a]pyrimidines (ART 301-315) 
 
A mixture of the aminoazole (0.01 mol), 3-methyl-1H-pyrazol-5(4H)-one (0.01 mol) 
and an appropriate aromatic aldehyde (0.01 mol) in ethanol (5 mL) was irradiated 
under microwave conditions at 120 °C for 10-12 min. The microwave irradiation was 
operated in 30-second cycles. The reaction mixture was allowed to stand overnight at 
room temperature and was then filtered to give the solid triazolopyrazolopyrimidine 
products ART 301-315, which were washed with ethanol and dried in air. 
Triazolopyrazolopyrimidine were obtained in high purity and did not require further 
purification by recrystallization. 
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5.7.3.1 4-(4-methoxyphenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-301) Yield: 69%; mp 204-206 
ºC; MS: m/z 282; Anal. Calcd. for C14H14N6O: C, 59.56; 
H, 5.00; N, 29.77. Found: C, 59.45; H, 4.92; N, 29.70%. 
 
  
 
5.7.3.2 4-(4-fluorophenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-302) Yield: 68%; mp 158-160 
ºC; MS: m/z 270; Anal. Calcd. for C13H11FN6: C, 57.77; 
H, 4.10; N, 31.10. Found: C, 57.66; H, 4.00; N, 31.01%. 
 
  
 
5.7.3.3 4-(4-nitrophenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-303) Yield: 75%; mp 185-187 
ºC; MS: m/z 297; Anal. Calcd. for C13H11N7O2: C, 52.52; 
H, 3.73; N, 32.98. Found: C, 52.40; H, 3.66; N, 32.89%. 
 
  
 
5.7.3.4 4-(4-chlorophenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-304) Yield: 74%; mp 221-223 
ºC; MS: m/z 286; Anal. Calcd. for C13H11ClN6: C, 54.46; 
H, 3.87; N, 29.31. Found: C, 54.32; H, 3.76; N, 29.22%. 
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5.7.3.5 4-(4-methylphenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-305) Yield: 56%; mp 205-207 
ºC; IR (cm-1): 3356 (N-H stretching of secondary amine), 
3095 (C-H stretching of aromatic ring), 2974 (C-H 
asymmetrical stretching of CH3 group), 2889 (C-H 
asymmetrical stretching of CH3 group), 1693 (C=N 
stretching), 1606 (N-H deformation of pyrimidine ring), 
1506, 1471 and 1400 (C=C stretching of aromatic ring), 1440 (C-H asymmetrical 
deformation of CH3 group), 1352 (C-H symmetrical deformation of CH3 group), 1352 
(C-N stretching), 812 (C-H out of plane bending of 1,4-disubstituion); 1H NMR 
(DMSO-d6) δ ppm: 2.37 (s, 2×3H, Ha), 7.18-7.20 (d, 2H, Hbb’, J = 8.00 Hz), 7.39 (s, 
1H, Hc), 7.51-7.53 (d, 2H, Hdd’, J = 7.96 Hz), 7.93 (s, 1H, He), 11.47 (s, aH, Hf); MS: 
m/z 266; Anal. Calcd. for C14H14N6: C, 63.14; H, 5.30; N, 31.56. Found: C, 63.01; H, 
5.22; N, 31.48%. 
 
5.7.3.6 4-(4-hydroxyphenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-306) Yield: 72%; mp 216-218 
ºC; MS: m/z 268; Anal. Calcd. for C13H12N6O: C, 58.20; 
H, 4.51; N, 31.33. Found: C, 58.10; H, 4.39; N, 31.25%. 
 
  
 
5.7.3.7 4-(3-nitrophenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-307) Yield: 58%; mp 226-228 
ºC; IR (cm-1): 3261 (N-H stretching of secondary amine), 
3080 (C-H stretching of aromatic ring), 2999 (C-H 
asymmetrical stretching of CH3 group), 2862 (C-H 
asymmetrical stretching of CH3 group), 1699 (C=N 
stretching), 1614 (N-H deformation of pyrimidine ring), 
1566, 1525 and 1494 (C=C stretching of aromatic ring), 1440 (C-H asymmetrical 
deformation of CH3 group), 1388 (C-H symmetrical deformation of CH3 group), 1350 
(C-N stretching), 705 (C-H out of plane bending of 1,3-disubstituion); 1H NMR 
(DMSO-d6) δ ppm: 2.57 (s, 3H, Ha), 7.63-7.68 (t, 1H, Hb), 8.04-8.06 (d, 1H, Hc), 8.10 
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(s, 1H, Hd), 8.20-8.22 (d, 2H, He), 8.30 (s, 1H, Hf,), 8.45-8.46 (s, 1H, Hg), 11.95-12.04 
(s, 1H, Hh); MS: m/z 297; Anal. Calcd. for C13H11N7O2: C, 52.52; H, 3.73; N, 32.98. 
Found: C, 52.45; H, 3.64; N, 32.90%.  
 
5.7.3.8 4-(3-chlorophenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-308) Yield: 68%; mp 188-190 
ºC; MS: m/z 286; Anal. Calcd. for C13H11ClN6: C, 54.46; 
H, 3.87; N, 29.31. Found: C, 54.34; H, 3.77; N, 29.20%. 
  
 
5.7.3.9 4-(3-hydroxyphenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-309) Yield: 75%; mp 198-200 
ºC; MS: m/z 268; Anal. Calcd. for C13H12N6O: C, 58.20; 
H, 4.51; N, 31.33. Found: C, 58.12; H, 4.41; N, 31.22%. 
  
 
5.7.3.10 4-(3-bromophenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-310) Yield: 72%; mp 212-214 
ºC; MS: m/z 331; Anal. Calcd. for C13H11BrN6: C, 47.15; 
H, 3.35; N, 25.38. Found: C, 47.02; H, 3.21; N, 25.57%. 
  
 
5.7.3.11 4-(3,4-methoxyphenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triaz 
olo[1,5-a]pyrimidine (ART-311) Yield: 68%; mp 148-
150 ºC; MS: m/z 312; Anal. Calcd. for C15H16N6O2: C, 
57.68; H, 5.16; N, 26.91. Found: C, 57.59; H, 5.02; N, 
26.82%. 
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5.7.3.12 4-(2-nitrophenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-312) Yield: 72%; mp 235-237 
ºC; MS: m/z 297; Anal. Calcd. for C13H11N7O2: C, 52.52; 
H, 3.73; N, 32.98. Found: C, 52.41; H, 3.66; N, 32.89%. 
  
 
5.7.3.13 4-(2-chlorophenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-313) Yield: 69%; mp 208-210 
ºC; MS: m/z 286; Anal. Calcd. for C13H11ClN6: C, 54.46; 
H, 3.87; N, 29.31. Found: C, 54.38; H, 3.74; N, 29.24%. 
  
 
5.7.3.14 4-(2-hydroxyphenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
[1,5-a]pyrimidine (ART-314) Yield: 70%; mp 201-203 
ºC; MS: m/z 268; Anal. Calcd. for C13H12N6O: C, 58.20; 
H, 4.51; N, 31.33. Found: C, 58.10; H, 4.43; N, 31.20%. 
 
 
5.7.3.15 4-(phenyl)-3-methyl-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo[1,5-a] 
pyrimidine (ART-315) Yield: 59%; mp 193-195 ºC; IR 
(cm-1): 3213 (N-H stretching of secondary amine), 3080 
(C-H stretching of aromatic ring), 2949 (C-H 
asymmetrical stretching of CH3 group), 2882 (C-H 
asymmetrical stretching of CH3 group), 1689 (C=N 
stretching), 1602 (N-H deformation of pyrimidine ring), 
1560, 1520 and 1491 (C=C stretching of aromatic ring), 1448 (C-H asymmetrical 
deformation of CH3 group), 1384 (C-H symmetrical deformation of CH3 group), 1340 
(C-N stretching); 1H NMR (DMSO-d6) δ ppm: 2.53 (s, 3H, Ha), 7.37-7.73 (m, 6H, 
Hbb’-f), 11.73 (s, 1H, Hg); MS: m/z 252; Anal. Calcd. for C13H12N6: C, 61.89; H, 4.79; 
N, 33.31. Found: C, 61.80; H, 4.68; N, 33.21%. 
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5.7.4 General procedure for the synthesis of 4-(aryl)-3-amino-4,9-dihydro-1H-
pyrazolo[3,4-d][1,2,4]triazolo[1,5-a]pyrimidines (ART 316-330) 
 
A mixture of the aminoazole (0.01 mol), 3-amino-1H-pyrazol-5(4H)-one (0.01 mol) 
and an appropriate aromatic aldehyde (0.01 mol) in ethanol (5 mL) was irradiated 
under microwave conditions at 120 °C for 10-12 min. The microwave irradiation was 
operated in 30-second cycles. The reaction mixture was allowed to stand overnight at 
room temperature and was then filtered to give the solid triazolopyrazolopyrimidine 
products ART 316-330, which were washed with ethanol and dried in air. 
Triazolopyrazolopyrimidine were obtained in high purity and did not require further 
purification by recrystallization. 
 
5.7.4.1 4-(4-methoxyphenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-316) Yield: 66%; mp 238-240 
ºC; IR (cm-1): 3412 (N-H stretching of primary amine), 
3215 (N-H stretching of secondary amine), 3090 (C-H 
stretching of aromatic ring), 2964 (C-H asymmetrical 
stretching of CH3 group), 2835 (C-H asymmetrical 
stretching of CH3 group), 1691 (C=N stretching), 1668 
(N-H deformation of primary amine), 1608 (N-H deformation of pyrimidine ring), 
1568, 1516, 1465 (C=C stretching of aromatic ring), 1425 (C-H asymmetrical 
deformation of CH3 group), 1384 (C-H symmetrical deformation of CH3 group), 1336 
(C-N stretching), 837 (C-H out of plane bending of 1,4-disubstituion); 1H NMR 
(DMSO-d6) δ ppm: 3.84 (s, 3H, Ha), 3.94 (s, 2H, Hb), 6.90-6.92 (d, 2H, Hcc’, J = 8.8 
Hz), 7.57-7.59 (d, 2H, Hdd’, J = 8.8 Hz), 7.71 (s, 1H, He), 7.93 (s, 1H, Hf), 11.62 (s, 
1H, Hg); MS: m/z 283; Anal. Calcd. for C13H13N7O: C, 55.12; H, 4.63; N, 34.61. 
Found: C, 55.02; H, 4.56; N, 34.52%. 
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5.7.4.2 4-(4-fluorophenyl)-3 amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-317) Yield: 71%; mp 213-215 
ºC; IR (cm-1): 3466 (N-H stretching of primary amine), 
3290 (N-H stretching of secondary amine), 3090 (C-H 
stretching of aromatic ring), 1691 (C=N stretching), 1674 
(N-H deformation of primary amine), 1602 (N-H 
deformation of pyrimidine ring), 1564, 1546, 1510 (C=C 
stretching of aromatic ring), 1430 (C-H asymmetrical deformation of CH3 group), 
1373 (C-H symmetrical deformation of CH3 group), 1340 (C-N stretching), 837 (C-H 
out of plane bending of 1,4-disubstituion); 1H NMR (DMSO-d6) δ ppm: 3.94 (s, 3H, 
Ha), 7.35-7.38 (d, 2H, Hbb’), 7.58-7.62 (d, 2H, Hcc’), 7.65 (s, 1H, Hd), 7.96 (s, 1H, He), 
11.79 (s, 1H, Hf); MS: m/z 271; Anal. Calcd. for C12H10FN7: C, 53.13; H, 3.72; N, 
36.15. Found: C, 53.01; H, 3.61; N, 36.03%. 
 
5.7.4.3 4-(4-nitrophenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
[1,5-a]pyrimidine (ART-318) Yield: 63%; mp 218-220 
ºC; IR (cm-1): 3412 (N-H stretching of primary amine), 
3254 (N-H stretching of secondary amine), 3086 (C-H 
stretching of aromatic ring), 1695 (C=N stretching), 1589 
(N-H deformation of pyrimidine ring), 1518 and 1483 
(C=C stretching of aromatic ring), 1450 (C-H 
asymmetrical deformation of CH3 group), 1377 (C-H symmetrical deformation of 
CH3 group), 1346 (C-N stretching), 852 (C-H out of plane bending of 1,4-
disubstituion); 1H NMR (DMSO-d6) δ ppm: 3.96 (s, 2H, Ha), 7.55 (s, 1H, Hb), 7.82-
7.85 (d, 2H, Hcc’), 8.08 (s, 1H, Hd), 8.23-8.25 (d, 2H, Hee’, J = 7.68 Hz), 12.07 (d, 2H, 
Hf); MS: m/z 298; Anal. Calcd. for C12H10N8O2: C, 48.32; H, 3.38; N, 37.57. Found: 
C, 48.21; H, 3.29; N, 37.48%.  
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5.7.4.4 4-(4-chlorophenyl)-3- amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-319) Yield: 79%; mp 221-223 
ºC; MS: m/z 287; Anal. Calcd. for C12H10ClN7: C, 50.10; 
H, 3.50; N, 34.08. Found: C, 50.00; H, 3.39; N, 34.00%. 
  
 
 
5.7.4.5 4-(4-methylphenyl)-3- amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-320) Yield: 78%; mp 179-181 
ºC; MS: m/z 267; Anal. Calcd. for C13H13N7: C, 58.42; H, 
4.90; N, 36.68. Found: C, 58.31; H, 4.88; N, 36.59%. 
  
 
 
5.7.4.6 4-(4-hydroxyphenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-321) Yield: 82%; mp 167-169 
ºC; MS: m/z 269; Anal. Calcd. for C12H11N7O: C, 53.53; 
H, 4.12; N, 36.41. Found: C, 53.48; H, 4.01; N, 36.29%. 
  
 
 
5.7.4.7 4-(3-nitrophenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-322) Yield: 78%; mp 148-150 
ºC; MS: m/z 298; Anal. Calcd. for C12H10N8O2: C, 48.32; 
H, 3.38; N, 37.57. Found: C, 48.23; H, 3.27; N, 37.49%. 
  
 
5.7.4.8 4-(3-chlorophenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-323) Yield: 75%; mp 207-209 
ºC; MS: m/z 287; Anal. Calcd. for C12H10ClN7: C, 50.10; 
H, 3.50; N, 34.08. Found: C, 50.01; H, 3.39; N, 33.99%. 
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5.7.4.9 4-(3-hydroxyphenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-324) Yield: 71%; mp 208-210 
ºC; MS: m/z 269; Anal. Calcd. for C12H11N7O: C, 53.53; 
H, 4.12; N, 36.41. Found: C, 53.44; H, 4.03; N, 36.30%. 
  
 
5.7.4.10 4-(3-bromophenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-325) Yield: 61%; mp 229-231 
ºC; MS: m/z 332; Anal. Calcd. for C12H10BrN7: C, 43.39; 
H, 3.03; N, 29.52. Found: C, 43.27; H, 2.95; N, 29.40%. 
  
 
5.7.4.11 4-(3,4-methoxyphenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triaz 
olo[1,5-a]pyrimidine (ART-326) Yield: 72%; mp 177-
179 ºC; MS: m/z 313; Anal. Calcd. for C14H15N7O2: C, 
53.67; H, 4.83; N, 31.29. Found: C, 53.56; H, 4.77; N, 
31.21%. 
  
 
5.7.4.12 4-(2-nitrophenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-327) Yield: 68%; mp 183-185 
ºC; MS: m/z 298; Anal. Calcd. for C12H10N8O2: C, 48.32; 
H, 3.38; N, 37.57. Found: C, 48.22; H, 3.27; N, 37.49%. 
  
 
5.7.4.13 4-(2-chlorophenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
 [1,5-a]pyrimidine (ART-328) Yield: 68%; mp 213-215 
ºC; MS: m/z 287; Anal. Calcd. for C12H10ClN7: C, 50.10; 
H, 3.50; N, 34.08. Found: C, 50.01; H, 3.39; N, 33.99%. 
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5.7.4.14 4-(2-hydroxyphenyl)-3-amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo 
[1,5-a]pyrimidine (ART-329) Yield: 75%; mp 238-240 
ºC; MS: m/z 269; Anal. Calcd. for C12H11N7O: C, 53.53; 
H, 4.12; N, 36.41. Found: C, 53.42; H, 4.01; N, 36.29%. 
 
 
5.7.4.15 4-(phenyl)-3- amino-4,9-dihydro-1H-pyrazolo[3,4-d][1,2,4]triazolo[1,5-a] 
pyrimidine (ART-330) Yield: 70%; mp 186-188 ºC; MS: 
m/z 253; Anal. Calcd. for C12H11N7: C, 56.91; H, 4.38; N, 
38.71. Found: C, 56.79; H, 4.26; N, 38.60%. 
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5.8 Spectral discussion 
5.8.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
5.8.1.1 Mass fragmentation pattern for ART-305 
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5.8.1.2 Mass fragmentation pattern for ART-318 
N
H
N
N
N
N
N
H
H2N
m/z = 271 m/z = 251
m/z = 176
+
+
m/z = 166
m/z = 193
N
H
N
N
N
N
N
H
H2N
NO2
N
H
N
N
N
N
N
H
H2N
N
H
N
N
N
N
H
H2N
NO2
N
NH
H2N
NO2
N
H2N
NO2
NO2
m/z = 298
+
+
m/z = 205
+
+
 
 
5.8.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For pyrazolo-triazolo-pyrimidines ART-301 to 315, 
confirmatory bands for secondary amine and C=N stretching band was observed at 
3213-3356 cm-1 and 1689-1693 cm-1 respectively, which suggested formation of 
desired products ART-301 to 315.   
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While, for pyrazolo-triazolo-pyrimidines ART-316 to 330 confirmatory bands 
for secondary amine and C=N stretching band was observed at 3215-3290 cm-1 and 
1691-1695 cm-1 respectively, along with a characteristic stretching band for primary 
amine at 3412-366 cm-1 suggested formation of desired products ART-316 to 330.  
  
5.8.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
1H NMR spectra confirmed the structures of pyrazolo-triazolo-pyrimidines 
ART-301 to 330 on the basis of following signals: a singlet for the methine proton of 
pyrimidine ring at 7.39-8.10 δ ppm and a singlet for the methine proton of triazole 
ring at 7.93-8.30 δ ppm. The aromatic ring protons and J value were found to be in 
accordance with substitution pattern on phenyl ring.  
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IR spectrum of ART-305 
 
 
Mass spectrum of ART-305 
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1H NMR spectrum of ART-305 
 
 
Expanded 1H NMR spectrum of ART-305 
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IR spectrum of ART-307 
 
 
Mass spectrum of ART-307 
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1H NMR spectrum of ART-307 
 
 
Expanded 1H NMR spectrum of ART-307 
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IR spectrum of ART-315 
 
 
Mass spectrum of ART-315 
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1H NMR spectrum of ART-315 
 
 
Expanded 1H NMR spectrum of ART-315 
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IR spectrum of ART-316 
 
 
Mass spectrum of ART-316 
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1H NMR spectrum of ART-316 
 
 
Expanded 1H NMR spectrum of ART-316 
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IR spectrum of ART-317 
 
 
Mass spectrum of ART-317 
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1H NMR spectrum of ART-317 
 
 
Expanded 1H NMR spectrum of ART-317 
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IR spectrum of ART-318 
 
 
Mass spectrum of ART-318 
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1H NMR spectrum of ART-318 
 
 
Expanded 1H NMR spectrum of ART-318 
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5.9 Biological evaluation 
5.9.1 Antimicrobial evaluation 
All of the synthesized compounds (ART-301 to 330) were tested for their antibacterial 
and antifungal activity (MIC) in vitro by broth dilution method [51-53] with two 
Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus pyogenes 
MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, Pseudomonas 
aeruginosa MTCC 441 and three fungal strains Candida albicans MTCC 227, 
Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking ampicillin, 
chloramphenicol, ciprofloxacin, norfloxacin, nystatin, and griseofulvin as standard 
drugs. The standard strains were procured from the Microbial Type Culture Collection 
(MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [51].  Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations of 
1.56, 3.12, 6.25, 10, 12.5, 25, 50, 62.5, 100, 125, 250, 500 and 1000 µg mL-1. The 
tubes were inoculated with 108 cfu mL-1 (colony forming unit/mL) and incubated at 
37 ºC for 24 h. The MIC was the lowest concentration of the tested compound that 
yields no visible growth (turbidity) on the plate. To ensure that the solvent had no 
effect on the bacterial growth, a control was performed with the test medium 
supplemented with DMSO at the same dilutions as used in the experiments and it was 
observed that DMSO had no effect on the microorganisms in the concentrations 
studied. The results obtained from antimicrobial susceptibility testing are depicted in 
Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds ART-301 to 330 
 
 
 
 
 
 
 
 
 
 
 
Minimum inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
Code 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
ART-301 1000 500 500 1000 250 1000 500 
ART-302 250 1000 100 500 500 250 >1000 
ART-303 50 500 250 500 >1000 100 500 
ART-304 125 100 500 125 250 500 500 
ART-305 500 500 1000 500 1000 1000 250 
ART-306 500 500 >1000 1000 500 1000 >1000 
ART-307 62.5 250 500 125 1000 100 500 
ART-308 100 500 1000 1000 500 500 100 
ART-309 1000 1000 250 >1000 500 250 1000 
ART-310 250 250 500 500 1000 100 1000 
ART-311 250 1000 1000 250 >1000 1000 500 
ART-312 125 500 >1000 1000 500 250 500 
ART-313 100 500 500 500 125 250 250 
ART-314 500 1000 250 1000 500 1000 500 
ART-315 250 100 500 >1000 1000 500 1000 
ART-316 1000 500 250 500 500 500 1000 
ART-317 100 100 1000 250 1000 100 1000 
ART-318 250 250 1000 1000 250 >1000 500 
ART-319 500 25 500 125 100 100 250 
ART-320 >1000 500 1000 1000 500 1000 500 
ART-321 1000 500 250 250 >1000 >1000 1000 
ART-322 250 500 500 1000 250 500 250 
ART-323 1000 1000 500 >1000 1000 1000 500 
ART-324 >1000 1000 250 500 500 500 500 
ART-325 1000 500 1000 500 125 250 1000 
ART-326 500 250 500 100 500 100 250 
ART-327 250 100 1000 500 250 1000 500 
ART-328 1000 500 500 500 500 500 >1000 
ART-329 250 1000 62.5 250 500 250 500 
ART-330 500 250 250 500 >1000 500 500 
Ampicillin 250 100 1000 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
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5.9.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds ART-301 to ART-330 is currently under investigation and results are 
awaited.  
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Summary 
 
The work presented in the Thesis entitled “Studies on Some Compounds of Medicinal 
Interest” can be summarized as below. 
 
Chapter 1 briefly introduces importance of bicyclic and tricyclic aromatic 
heterocycles in drug discovery as well as concept of “privileged structures”. Chapter 1 
further describes aims and objectives of the proposed research work. 
Chapter 2 outlines the biological significance and medical significance of 
pyrimidines. Also, an attempt has been made to include most of the physiologically as 
well as medicinally important compounds containing pyrimidine and its derivatives to 
further elaborate the importance of these class of compounds. 
In Chapter 3, synthesis of thirty novel thieno[2,3-d]pyrimidines is reported, 
which occupy a special position among fused pyrimidines due to a very wide 
spectrum of their biological activities. The synthesis of these derivatives was affected 
from novel 2-aminothiophenes containing an acetoacetamide fragment by acid 
catalysed cyclocondensation with formic acid, gl. acetic acid and trifluoroacetic acid, 
respectively.  
Recently, 1,2,4-triazolo[1,5-a]pyrimidines have aroused increasing from the 
standpoint of biological activity, due to their diverse pharmacological activities. 
Chapter 4 includes the brief review of the reported synthetic strategies for the 
synthesis of these classes of compound. Forty 1,2,4-triazolo[1,5-a]pyrimidines were 
synthesized by Biginelli like cyclocondensation of aromatic aldehydes and 
acetoacetanilide derivatives with aminoazole. The synthesis was accomplished by 
refluxing in small amount of DMF within a very short period of time of just 12-15 
min.  
Chapter 5 describes applications of microwaves in heterocyclic ring formation. 
Pyrazolo-triazolo-pyrimidines have been the subject of intense research due to the 
interesting pharmacological activities found for several of their derivatives. Chapter 5 
includes synthesis of thirty novel pyrazolo[3,4-d][1,2,4]triazolo[1,5-a]pyrimidines 
with the aim to extend the synthetic pathways to new planar heterocyclic ring 
systems, chemistry of which have never been explored, and there are no reports on the 
synthesis and chemical properties of these class of compounds. The synthesis was 
achieved by using a one pot, microwave-assisted, catalyst-free biginelli like 
condensation of aminoazole, 3-substituted-pyrazol-5(4H)-ones, and an appropriate 
aromatic aldehyde in ethanol. Thus, a new green chemistry approach was developed 
leading to the improvement in the reaction time, yield and simplicity of work up 
procedure. 
All the synthesized compounds were characterized by IR, Mass, 1H NMR 
spectroscopy and elemental analyses. 
Thus, 110 compounds are synthesized and characterized in entire thesis work. 
The synthesized compounds are screened for antimicrobial activity, results of which 
are incorporated in the thesis. Looking at the antimicrobial activity results (i.e. 
antibacterial and antifungal), remarkable number of compounds have demonstrated 
excellent antimicrobial activity as compared to the standard drugs.  
All the newly synthesized compounds are also under antimycobacterial, 
anticancer and antiviral evaluation and their results are awaited.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications 
 
 
1. Synthesis and antimycobacterial evaluation of various 6-substituted pyrazolo[3,4-
d]pyrimidine derivatives, by Amit R. Trivedi, Shailesh J. Vaghasiya, Bipin H. 
Dholariya, Dipti Dodiya and Viresh H. Shah. Journal of Enzyme Inhibition and 
Medicianl Chemistry, Accepted, In Press. 
2. Synthesis, characterization and biological screening of some novel 
tetrahydroquinazoline derivatives, by S. J. Vaghasia, D. K. Dodiya, A. R. Trivedi, 
H. K. Ram and V. H. Shah. Indian Journal of Chemistry (Section B), Accepted, In 
Press.     
3. Synthesis and antimicrobial evaluation of novel benzo[b]thiophenes comprising β-
lactam nucleus, by Amit R. Trivedi, Jignesh M Desai, Bipin H. Dholariya, Dipti 
Dodiya and Viresh H. Shah. Medicinal Chemistry Research, Under Revision. 
4. Synthesis, Biological Evaluation and Molecular Docking studies of pyrimidine, 
pyran and pyridine derivatives as potential CDK-1 and GSK-3 inhibitors, by Amit 
R Trivedi, Ketan H Shikotra, Kishor J Aahir, Naresh R Ravat, Viresh H Shah, 
Raghuvir RS Pissurlenkar and Evans C Coutinho. Chemical Biology & Drug 
Design, Under Revision.  
5. Synthesis and anti-tubercular evaluation of some novel pyrazolo[3,4-d]pyrimidine 
derivatives, by Amit R. Trivedi, Arif B. Siddiqui, Bipin H. Dholariya and Viresh 
H. Shah. Chemotherapy, Submitted, Under Review. 
6. Synthesis, Characterization, Crystal and Molecular Structure Analysis of 2,6-
Dimethyl-3-acetyl-5-carbomethoxy-4-phenyl-1,4-dihydropyridine, by Amit 
Trivedi, Neetha Gowda, Yogesh Naliapara, M. Sridhar, J. Shashidhara prasad, 
Anamik Shah. Journal of Chemical Crystallography, Submitted, Under Review.  
7. Novel dihydropyrimidines as a potential new class of antitubercular agents, by 
Amit R. Trivedi, Vimal R. Bhuva, Bipin H. Dholariya, Dipti K. Dodiya and 
Viresh H. Shah. Manuscript Under Preparation. 
8. A facile Synthesis of some indolylazetidinones and substituted 
indolylthioazetidinones, by P. R. Vachharajani, Bhavin Trivedi, Gaurang Dubal, 
Manish Solanki, Amit Trivedi. Organic Chemistry (Rajkot, India), 5(3), 266-269, 
2009. 
  
9. A new synthetic approach and biological evaluation of novel phenothiazines 
bearing tert-butyl group, by Amit R. Trivedi;  Arif B. Siddiqui;  Dipti K. Dodiya;  
Manish J. Soalnki; Viresh H. Shah. Journal of Sulfur Chemistry. 30(6), 590-595, 
2009, DOI: 10.1080/17415990903173511. 
10. Synthesis and Biological Evaluation of 1-aryl-3-methyl-4-(5’-chloro-3’-methyl-
1’-phenylpyrazilo-4’-yl)-4,4adihydro-6H-pyrazolo[3,4-d]-1,3-thiazolidino[3,2-a] 
pyrimidine-5-ones, by A. R. Trivedi, N. R. Ravat and V. H Shah J. Inst. Chemists 
(India). 81(1), 2009. 
11. Design, synthesis, characterization and antitubercular activity of some 2-
heterocycle-substituted phenothiazines, by Trivedi, Amit R.; Siddiqui, Arif B.; 
Shah, Viresh H. ARKIVOC. 2, 210-217, 2008. 
12. Facile one pot synthesis and antimycobacterial evaluation of pyrazolo[3,4-
d]pyrimidines, by Amit Trivedi, Dipti Dodiya, Janak Surani, Samir Jarsania, 
Hitesh mathukia, Naresh Ravat, Viresh shah. Archiv der Pharmazie. 341(7), 435-
439, 2008. 
13. Synthesis and biological evaluation of some new pyrimidines via a novel chalcone 
series, Trivedi, Amit R.; Dodiya, Dipti K.; Ravat, Naresh R.; Shah, Viresh H. 
ARKIVOC, (11), 131-141, 2008. 
14. Synthesis and biological screening of some novel pyrazolo[3’,4’:4,5]thieno[2,3-
d]pyrimidin-8-ones via Gewald reaction, by Shailesh J. Vaghasiya, Dipti K. 
Dodiya, Amit R. Trivedi and Viresh H. Shah. ARKIVOC. 12, 1-8, 2008. 
15. Synthesis and biological screening of some novel pyrazolo[3’,4’:4,5]thieno[2,3-
d]pyrimidin-5-ones via a Gewald reaction, by Shailesh J. Vaghasiya, Dipti K. 
Dodiya, Amit R. Trivedi, and Viresh H. Shah. J. Serb. Chem. Soc., 73(7), 683-
690, 2008.   
16. Synthesis and biological screening of some novel pyrazolo[3,4-d]pyrimidines, by 
Vaghasia, S. J.; Dodiya, D. K.; Shah, V. H. Indian Journal of Heterocyclic 
Chemistry, 18(1), 9-12, 2008. 
17. A facile synthesis of pyrazolo[3,4-d]pyrimidines, by Trivedi, A. R.; Dubal, G. G.; 
Ravat, N. R.; Shah, V. H. Indian Journal of Heterocyclic Chemistry, 17(4), 385-
386, 2008. 
 
18. Synthesis and biological studies of pyrazolo[3,4-d]pyrimidines, by A. R. Trivedi, 
N. R Ravat, V. H. Shah. International Journal of Synthesis and Characterization. 
1(1), 67-72, 2008. 
19. Synthesis, characterization and biological screening of some new 2-pyrazolin-5-
ones, by A. R. Trivedi, D. S. mehta, V. H. Shah. International Journal of 
Synthesis and Characterization. 1(1), 113-118, 2008. 
20. Simple and efficient synthetic routes to bioactive s-triazinyl dithiocarbamate 
derivatives, by R. M. Desai, D. K. Dodiya, A. R. Trivedi and V. H. Shah. 
Medicinal Chemistry Research, 17, 495. 2008, DOI: 10.1007/s00044-008-9093-4. 
21. Synthesis and biological evaluation of 4-aryl-3-methyl-1-phenyl-4,4a-dihydro-
6H-pyrazolo[3,4-d]-1,3-thiazolidino[3,2-a]pyrimidine-5-ones, by Trivedi, A. R.; 
Ravat, N. R.; Shah, V. H. Organic Chemistry (Rajkot, India), 3(4), 180-184, 2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conferences/Seminars participated 
 
1. National seminar on “Recent Advances in Chemical Sciences & An Approach to 
Green Chemistry” jointly organized by Department of Chemistry & Gujarat 
Council on Science and Technology (GUJCOST)-Gandhinagar at Rajkot, India 
(October 11-13, 2006).  
2. National Workshop on Management and Use of Chemistry Databases and Patent 
Literature jointly organized by Department of Chemistry & Gujarat Council on 
Science and Technology (GUJCOST)-Gandhinagar at Rajkot, India (February 27-
29, 2008).  
3. “National Workshop on Updates in Process & Medicinal Chemistry” jointly 
Organized by Department of Chemistry, Saurashtra University, Rajkot and 
National Facility for Drug Discovery Through NCE’s Development & 
Instrumentation Support to Small Manufacturing Pharma Enterprises and Think 
Pharma USA (March 3-4, 2009). 
4. “National Conference on Spectroscopy & Stereochemistry” Organized by 
Department of Chemistry, Saurashtra University, Rajkot Sponsored by UGC, New 
Delhi and Gujarat Council on Science and Technology (GUJCOST)-Gandhinagar 
(March 18-20, 2009). 
5. “Two Days National Workshop on Patents & IPR Related Updates” Organized by 
Technology Information, Forecasting Assessment Council (TIFAC)-New Delhi, 
Gujarat Council on Science and Technology (GUJCOST)-Gandhinagar and 
National Facility for Drug Discovery Through NCE’s Development & 
Instrumentation Support to Small Manufacturing Pharma Enterprises at 
Department of Chemistry, Saurashtra University, Rajkot (September 19-20, 2009). 
6. “International Seminar on Recent Developments in Structure and Ligand Based 
Drug Design” jointly organized by Schrodinger LLC, USA & Department of 
Chemistry and National Facility for Drug Discovery Through NCE’s 
Development & Instrumentation Support to Small Manufacturing Pharma 
Enterprises at Department of Chemistry, Saurashtra University, Rajkot (December 
23, 2009).   
 
 
Acknowledgements 
 
I would like to thank all people who have helped and inspired me during my doctoral 
study. I especially want to thank my advisor, Prof. V. H. Shah, for his guidance 
during my research and study at Saurashtra University. I am highly thankful to 
University Grant Commission, New Delhi for UGC Meritorious fellowship. 
 
 
 
 
